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Regulation of excitatory synapse development by the RhoGEF Ephexin5 
 
Abstract 
 
 The neuronal synapse is a specialized cell-cell junction that mediates communication 
between neurons.  The formation of a synapse requires the coordinated activity of signaling 
molecules that can either promote or restrict synapse number and function.  Tight regulation of 
these signaling molecules is critical to ensure that synapses form in the correct number, time and 
place during brain development.  A number of molecular mechanisms that promote synapse 
formation have been elucidated, but specific mechanisms that restrict synapse formation are less 
well understood.  The findings presented within this dissertation focus on how a specific Rho 
guanine nucleotide exchange factor (GEF) Ephexin5 functions to restrict early synaptic 
development and how perturbations in Ephexin5 signaling may lead to human 
neurodevelopmental disease.  
We find that Ephexin5 loss-of-function leads to an increase in the number of functional 
excitatory synapses in the hippocampus.  Ephexin5 overexpression restricts excitatory synapse 
number and this restriction requires the GEF activity of Ephexin5.  Interestingly, a de novo 
mutation in human Ephexin5 in an individual with infantile epileptic encephalopathy reduces its 
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GEF activity, suggesting that perturbing Ephexin5 signaling may have functional consequences 
in vivo.  Indeed, Ephexin5 heterozygote mice have increased susceptibility to seizures and 
heightened anxiety.   
We also uncovered two mechanisms that underlie Ephexin5-mediated synapse restriction.  
First, we find that EphB receptor tyrosine phosphorylation of Ephexin5 triggers degradation of 
Ephexin5 protein by the Angelman-syndrome associated ubiquitin ligase, UBE3A.  In contrast to 
Ephexin5, EphB receptors promote synapse formation, and therefore Ephexin5 signaling may 
serve to limit EphB-mediated synapse formation.  Second, we identified a number of 
serine/threonine phosphorylation sites in Ephexin5, two of which are reduced in vivo during later 
stages of synapse development and adulthood.  A subset of these phosphorylation sites are 
required for Ephexin5-mediated synapse restriction.  This suggests that reducing Ephexin5 
serine/threonine phosphorylation may be an important mechanism for inhibiting its activity in 
adulthood.  Taken together, we hypothesize that Ephexin5 serves as a brake during early synapse 
development and that precise control of Ephexin5 activity via degradation and phosphorylation 
are critical mechanisms to ensure that synapses form in the correct number, time, and place. 
  
.   
 
 
 
v 
 
Table of Contents 
Abstract...........................................................................................................................................iii 
List of Figures................................................................................................................................vii 
List of Tables..................................................................................................................................ix 
Acknowledgments...........................................................................................................................x 
Attributions....................................................................................................................................xii 
 
1   Introduction                                                                                                                           1 
1.1    Postsynaptic excitatory synapse development and the actin cytoskeleton.............................4 
1.2    Rho-family GTPase signaling and synapse development.....................................................13 
1.3    Rho-family GEFs: Mechanisms and Regulation..................................................................21 
1.4    RhoGEFs in Synapse Development......................................................................................28 
1.5    The Ephexin family...............................................................................................................31 
1.6    Summary of dissertation.......................................................................................................39 
 
2   EphB-mediated degradation of the RhoA GEF Ephexin5 relieves a developmental  
             brake on excitatory synapse formation                                                                         43 
 
2.1    Abstract.................................................................................................................................44 
2.2    Background and Rationale....................................................................................................45 
2.3    Results...................................................................................................................................48 
2.4    Discussion.............................................................................................................................91 
2.5    Materials and Methods..........................................................................................................97 
 
3   Human ArhGEF15/Ephexin5 mutations in epileptic encephalopathy                            107 
3.1    Abstract...............................................................................................................................108 
3.2    Background and Rationale..................................................................................................109  
3.3    Identification of a de novo mutation in ArhGEF15/Ephexin5 reduces GEF activity.........111 
vi 
 
3.4    Behavioral model of epilepsy and comorbidity: analysis of Ephexin5 +/-  mice...............119 
3.5    Discussion...........................................................................................................................122 
3.6    Material and Methods.........................................................................................................125  
 
4   Phospho-regulation of Ephexin5 during brain development                                            128 
4.1    Abstract...............................................................................................................................129 
4.2    Identification and analysis of serine/threonine Ephexin5 phosphorylation........................130 
4.3    Discussion...........................................................................................................................143 
4.4    Materials and Methods.......................................................................................................146 
5   Conclusion               152 
Bibliography                                                                                                                              157 
 
 
 
 
 
 
 
 
vii 
 
List of Figures 
1.1    Dendritic spines are enriched with actin.................................................................................5 
1.2    GEFs, GAPs, and GDIs regulate GDP- and GTP-bound forms of GTPases........................14 
1.3    Rac1, Cdc42, and RhoA downstream signaling cascades....................................................16 
1.4    Dbs exchange factor in complex with Cdc42.......................................................................24 
1.5    The murine Ephexin family of RhoGEFs.............................................................................34 
1.6    Model for bimodal inhibition of Ephexins by N-terminal repression..................................40 
2.1    Ephexin5 interacts with EphB2............................................................................................49 
2.2    Generation of Ephexin5 knockout mice and validation.......................................................52 
2.3    Ephexin5 is a guanine nucleotide exchange factor that activates RhoA..............................56 
2.4    Ephexin5 QSRL mutant does not affect GEF activity.........................................................59 
2.5    Ephexin5 knockdown by shRNA….....................................................................................60 
2.6    Ephexin5 negatively regulates excitatory synapse number..................................................63 
2.7    Ephexin5 negatively regulates synapses in vivo...................................................................67 
2.8    Ephexin5 restricts EphB2 control of synapse formation......................................................71 
2.9    EphB2 phosphorylates Ephexin5 at tyrosine-361................................................................72 
2.10  Specificity of EphB-mediated phosphorylation at tyrosine-361..........................................75 
2.11  EphB2-mediated degradation of Ephexin5 is kinase and proteasome dependent................78 
2.12  EphB2-mediated degradation of endogenous Ephexin5 is kinase dependent......................82 
2.13  EphB2-mediated degradation of Ephexin5 requires Ube3a.................................................86 
2.14  Structure and alignment of Ephexin5 UBD.........................................................................89 
2.15  Model of EphB- and Ephexin5-dependent synapse formation............................................92 
3.1    Human Ephexin5 protein alignment reveals conserved site at Arg.604.............................112 
3.2    De novo Arg to Cys mutations in Ephexin5 reduce RhoA GEF activity............................113 
3.3    Ephexin5-R612C has reduced RhoA GEF activity by RBD pulldown..............................115 
3.4    Ephexin5 mouse model has enhanced audiogenic seizure susceptibility...........................120 
viii 
 
3.5    Increased anxiety in Ephexin5 mouse model......................................................................121 
4.1    Ephexin5 knockout mouse have increased spine density at P15 but not in adulthood.......131 
4.2    Reduction of Ephexin5 phosphorylation during postnatal brain development..................134 
4.3   Identification of Ephexin5 phosphorylation sites by mass spectrometry............................135 
4.4   Validation of p.S107/109 antibody......................................................................................137 
4.5   Serine-107/109 is reduced during postnatal brain development..........................................139 
4.6   Ephexin5 serine/threonine phosphorylation is critical for synapse restriction....................141 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ix 
 
List of Tables 
3.1    Clinical Summary of Proband G with Arhgef15 mutation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
x 
 
Acknowledgements 
 Many people have contributed to my dissertation work.  I am grateful to everyone that 
helped me scientifically and emotionally throughout this process. A number of these individuals 
were published collaborators and are acknowledged throughout my thesis or in the attributions 
section.  
 Most importantly, I would like to thank my thesis advisor Michael Greenberg for the 
constant support, encouragement and mentorship.  Mike has the amazing capability to pick me 
up when I am struggling and to let it ride when things are going well.  He recognizes my 
strengths and weaknesses better than anyone I have ever encountered, including people I have 
known my whole life, and he has continued to help me wrestle my demons both in science and in 
life.  I hope to continue my relationship with him scientifically and personally as I move through 
my career.  I also learned a number of things from Mike but most importantly, I learned when to 
use the phrase “a number of things.”  If I completed my PhD work in another lab, I would have 
probably said “an amount of things.”        
 I was fortunate to work very closely with three individuals during my time in graduate 
school.  I would like to thank Caleigh Mandel-Brehm for all the scientific and emotional support 
she provided throughout this process.  Seth Margolis mentored me during the first few years in 
the lab and taught me a tremendous amount about what it takes to make it in this business.  I also 
had the opportunity to mentor Asa Barth-Maron.  He has a bright future ahead of him and always 
keeps me on my scientific toes, occasionally to the point where I do not know who is mentoring 
whom.   
xi 
 
Shannon Robichaud, our lab manager, fielded more of my questions than everyone else 
in this acknowledgements section combined and somehow had an answer to every single one of 
them. Heartfelt thanks to fellow graduate student lab members Caleigh, Athar Malik, Nikhil 
Sharma, Milena Andzelm, Mike Soskis, and Alan Mardinly for providing a fun environment 
throughout the years and giving me thoughtful advice.  I would like to thank Milena and 
Harrison Gabel for helpful advice in the writing of this thesis.  Harrison has also been a great 
friend, mentor, and soccer teammate (although not such a great PS3 FIFA player). 
 PiN program chair Rick Born along with administrators Karen Harmin and Gina 
Conquest kept me on track throughout this process.  My Dissertation Advisory Committee 
members John Blenis, Beth Stevens, and Thomas Schwarz provided me with invaluable advice 
for which I am grateful.  I want to particularly thank Tom Schwarz for serving as my Thesis 
Defense chair and for being my first scientific mentor in Boston.  He gave me the opportunity 
eight years ago to work as a technician in his lab.  I learned a great deal from his endless supply 
of scientific knowledge and his thoughtful perspectives on life.  I would also like to thank my 
undergraduate advisor, Eric Haag, who sparked my interest in molecular biology and instilled 
confidence in my abilities.  In addition, thank you to Pascal Kaeser, Zhigang He, and Li-Huei 
Tsai for taking time out of their busy schedules to serve on my Defense committee. 
 I would like to thank Joanne Makredes for her thoughtfulness over the past ten months; 
she has always been there when I needed advice and inspiration, and I am grateful for her 
support.  Lastly my parents George and Eugenia Salogiannis provided their unwavering 
emotional and financial support throughout my years in graduate school.  They grew up without 
a formal education and I am eternally grateful for all the sacrifices they made to put me in this 
position.  Their work ethic and focus throughout life has been a constant source of inspiration.   
xii 
 
Attributions 
In Chapter 1, Figure 1.1 is from Tolias et al., 2011; Figure 1.2 is from Huveneers & 
Danen, 2009.  Figure 1.3 is from Govek et al., 2005. Figure 1.4 from Rossman et al., 2005; 
Figure 1.5 is from Sahin et al., 2005.  Figure 1.6 is from Yohe et al., 2008. 
Chapter 2 is re-formatted from “Margolis, S.S.*, Salogiannis, J.*, Lipton, D.M., 
Mandel-Brehm, C., Wills, Z.P., Mardinly, A.R., Hu, L., et al. (2010).  EphB-mediated 
degradation of Ephexin5 relieves a developmental brake on synapse formation. Cell 143, 442-
455.  *authors contributed equally to this work 
Chapter 2: Ephexin5 knockout mice were generated by Mustafa Sahin and Tam 
Thompson in the Children’s Hospital Boston core facility.  All immunostaining and dendritic 
spine assays were performed in collaboration with Seth Margolis, Zak Wills David Lipton.  
Dissociated culture physiology was conducted by Seth Margolis.  Acute slice physiology was 
performed by Caleigh Mandel-Brehm.  Ephexin5 and tyrosine-361 antibodies were generated by 
Linda Hu.  I performed all other cell biological, molecular, and biochemical assays under the 
supervision of Michael Greenberg.    
Table 3.1, and Figure 3.1 are re-formatted from “Veeramah, K.R., Johnstone, L., Karafet, 
T.M., Wolf, D., Sprissler, R., Salogiannis, J. et al (2013). Exome sequencing reveals new causal 
mutations in children with epileptic encephalopathies. Epilepsia 54(5).   
Chapter 3: Whole exome sequencing of Probands and de novo mutation identification 
were performed by Michael Hammer and colleagues at the University of Arizona.  Behavior 
experiments were performed in collaboration with Caleigh Mandel-Brehm.  I performed all other 
xiii 
 
experiments with technical help from Asa Barth-Maron and under the guidance of Michael 
Greenberg. 
Chapter 4: I generated phospho-specific antibodies in collaboration with Linda Hu.  Mass 
spectrometry was conducted at the Taplan Mass Spectrometry facility Harvard Medical School 
with technical help from Ross Tamaino.  I performed all other experiments in this chapter with 
technical help from Asa Barth-Maron and under the guidance of Michael Greenberg. 
1 
 
Chapter 1 
Introduction 
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The human brain endows us with the ability to perceive the world around us.  Its 
enormous capacity to store and compute information relies on the communication between 
highly interconnected networks of approximately 100 billion nerve cells (i.e., neurons) 
(Drachman, 2005).  The majority of this communication (i.e., neurotransmission) occurs at 
points of contact between two neurons known as synapses.  During development, our genome 
provides the blueprint for the formation of this interconnected network and the structure of 
synapses within the network.  Genetic mutations that perturb the growth of a synapse underlie 
neurodevelopmental disorders such as autism, epilepsy, and intellectual disability (Ebert & 
Greenberg, 2013).  A major focus of neuroscience research has been on the identification and 
characterization of genetic components that are critical for the development of a synapse. 
Excitatory synapses begin to form as early as embryonic day 16 (Konig et al., 1975) and 
continue to develop throughout postnatal life.  Dendritic spines (referred to as spines) are the 
sites of postsynaptic contact for the majority of excitatory neurotransmission in the brain.  Spines 
are protrusions rich in filamentous-actin (F-actin) that exhibit highly dynamic structural changes 
throughout development (Matus, 2005; Tada & Sheng, 2006).  During early postnatal 
development, they can appear as long, thin, and highly motile filopodia that can contact 
presynaptic axonal partners and initiate synaptic contact (Jontes & Smith, 2000).  This period is 
followed by the development of mature, mushroom-shaped spines that are either maintained or 
eliminated in adulthood.  In adulthood, dendritic spines can actively remodel in response to 
sensory-experience (Holtmaat et al., 2006; Matsuzaki et al., 2004).  All stages of postnatal 
synapse development involve the regulation of the actin cytoskeleton (Matus, 2005; Dillion & 
Goda, 2005).  Regulation of the actin cytoskeleton depends on a subset of small cytosolic G-
proteins called RhoGTPases, which are activated by Rho-family GEFs (RhoGEFs).  RhoGTPase 
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signaling and the RhoGEFs, including RhoA and the Ephexins, have been implicated in synapse 
development and disease (Govek et al., 2005; Rossman et al., 2005)  For these reasons, 
understanding GTPase signaling has been a major focus in neuroscience research.  This 
dissertation focuses on elucidating the mechanism of the RhoGEF Ephexin5, and its function in 
synapse development and disease.  
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1. 1 Synapse Development and the actin cytoskeleton 
Mature excitatory synapses are rich in F-actin    
 The mammalian excitatory synapse in the central nervous system is a specialized junction 
composed of a presynaptic axonal terminal (or bouton), and a postsynaptic dendritic spine that is 
separated by a synaptic cleft.  Mature dendritic spines are small (<2 µm) mushroom-shaped 
protrusions characterized by a head and a thin neck that contacts the dendrite at its base (Figure 
1.1; Tashiro & Yuste, 2004).  Excitatory synapses contain two types of actin, free actin 
monomers (G-actin) and filamentous actin (F-actin), whose equilibrium dictates the shape and 
size of pre- and post-synaptic compartments during development (Penzes & Cahill, 2012).  In the 
presynaptic terminal F-actin surrounds synaptic vesicle clusters and is present in the active zone 
where it may help regulate the availability of the reserve pool of synaptic vesicles (Dillion & 
Goda, 2005).  In the dendritic spine, F-actin is thought to play two key roles:  First, it tethers to 
the postsynaptic density (PSD), and regulates the stability of AMPA, NMDA receptors, and cell 
surface receptors (Allison et al., 1998; Penzes & Cahill, 2012).  Second, its assembly and 
disassembly plays a critical role in spine morphogenesis, which is required for the maturation of 
a functional mushroom-shaped spine.  
Postsynaptic filopodial protrusions are precursors to mature dendritic spines 
  Before the emergence of mature dendritic spines, the majority of dendritic protrusions 
are thin, long, and extremely motile filopodia (Dailey & Smith, 1996; Dunaevsky & Mason, 
2003; Tolias et al., 2012) that can grow and retract within minutes, a process that is blocked by 
the actin-polymerization inhibitor Cytochalasin-D.  (Fischer et al., 1998; Wong & Wong, 2000).  
Early work examining the movement of growing spines demonstrated that during growth and  
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Figure 1.1: Dendritic spines are enriched with actin 
Dendrite of a GFP-transfected neuron (green) indicating mushroom-shaped spine (top panel).  
Structure of a mature excitatory synapse (bottom panel): Presynaptic terminal contacting a 
postsynaptic dendritic spine with F-actin (Grey, crosslinks), postsynaptic density (PSD), and a 
complement of AMPA- and NMDA-receptors.  Image taken from Tolias et al., 2011. 
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retraction, filopodia contact axons (Ziv & Smith, 1996; Lohmann & Bonhoeffer, 2008).  These 
observations led to the hypothesis that filopodia sample their extracellular environment during 
early development, and are stabilized into mature dendritic spines via axo-dendritic contact 
(Jontes & Smith, 2000; Dunaevsky & Mason, 2003; Yuste & Bonhoeffer, 2004).  Such contact is 
a stochastic event in which some protrusions are stabilized and others removed (Berglund & 
Augustine, 2008).  Protrusions have a higher probability of becoming stabilized when they 
exhibit three characteristics: longer-lasting axo-dendritic contacts (more than an hour), contact to 
axons of excitatory neurons, and a display of an increase in the frequency of local calcium 
transients at the head of the filopodia (Lohmann & Bonhoeffer, 2008).  Stabilization of a 
protrusion leads to an increase in spine head width, and a concomitant reduction of spine length.  
Simultaneously, presynaptic vesicular packets (Ahmari et al., 2000; Zhai et al., 2001; Matus, 
2005), and postsynaptic clusters including the neurotransmitter subunits NR1, and scaffolding 
proteins PSD95 and Shank2/3 are delivered to nascent synaptic sites (Okabe et al., 2001; Ebihara 
et al., 2003; Bresler et al., 2004). The recruitment of pre- and postsynaptic components can occur 
within minutes (Bresler et al., 2004; Zito et al., 2009).  Adding latrunculin A, a toxin that 
prevents G-actin monomers from polymerizing with actin filaments, results in a loss of 
presynaptic markers bassoon and synaptophysin,  and also unhinges the postsynaptic density 
(PSD) (Zhang & Benson, 2001).  This suggests a critical role for actin in the recruitment and 
stabilization of components at a newly formed central synapse. 
Two modes of neuronal activity in spine motility and early synapse formation 
It is hypothesized that neuronal activity is dispensable for these early stages of excitatory 
synapse development (Verhage et al., 2000; Varoqueaux et al., 2003).  Mutations in mice that 
lack neurotransmitter release throughout embryonic development have normal neuronal 
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proliferation, migration, and differentiation.  Importantly, these neurons have the normal 
abundance of synaptic proteins and normal ultrastructure of excitatory synapses at embryonic 
day 18.  Since the mice die at an early age due to respiratory failure, the investigators cultured 
these neurons; the proper formation of excitatory synapses still occurred (Varoqueaux et al., 
2003).  This data suggested that the initiation of synapse development does not require neuronal 
activity.  Another study found that cerebellar Purkinje cells formed normal mature dendritic 
spines despite not having axonal innervation from cerebellar granule cells, their main source of 
presynaptic contact (Sotelo, 1991).  Of course in this latter study, Purkinje cells also lacked axo-
dendritic contact.  This implies that perhaps some neurons have cell-intrinsic differences in their 
ability to form a dendritic spine (Matus, 2005). 
   Some studies, however, offer alternative hypotheses to the filopodia-first, activity-
independent model of early synapse development.  In cortical pyramidal neurons, pulses of 
glutamate are sufficient to induce de novo spine formation (Kwon & Sabatini, 2011).  
Importantly, glutamate-induced spinogenesis did not go through a filopodial stage and was 
dependent on NMDAR (ligand-gated N-methyl-D-aspartate-type glutamate receptor)-activation 
of protein kinase A (PKA) signaling.   
In the brain in vivo depriving sensory stimulation reduced filopodia/spine motility in the 
somatosensory cortex but did not have any effect on their number or morphology (Lendvai et al., 
2000).  The reduced motility only occurred in a specific time window between rat postnatal day 
11-13 (P11-13), and not in young (P8-P10) or older (P14-P16) animals.  Other studies found that 
sensory deprivation in the visual cortex also led to reduced motility but no reduction in size or 
density (Majewska et al., 2003; Konur & Yuste, 2004).  The conclusion made from these studies 
is that although experience did not alter the growth of dendritic protrusions (i.e., spines and 
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filopodia), it served to rearrange synaptic connections critical for sensory maps later in life 
(Lendvai et al., 2000; Majewska et al., 2003).  Taken together, these data suggest that there are 
two distinct modes of early spine development: One mode may involve activity-independent 
filopodia that eventually transition into mature spines and the other may involve experience-
dependent motility during later phases of postnatal development (Matus, 2005). 
Activity-dependent synapse elimination 
  After the establishment of synaptic contacts, activity-dependent refinement is important 
for shaping a functional neural circuit.  During postnatal development, a subset of synapses are 
maintained and strengthened, while others are eliminated.  The best characterized model of 
mammalian synapse elimination is at the neuromuscular junction (NMJ) (Sanes & Lichtman, 
1999).  At central synapses, elimination has been extensively studied at the climbing fiber (CF) 
to Purkinje cell synapse (PC) in the cerebellum and at the retinal ganglion cell (RGC)-lateral 
geniculate nucleus (LGN) synapse in the thalamus (Kano & Hashimoto, 2009).  At the CF-PC 
synapse, weak synaptic inputs innervate a single PC within the first postnatal week.  During this 
time period, some CF-PC synapses become stronger, while others weaken.  By the third 
postnatal week, only one strong CF-PC synapse remains.  At the LGN synapse, as many as 20 
weak RGC inputs innervate the LGN during the first two weeks of postnatal development and 
only 1-3 remain after four weeks (Chen & Regehr, 2000).  In this case, spontaneous activity 
drives an early phase of synaptic refinement in the LGN and it is followed by a phase that is 
dependent on visual experience (Hooks & Chen, 2006). 
Mature dendritic spines are plastic and can undergo morphological changes in adulthood 
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 Long-term potentiation (LTP) leads to the formation of spines and the enlargement of 
preexisting spines (Matsuzaki et al., 2004; Tada & Sheng, 2005).  LTP-induced spine growth is 
blocked by drugs that inhibit actin dynamics (Matus, 2005).  In support of this, LTP induction 
leads to an increase in actin polymerization and selective recruitment of AMPA receptors to the 
stimulated spine in vivo (Fukazawa et al., 2003).  Conversely, long-term depression (LTD) leads 
to a reduction in spine turnover and spine shrinkage/retraction (Matus, 2005; Tada & Sheng, 
2005).  These data highlight the importance of the actin cytoskeleton on morphological plasticity 
during neuronal activity. 
 In vivo, spines are relatively stable in adulthood compared to postnatal development 
(Grutzendler et al., 2002; Trachtenberg et al., 2002).  Despite this, a subset still remains motile 
and can change their length within minutes.  One pioneering study investigated the role of 
prolonged sensory experience on the stability of spines in adulthood (Holtmaat et al., 2006).  
They found that prolonged whisker removal stabilized new spines in rat somatosensory cortex, 
and eliminated a subset of pre-existing spines.  Subsequent studies found that novel sensory 
experience and behavioral learning paradigms can induce the rapid formation of new stable 
spines, and the elimination of pre-existing spines (Xu et al., 2009; Yang et al., 2009; Roberts et 
al., 2010)   Importantly, in all these paradigms newly formed stable spines incorporated into the 
pre-existing circuit, suggesting that dendritic spines are a structural basis for memory storage.  
Synaptogenic organizers: EphB receptors and other cell adhesion molecules 
 Excitatory synapse development requires that an axonal growth cone reaches its target 
area and selects amongst a number of postsynaptic partners.  This is followed by a rapid growth 
and stabilization of pre- and post-synaptic elements.  Considerable effort has been made to 
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identify molecules that can coordinate both phases in this process (Brose, 2009).  Cell adhesion 
proteins have emerged as likely synaptogenic candidates for their ability to induce recruitment of 
synaptic markers and their capacity for bidirectional signaling into pre- and post-synaptic 
compartments (Dalva et al., 2007). 
   Neuroligin1 and 2 are postynaptically localized cell adhesion proteins.  When expressed 
in nonneuronal cells and co-cultured with neurons, they are able to induce morphological and 
functional presynaptic differentiation (Scheiffele et al., 2000).  Conversely, the neurexins, which 
are presynaptic adhesion proteins that bind neuroligins, are able to induce postsynaptic 
specializations (Graf et al., 2004).  Cell adhesion molecule pairs with synaptogenic activity 
include SynCAMs/Necls, EphB/EphrinBs, netrin G/NGL, and the LRRTM receptors (Dalva et 
al., 2007; Linhoff et al., 2009).   
Interestingly, EphB-receptor tyrosine kinases are not only critical for triggering 
synaptogenic organization, but also for regulating filopodial motility during early synapse 
formation (Kayser et al., 2008).  They can promote aspects of activity-independent and 
dependent synapse formation, suggesting that they are an ideal synaptogenic organizer (Dalva et 
al., 2000; Takasu et al., 2002; Henkemeyer et al., 2003; Dalva et al., 2007).   
Eph receptors are the largest family of receptor-tyrosine kinases and are characterized by 
an extracellular ligand (ephrin)-binding domain and an intracellular tyrosine kinase domain 
(Flanagan & Vanderhaeghen, 1998).   Ephs can be divided into two classes, EphA and EphB, 
based on their ability to bind the ligands EphrinA and EphrinB, respectively (reviewed in 
Flanagan & Vanderhaeghen, 1998). EphBs are expressed postsynaptically on the surface of 
developing dendrites, while their cognate ligands, the EphrinBs, are expressed on both the 
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developing axon and dendrite (Grunwald et al., 2004; Grunwald et al., 2001; Lim et al., 2008).  
During the initial stages of synapse development, the EphrinB/EphB interaction triggers a 
cascade of forward signaling events through the EphB receptor and a cascade of reverse 
signaling events through the ephrinB ligand, both of which are critical for promoting excitatory 
synapse development (Dalva et al., 2000).  The forward signaling pathway comprises two main 
signaling events: One is the activation of the EphB receptor tyrosine kinase and the second is the 
recruitment of a Src family member to an EphB and NMDAR complex that is independent of 
kinase activity (Flanagan & Vanderhaeghen, 1998; Dalva et al., 2000).  EphB-mediated 
NMDAR clustering at the developing post-synaptic specialization leads to the calcium-mediated 
phosphorylation of the RhoGEF, Tiam1, as well as other synaptic molecules critical for 
promoting dendritic spine and synapse maturation (Dalva et al., 2000; Tolias et al., 2005; Tolias 
et al., 2007; Dalva et al., 2007).  Forward signaling through the Eph tyrosine kinase domain can 
phosphorylate RhoGEFs and other molecules critical for actin remodeling and excitatory synapse 
development (Noren et al., 2004; Klein, 2009; also discussed in Section 1.4).  However, new data 
demonstrates that Eph-kinase activity is dispensable for excitatory synapse formation in 
dissociated cortical culture (Soskis et al., 2012).  This suggests that EphBs may only regulate 
early phases of synapse development through kinase-independent mechanisms perhaps through 
NMDARs or by recruitment of Src family kinases.  
Taken together, EphBs are synaptogenic factors important for promoting the development 
of excitatory synapses through three distinct domains: reverse signaling via Ephrin ligands into 
the presynaptic terminal, signaling via extracellular interactions with other membrane receptors, 
and tyrosine kinase signaling.  In Chapter 2 of this dissertation, we hypothesize that neurons 
might have evolved mechanisms to restrict EphB-mediated synapse formation.  Chapter 2 
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focuses on the characterization of an EphB-dependent signaling pathway that interacts with the 
RhoGEF Ephexin5 to regulate excitatory synapse development. 
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1.2  Rho GTPase signaling during synapse development 
 Given the prominent role of actin in all stages of synapse development, elucidating the 
function of RhoGTPase signaling has received much attention.  The mammalian Rho-family 
GTPases (RhoGTPases) consist of 22 members, which comprise a branch of the Ras superfamily 
of small (~21 kDa) cytosolic G-proteins (Schmidt & Hall, 2002).  GTPases are hydrolase 
enzymes that bind and hydrolyze guanosine triphosphate (GTP) (Schmidt & Hall, 2002).  
RhoGTPases are implicated in actin-dependent processes as diverse as endosomal trafficking, 
neurite outgrowth, cell morphogenesis, and synapse formation (Govek et al., 2005).  They have 
been described in two ways: classically activated and atypical (Heasman & Ridley, 2008).  12 of 
the 22 members are classically activated, acting as bi-molecular switches between an inactive 
GDP-bound form and an active GTP-bound form.  In contrast, atypical RhoGTPases are 
constitutively GTP bound and not thought to be regulated by GEFs.  Cycling between GDP- and 
GTP-bound forms of classically activated GTPases is catalyzed by three classes of regulatory 
molecules: GTPase activating proteins (GAPs), guanine nucleotide dissociation inhibitors (GDIs) 
and guanine-nucleotide exchange factors (GEFs) (Bos et al., 2007; Cherfil & Zhegouf, 2013).  
GAPs accelerate the intrinsic GTP hydrolysis from GTP to GDP, GDIs sequester the GDP-bound 
form away from the plasma membrane, and GEFs catalyze the exchange of GDP for GTP.  
Therefore, GAPs and GDIs effectively inhibit by promoting a GDP-bound GTPase, while 
RhoGEFs activate by promoting a GTP-bound form (Figure 1.2).   
Rac1, Cdc42, and RhoA are the most extensively studied RhoGTPases.  When activated 
in NIH 3T3 cells and other fibroblast cell lines, Rac1 induces lamellipodia (membrane 
ruffles),Cdc42 induces filopodia (micro-spikes) and RhoA induces stress fibers by actomyosin  
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Figure 1.2: GEFs, GAPs, and GDIs regulate GDP- and GTP-bound forms of GTPases 
Inactive GDP-bound and active GTP-bound forms of the small cytosolic G-proteins are regulated 
by three proteins: Guanine nucleotide exchange factors (GEFs) catalyze the exchange of GDP to 
GTP, GTPase-activating proteins (GAPs) accelerate the intrinsic hydrolysis of GTPases and 
promote GDP, and guanine-dissociation inhibitors (GDIs) sequester GDP-bound GTPases away 
from the plasma membrane.  Image taken from Huveneers & Danen, 2009.  
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filaments (Schmidt & Hall, 2002).  In the nervous system, these molecules regulate a number of 
neurodevelopmental processes including axon guidance, neuronal migration, dendritogenesis, 
and synapse development.  It is generally thought that Rac1 and Cdc42 promote these events, 
while RhoA restricts them. 
Once activated, RhoGTPases can sometimes translocate to the plasma membrane and are 
capable of recognizing downstream effectors important for actomyosin contractility, 
polymerization, and filament assembly (Figure 1.3; Michaelson et al., 2001; Govek et al., 2005).  
GTP-bound RhoA can bind and activate Rho kinase (ROCK), which subsequently 
phosphorylates myosin-light chain (MLC) and promotes actomyosin contractility.  Rac1 and 
Cdc42 promote actin nucleation and polymerization by activating and recruiting proteins such as 
PAK (p21-activated kinase), IRSp53, WASP, and Arp2/3.  Rho-signaling cascades also regulate 
gene expression.  For example, RhoA-signaling can turn on serum-response factor (SRF), a 
transcription factor that activates genes such as c-fos and Jun (Hill et al., 1995; Sotiropolous et 
al., 1999), leading to transciptional changes in cell morphogenesis.   
Since RhoGTPases are ubiquitously expressed (Hall, 1994), they rely on upstream 
regulators such as the GEFs and GAPs to activate or suppress their activity in a spatial, temporal 
and cell-specific manner.  It is hypothesized that these upstream activators dictate which 
downstream partners a particular GTPase will activate (ie., ROCK, mDIA, WASP).  This is 
likely due to compartmentalization or subcellular localization of the signals necessary to activate 
them.  At excitatory synapses, a variety of cell surface receptors, neurotransmitter receptors, and 
scaffolding proteins are capable of locally activating GTPases and their effector proteins to 
sculpt specific dendritic spines and synapses. 
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Figure 1.3: Rac1, Cdc42, and RhoA downstream signaling cascades 
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RhoA negatively regulates dendritic spine and excitatory synapse development 
In general, RhoA restricts (i.e., negatively regulates) the formation and maintenance of 
dendritic spines and synapses.  Initial studies ascertained this role by expressing a constitutively 
active (CA) form of RhoA (CA RhoA or RhoAV14) where the GTP is non-hydrolyzable 
(Tashiro et al., 2000; Nakayama et al., 2000; Pipel & Segal, 2004).  Overexpression of CA RhoA 
in cultured mouse and rat hippocampus reduces the density and length of dendritic spines on 
pyramidal neurons.  Addition of the ROCK inhibitor Y-27632 reversed this effect, suggesting 
that RhoA signals through ROCK to regulate spine formation (Nakayama et al., 2000).  This is 
likely due to the ability of RhoA-ROCK to induce actomyosin contractility (Govek et al., 2005)   
CA RhoA overexpression also causes a reduction in the colocalization of the presynaptic marker 
synaptophysin and postsynaptic marker spinophilin, indicating that overall excitatory synapse 
number is perturbed (Pipel & Segal, 2004).  Transfection of C3-transferase, a botulinum toxin 
that specifically inhibits the RhoA-subfamily proteins RhoA, RhoB, and RhoC, increases the 
density of immature filopodia, and results in increased dendritic spine length and width in the 
hippocampus (Tashiro et al., 2000; Nakayama et al., 2000). C3 and Y-27632 addition also 
increase the number of excitatory synapses in hippocampal cultures (Wills et al., 2012).  
However, there are conflicting reports on C3 and Y-27632’s effects on overall density of spines; 
some studies report a reduction, some report an increase, while others report no change (Tashiro 
et al., 2000; Nakayama et al., 2000; Pipel & Segal, 2004).  This discrepancy could be due to what 
is classified as a spine in these studies, differences in the duration of the manipulation or 
differences in the developmental age of the cultures (Govek et al., 2005).  In fact, Yuste and 
colleagues demonstrated that the age of the cultures can affect how cultures respond to C3 and 
Y-27632 (Tashiro et al., 2000; Tashiro & Yuste, 2004).   The discrepancies in spine/filopodial 
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densities observed in the C3 and Y-27632 could also be because of distinct Rho-dependent 
signaling events.  C3 inhibits RhoA while Y-27632 only inhibits the downstream effector 
ROCK.  It has been proposed that RhoGTPase signaling is responsible for distinct developmental 
events during spine development that may require different downstream mechanisms (Tashiro & 
Yuste, 2004).  In particular, there are two processes to highlight:  First, RhoA activation can 
restrict overall spine growth regardless of type during initial stages of spine development 
(Tashiro et al., 2000; Nakayama et al., 2000).  This is likely through Rho-ROCK-MLC-mediated 
actomyosin contractility.  Second, RhoA signaling actively deconstructs mature spines into 
immature filopodia during the maintenance phase of spine formation (Nakayama et al., 2000; 
Tashiro & Yuste, 2004).  In this scenario, the conversion of mature to immature spines would 
require actin polymerization along the length of the spine, and depolymerization along the width.  
This process could rely on the Rho-ROCK-LimK pathway, the Rho-DIA pathway, or Rho-
ROCK-MLC pathway (Shi et al., 2009; see Figure 1.3).  Both of these events are consistent with 
the observations that C3 and Y-27632 addition enhances the colocalization of pre- and post-
synaptic markers (Wills et al., 2012).  On the other hand, it is possible that RhoA coordinates 
with other GTPases to convert long immature spines into mature ones.  RhoA has been reported 
to promote certain aspects of spine development (Tashiro & Yuste, 2004; Pipel & Segal, 2004; 
Shi et al., 2009).   
Rac1 and Cdc42 promote mature spine formation in synapse development 
 The GTPases Rac1 and Cdc42 have been shown to promote the formation and 
maintenance of excitatory synapses, thus antagonizing the effects of RhoA.  Dominant-negative 
Cdc42 and Cdc42 RNAi inhibit spine formation (Irie & Yamaguchi, 2002; Wegner et al., 2008).  
Transgenic mice overexpressing constitutively active Rac1 (CA Rac1 or Rac1V12) in cerebellar 
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Purkinje cells have increased spine numbers, but a decrease in overall spine size (Luo et al., 
1996).  Subsequent studies using hippocampal cultures demonstrated that CA Rac1 enhances the 
number of lamellopodial-like ruffles or “mini-spines” (Tashiro et al., 2000; Nakayama et al., 
2000; Pipel & Segal, 2004).  These mini-spines often contained super-numerary synapses by 
electron microscopy and a concomitant upregulation of PSD95 to spines, which is consistent 
with Rac1 being a promoter of excitatory synapse number (Luo et al., 1996; Nakayama et al., 
2000).  When overexpressed in older cultures, CA Rac1 can also induce an increase in spine 
head size of more mature spines (Tashiro & Yuste, 2004).  Conversely, inhibition of Rac1 by a 
dominant-negative construct (DN Rac1) leads to a reduction in spine density and an increase in 
the number of long immature spines (Nakayama et al., 2000; Tashiro & Yuste, 2004).   
Real-time imaging of RhoA and Cdc42 activation during synaptic activity reveals the 
highly dynamic nature of GTPase signaling 
The preferential appearance and loss of individual spines during synapse development, 
and the observation that spines quickly respond to neuronal activity, suggests that signaling to 
the actin cytoskeleton is a relatively local process.  Work by Yasuda and colleagues examining 
the coordination of RhoA and Cdc42 signaling in mature neurons undergoing LTP at single 
spines in real time, recently demonstrated important aspects of activity-dependent spine 
dynamics (Murakoshi et al., 2011).  To induce LTP-dependent plasticity, they uncaged glutamate 
at single spines which resulted in an initial swelling of the spine volume up to 300%, followed by 
a sustained increase of about 75%  over the course of 30 minutes.  To visualize the 
spatiotemporal dyamics of RhoA and Cdc42 activity, they created a fluorescence resonance 
energy transfer (FRET)-based sensor consisting of a mEGFP-tagged GTPase and an mRFP 
tagged effector.  RhoA and Cdc42 activity increases rapidly within a minute of stimulation, 
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decayed over 3-5 minutes, and sustained for 30 minutes, a profile reminiscent of the 
morphological changes in LTP-induced spines.  However, the spatial profiles of the two 
GTPases differed; whereas Cdc42 was compartmentalized within the spine and persistently 
activated, RhoA diffused out of the spine and spread out along the dendrite.  Inhibition of Rho 
proteins with C3-transferase as well as inhibition of ROCK reduced both the transient and 
sustained phases of spine growth.  Interestingly, Cdc42 and downstream Pak1 inhibition only 
reduced the sustained phase of spine growth.  This suggests that RhoA can initiate enhanced 
spine growth in mature neurons but coordinates with Cdc42 to sustain this increase.    
Taken together, these data highlight the importance of GTPase signaling in all stages of 
synapse development and the importance of local biochemical signaling on regulating local 
synaptic morphogenesis.  It also illustrates that there is significant cross-talk between the RhoA, 
Rac1 and Cdc42 pathways, which can make it difficult to ascribe a specific GTPase signaling 
cascade to a particular biological process (see Figure 1.2).  For example, EphB-receptors 
activate focal-adhesion kinase signaling through a RhoA-ROCK-LimK pathway thought to be 
critical for actin polymerization and spine growth (Shi et al., 2009).  However, this result is 
difficult to interpret because EphBs can activate Rac1/Cdc42-dependent pathways as well, and 
implies there is significant cross-talk between GTPases downstream of Eph signaling.  For these 
reasons, a major research focus in GTPase signaling is in understanding how upstream activators 
of GTPases, the RhoGEFs can influence signaling at the synapse.   
 
 
 
21 
 
1.3  RhoGEFs: Mechanism and Regulation  
 Given the important role for RhoGTPases in regulating the morphogenesis and dynamics 
of dendritic spines it is important to understand the molecular mechanisms that lead to the 
activation and suppression of these signaling molecules.  Since RhoGTPases are ubiquitously 
expressed (Hall, 1994), they rely on upstream regulators such as the GEFs and GAPs to regulate 
their activity in a spatial, temporal and cell-specific manner.  The majority of studies elucidating 
the mechanisms of RhoGTPases during synapse development use constitutively active, dominant 
negative constructs, or pan-inhibitors.  These approaches are problematic because they can 
sequester key activators/inhibitors within the cell, and they may activate indirect pathways not 
required for synapse development.  There is also evidence suggesting that precise balance 
between GTPases is critical for proper spine morphogenesis (Murakoshi et al., 2011; Penzes & 
Cahill, 2012).  In fact, prolonged Rac1 activity in vivo can inhibit spine morphogenesis instead of 
promoting it.  Therefore, it may be necessary for GTPases to properly cycle between GDP- and 
GTP-bound states in these hyperactivation paradigms (Hayashi-Takagi et al., 2010).  For these 
reasons, recent research has focused on the regulators of GTPase signaling, most notably, the 
guanine nucleotide exchange factors.    
The Rho-family GEFs are critical for activating the Rho-family GTPases by catalyzing 
the exchange of GDP for GTP.  There are 2 classes of GEFs in mammals: 69 members 
containing a Dbl-homology (DH) domain and 11 members containing a Dock-Homology Region 
(DHR) (reviewed in Cote & Vuori, 2007).  The DH-containing GEFs have been studied in 
greater detail than the DHRs.  Since the focus of the dissertation is on the DH-containing GEF, 
Ephexin5, I will only highlight literature pertaining to this subclass of GEFs.   
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 RhoGTPases including Cdc42, RhoA, and Rac1, are regulators of the actin cytoskeleton, 
gene transcription and cell-cycle progression (Heasman & Ridley, 2008).  Consequently, 
RhoGEFs have been implicated in diverse cellular processes including cell adhesion, migration, 
growth, survival, and polarization (Schmidt & Hall, 2002).  In the nervous system they are key 
regulators of neurite outgrowth, axon guidance, growth cone dynamics, and synapse 
development.  Not suprisingly then, perturbations in RhoGEF signaling is prevalent in a diverse 
set of diseases such as human cancers, skeletal malformations, intellectual disability and viral 
pathogenesis (Newey et al., 2005). 
History of RhoGEFs 
 The first RhoGEF, Dbl, was isolated from a human B-cell lymphoma line in a screen for 
transformation activity in NIH 3T3 cells (Eva & Aaronson, 1985).  Dbl contains a region of 
homology to the yeast protein Cdc24Sc, previously shown to interact with the GTP-binding 
protein Cdc42Sc (Ron et al., 1991).  A putative function for the Cdc24Sc/Cdc42Sc interaction 
was first described when Dbl was shown to stimulate the dissociation of GDP from Cdc42 (Hart 
et al., 1991).  The region of homology between Cdc24Sc and Dbl was subsequently termed the 
Dbl (DH) homology domain.   The DH domain is invariably followed by an adjacent Pleckstrin 
homology (PH) domain which is can regulate cellular targeting and in some cases, modulate 
enzymatic activity.  The tandem DH-PH domain is considered the minimal structural unit 
required for RhoGEF exchange activity in vivo.  There are 69 DH-containing mammalian genes 
and only 12 classically hydrolyzing RhoGTPases (Heasman & Ridley, 2008).  At first glance this 
~6 to 1 ratio seems redundant and unnecessary.  Research over the past decade however, 
indicates that RhoGEFs have differential selectivity for GTPases, they differ in their spatial and 
temporal expression, and they can be activated by a variety of extracellular cues.  These diverse 
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modes of regulation lead to tight control of RhoGTPase function, the actin cytoskeleton, and 
cellular morphogenesis.   
Mechanism of catalytic GEF exchange   
 GEFs catalyze the release of GDP bound to small GTPases.  The affinity of GDP/GTP 
for a GTPase is extremely high, and without GEFs the release of GDP would be in the range of 
hours, not the minutes required for effective signaling in vivo. Due to the higher intracellular 
ratio of GTP:GDP, rebinding of a new nucleotide favors GTP.  Thus the activity of the GEFs to 
remove GDP serves to replenish GTP active forms of GTPases and promote G protein mediated 
activity. 
Crystal structures of either RhoGEFs alone or GEF-bound to their cognate GTPases 
clarified how this mechanism works (Aghazadeh et al., 1998; Liu et al., 1998; Soisson et al., 
1998; Snyder et al., 2002; reviewed in Rossman et al., 2005).  The DH domain causes a 
conformational change in two GTPase regions (switch 1 and switch 2) that subsequently eject the 
bound nucleotide (Bos et al., 2007).  The DH domain comprises a bundle of 10-15 alpha-helices 
containing three highly conserved regions (CR1-CR3) and other critical C-terminal residues 
termed the “seat-back” region.  CR1/CR3 regions extensively contact the switch 1 region of the 
GTPase, while the CR3/seat-back regions contact switch 2 and a variable GTPase interface 
located between the switch regions (Figure 1.4; Rossman et al., 2005).  Mutations in CR1/CR3 
of Dbl and other RhoGEFs will abolish all catalytic activity (Zhu et al., 2000).   
GEF selectivity in vitro 
Although RhoGEFs utilize the CR1/CR3 domains via similar mechanisms, studies have 
shown that the highly variable seat-back/GTPase interface dictates GEF-selectivity towards  
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Figure 1.4: Dbs exchange factor in complex with Cdc42 
Dbs DH domain (yellow) and PH domain (blue) contacting the GTPase interface of Cdc42 
(green).  CR1 and CR3 regions (magenta) contact switch 1 (S1) and switch 2 (S2) regions (red) 
of Cdc42.  Also the “seat-back” region (gray outline) forms complementary interfaces with 
Cdc42 and is responsible for selectivity.  Image taken from Rossman et al., 2005.  In Chapter 2, 
we abolished GEF activity with a mutation in Ephexin5 that specifically targeted the CR3 region.  
In Chapter 4, we suggest that an epilepsy mutation may disrupt the integrity  of the DH-PH 
structure. 
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specific GTPase family members (Cheng et al., 2002; Snyder et al., 2002).  For example, FGD1 
and Intersectin are specific to Cdc42 (Zheng et al., 1996; Snyder et al., 2002).   Lfc and Lbc are 
RhoA specific (Glaven et al., 1996).  Tiam1 and Trio preferentially activate Rac1 (Rossman et 
al., 2005).  Vav1, Vav2, and Ephexin1 are able to activate RhoA, Rac1, and Cdc42 (Abe et al., 
2000; Sahin et al., 2005).  Dbl and Dbs can activate RhoA and Cdc 42, but not Rac1.  Numerous 
studies have demonstrated that mutations in the seat-back regions can alter GEF selectivity 
(Cherfils & Zhegouf, 2013).For instance, structure/function mutagenesis of the Dbs seat-back 
region altered its GEF activity by keep the RhoA interaction intact while abolishing Cdc42 
activity, and vice-versa (Snyder et al., 2002; Cheng et al., 2002).  The RhoA interface contains a 
glutamic acid (Glu-54) that interacts with a basic residue at Lys-758 of Dbs.  In contrast to 
RhoA, Cdc42 contains a threonine (Thr-52) at the equivalent site, which is not predicted to 
engage Lys-758.  The contact between Lys-758 and Glu-54, but not Thr-52, would suggest that 
the Lys-758 interaction is only important for RhoA.  Indeed, mutating this residue (K758A) 
alters Dbs-activation of RhoA, but not Cdc42 (Snyder et al., 2002).  Similar approaches were 
used for the Cdc42-specifc RhoGEF Intersectin.  By mutating two residues (G1368L/M1369L) 
in the seat back region, Intersectin ectopically activated RhoA (Snyder et al., 2002).   
While previous data demonstrates that the DH domain, specifically CR1, CR3, and the 
seat-back regions, are necessary for GEF exchange and selectivity, most of these studies 
elucidating the mechanisms of GEF activity were conducted in cell-free in vitro assays.  
Additional complexity arises when GEFs are expressed in mammalian cells.  Discrepancies have 
been reported between in vitro activity and activity in mammalian cells (Schmidt and Hall, 
2002).  For example, Tiam1 can activate Rac1, Cdc42, and RhoA in vitro but only Rac1 in the 
cell.  There are few potential reasons for this discrepancy: First, activation in vitro is measured 
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within minutes after GEF addition, compared to a cell transfection, which measures the 
activation after a couple of days.  Second, due to technical issues with recombinant protein 
purification, most in vitro assays are conducted with truncated forms of the GEF, many times 
with just the DH-PH domains.  As discussed below, other modular domains are critical for 
regulating the DH-PH domain.  Third, RhoGEFs display significant diversity in protein 
functional domains, which can contribute to cell-intrinsic regulation and signaling.  In these 
cases, protein interactions and upstream activation via posttranslational modification can alter the 
specificity of GEF activity.   
Taken together, studies in vitro have provided invaluable insight into how the 
GEF/GTPase complexes form and how GEF selectivity is occurs.  It is clear, however, that GEFs 
require more than their core catalytic activity to achieve cellular specific functions.  
Complementary approaches in vivo should help clarify GEF specific regulatory mechanisms that 
fine tune this core catalytic activity. 
PH domain regulation 
 The majority (~95%) of RhoGEFs contain a PH-domain adjacent to the DH-domain.  
RhoGEFs utilize the PH domain in a variety of ways.  Traditionally they are known for binding 
to phosphoinositides (PIPs) (Haslam et al., 1993).  It is proposed that a major function of the PH 
domain is to target the RhoGEF to the plasma membrane, as well as to anchor the DH domain in 
proper orientation for GEF activation.  In certain cases, PH domain deletions result in loss of 
NIH 3T3 fibroblast transformation activity (Rossman et al., 2005; Cherfils & Zhegouf, 2013).  In 
the cases of Sos1, Tiam1, and Vav however, the PH domain is not sufficient for cellular targeting 
and RhoGEFs may rely on other protein domains for this function (Snyder et al., 2001).  In these 
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instances, the PH domain may serve a modulatory role for additional membrane anchoring or for 
allosteric interaction (Rossman et al., 2005).  It is also possible that they directly function in 
catalytic exchange.  In support of the latter, some bacterially expressed DH-PH domains have 
enhanced GEF activity compared to the DH alone (Rossman & Campbell, 2000).  In fact, Dbs 
and Sos both utilize their PH domains for catalytic exchange, albeit by different mechanisms.  
The PH domain of Dbs directly contacts Cdc42 and RhoA (Rossman et al., 2002; Snyder et al., 
2002).  In the case of Sos1, the PH domain binds to the seat-back region and occludes Rac1 
binding (Sondermann et al., 2004).  While there is no rule of thumb that guides PH signaling, the 
activity is indispensable in many if not all cases, thus the DH/PH tandem is considered the 
minimal structural unit required for GEF activity in vivo.   
Other modes of regulation 
 Outside of the DH/PH domains, RhoGEFs display significant diversity in protein 
functional domains (Schmidt & Hall, 2002).  RhoGEFs such as the Ephexins, and Vavs contain 
Src-homology domain 2 and 3 (SH2 and SH3) and PDZ domains, which contribute to subcellular 
targeting and diverse protein-protein interactions.  Sos, RasGRF2, and Aslin also contain 
additional GEF domains that confer catalytic exchange selectivity towards other Ras superfamily 
GTPases including Ras and Ran.  Dual function RhoGEFs such as Kalirin, Trio and BCR contain 
serine/threonine kinase domains.  Taken together, diverse functional domain couple RhoGEFs to 
specific upstream and downstream signaling pathways (reviewed in Rossman et al., 2005). 
 One common mode of regulation is autoinhibition of GEF activity from regions outside 
the DH-PH domain, usually near the N-terminus.  N-terminal truncations of some RhoGEFs 
including Vav1, Ephexin1, TIM, Tiam, Ect2, Asef, and Sos1 leads to constitutive activation of 
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GEF activity (Schmidt & Hall, 2002).  C-terminal truncations in p115RhoGEF and Lbc also lead 
to constitutive activation.  In most of these cases, it is hypothesized that relief of autoinhibition 
occurs via posttranslational modifications such as phosphorylation, or intermolecular protein 
binding.  In most cases, however, mechanistic analysis demonstrating how this occurs has not 
been performed (Bos et al., 2007). 
 TIM, Asef, and Intersectin are autoinhibited by SH3 domains that bind directly to the DH 
domains or in nearby regulatory sequences (Yohe et al., 2008; Cherfils & Zhegouf, 2013).  In the 
case of Intersectin, a neuronally expressed Cdc42-specifc GEF involved in the formation of 
clathrin-coated vesicles, the relief of SH3-autoinhibition may occur by the binding of N-WASP 
in vivo (Hussain et al., 2001; Tsyba et al., 2011).  A similar mechanism has also been proposed 
for the Ephexin family member TIM (discussed in Section 1.6).  
 Probably the best characterized mechanism of autoinhibition comes from the RhoGEF 
Vav.  The Vav family consists of three proteins, Vav1, Vav2, and Vav3 that can activate Cdc42, 
Rac1, and RhoA (Rossman et al., 2005).  N-terminal truncations lead to cellular transformation 
in fibroblasts (Katsav et al., 1989).  Vav signaling is involved in the development of immune 
cells, the nervous system, and hematopoietic cells (Bustelo et al., 2001; Cowan et al., 2005).  
They contain eight domains: calponin homology (CH), acidic (Ac), DH/PH domains, Zinc 
Finger (ZF), SH2, and two SH3 domains.  Deletion of the Ac or CH domains on the N-terminus 
of Vav1 enhances its GEF activity (Katsav et al., 1989; Bustelo, 2001; Yu et al., 2010).   
Structural studies demonstrate that the Ac domain binds to the DH active site and blocks GTPase 
binding (Abe et al., 1999; Yu et al., 2010).  Subsequently, the CH domain contacts both the Ac 
and DH domain and enhances Ac/DH repression.  Rosen and colleagues suggest a stepwise relief 
of this autoinhibition (Yu et al., 2010).  The CH domain is phosphorylated at residues Tyr-142, 
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and Tyr-160, which removes contact from the Ac/DH domains.  This event leaves Vav more 
accessible to Src- and Syk-family kinases, which are now able to phosphorylate the Ac domain at 
Tyr-174 and remove the Ac/DH interaction.  This multidomain mechanism could ensure that 
GEF activity is generally repressed within the cell, only to be activated in specific subcellular 
locales that contain the signaling components necessary for activation.  A similar step-wise 
activation model has been proposed for the Ephexins (see Section 1.6). 
 In an interesting study, Yeh et al. demonstrated that autoinhibition of the DH domain can 
be used modularly to regulate the GEF activity of heterologous proteins (Yeh et al., 2007).  They 
took the DH-PH domains of five different RhoGEFs including the Cdc42-specific Intersectin and 
the Rac1-specific Trio, and synthesized new autoinhibitory domains.  By fusing a DH-PH 
domain to an N-terminal PDZ domain and a C-terminal kinase recognition site, they were able to 
introduce a new regulatory activity to the fusion protein, allowing for modulation the newly 
synthesized GEF by protein kinase A (PKA).  They added the PKA activator forskolin to 
fibroblast cells overexpressed with the GEF, and were able to artificially induce lamellopodial 
ruffling and filopodial spikes.  This suggests that protein domains in the RhoGEFs evolved a 
flexible, combinatorial framework to function in a variety of cellular environments, and that a 
range of regulation has been acquired based on which regulatory module is linked to the DH-PH 
domains. 
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1.4  RhoGEFs during synapse development 
Excitatory synapses contain a variety of cell surface receptors, neurotransmitter receptors, 
and scaffolding proteins capable of transducing extracellular stimuli into intracellular signaling 
(Nimchinsky et al., 2002).  Section 1.1 – 1.3 outlined how excitatory synapses are dynamic 
throughout development and are regulated by changes in the actin cytoskeleton.  GTPases, 
critical mediators of the actin cytoskeleton play an important role in synapse development:  
Cdc42 and Rac1 promote aspects of excitatory synapse development, while RhoA restricts this 
process (Penzes & Cahill, 2012).  Since GTPases are ubiquitously expressed throughout the cell 
and since their functions involve many cytoskeletal processes including dendritogenesis, neurite 
outgrowth andendosomal trafficking, it is hypothesized that the RhoGEFs provide the 
spatiotemporal activation required for local GTPase signaling (Tolias et al., 2011).  Section 1.4 
suggested GEFs rely on a variety of protein functional domains for GEF activation and 
regulation.  At the synapse, they respond to a diverse set of extracellular cues critical for 
dendritic spine morphogenesis and excitatory synapse development.  RhoGEFs have differential 
expression patterns in the brain and somewhat nonoverlapping roles during the activity-
independent and activity-dependent phases of synapse development. This suggests that they are 
the good candidates for spatial and temporal refinement of the actin cytoskeleton during synapse 
development (Tolias et al., 2011).  Below is a summary of synaptic RhoGEFs, their function, and 
regulation during synapse development.  
Rac1-specific GEFs Kalirin-7 and Tiam1 promote synapse development 
Kalirin-7 is a Rac1-specific GEF that promotes spine and excitatory synapse 
development in the cortex and hippocampus (Penzes et al., 2001; Cahill et al., 2009).  It localizes 
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to the dendritic spine where it interacts with PSD proteins including PSD95 and SAP102 via its 
PDZ-domain (Penzes et al., 2000; Penzes et al., 2001).  EphB2- and N-cadherin-dependent 
clustering of Kalirin-7 is required for spine morphogenesis (Penzes & Cahill, 2012).  Three 
pieces of evidence suggest that Kalirin-7 functions predominantly during the activity-dependent 
phase of excitatory synapse formation (Penzes & Cahill, 2012).  First, Kalirin-7 protein 
expression begins around P10-P15 after many activity-independent processes have already taken 
place.  Second, NMDA-stimulation induces calcium-dependent phosphorylation and this event is 
required for spine enlargement, but not spine formation (Xie et al., 2007).  Third, early excitatory 
synapse development appears normal in Kalirin-7 knockouts, are only defective after 3 weeks in 
cortical culture (Cahill et al., 2009). 
Similar to Kalirin-7, the Rac1 GEF Tiam1 also promotes excitatory synapse number, and 
is required for EphB- and activity-induced spine morphogenesis (Tolias et al., 2005; Tolias et al., 
2007).  EphB-tyrosine phosphorylation of Tiam1 at Tyr-829 enhances its Rac1 activation and 
provides a link between Eph-receptor signaling and excitatory synapse development (Miyamoto 
et al., 2006; Tolias et al., 2007).  In the case of Tiam1, it is not clear whether it functions in early 
or later phases of synaptic development.  Given that it is expressed much earlier in brain 
development than Tiam1 (Tolias et al., 2005) its intriguing to speculate that they activate Rac1 
during nonoverlapping phases of synapse development. 
β-Pix and Intersectin promote synapses on opposite sides of Eph-signaling  
Intersectin is a Cdc42-specific GEF that interacts with N-WASP to regulate EphB-
dependent signaling (Irie & Yamaguchi, 2002).  β-Pix is a Cdc42/Rac1 GEF that localizes to the 
synapse and complexes with the scaffolding protein GIT1 (Tolias et al., 2012).  Similar to 
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Kalirin-7, Tiam1, and intersectin, β-Pix is dynamically phosphorylated in response to NMDAR-
stimulation (Tolias et al., 2011).  Unlike them however, β-Pix seems to play a role in EphrinB-
reverse signaling where it regulates EphrinB presynaptic signaling (Klein., 2009).  This suggests 
that postsynaptic EphB signaling through Rac1 and Cdc42 require Tiam1, Intersectin, and 
Kalirin-7 whereas presynaptic differentiation requires β-Pix. 
RhoA-specific GEFs Lfc, Ephexin1, and Ephexin5 restrict excitatory synapse development 
 Lfc is a RhoA-specific GEF that is highly expressed in the PSD and dendrite (Ryan et al., 
2005; Kang et al., 2009).  When overexpressed, Lfc activates RhoA in neurons and reduces the 
size and density of dendritic spines (Ryan et al., 2005; Kang et al., 2009).  There are two 
conflicting reports on the how it achieves this: One model suggests that activity induces 
dendritically localized Lfc to the spine and the other model suggests that it is poised at the PSD 
Nonetheless, one key feature is consistent: Lfc restricts activity-dependent spine morphogenesis 
(Ryan et al., 2005; Kang et al., 2009).  This finding suggests that Lfc is a molecular mechanism 
required to fine-tune synaptic structure during bouts of neuronal activity.   
RhoA-GEFs Ephexin1 and Ephexin5 also negatively regulate spine and synapse 
formation in the hippocampus (Fu et al., 2007; Margolis et al., 2010; also see Chapter 2 and 4).  
Section 1.5 discusses Ephexin subfamily of RhoGEFs and their mechanisms in greater detail.  
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1.5   The Ephexin family 
The murine Ephexin (Eph interacting exchange protein) subfamily of RhoGEFs consists 
of five members (Shamah et al., 2001; Rossman et al., 2005) (Figure 1.5).  They are expressed 
in a wide range of tissues including heart, lung, brain and a variety of human cancer cell lines 
(Sahin et al., 2005; Xie et al., 2005).  Ephexin1 is predominantly expressed in the brain and 
muscle.  Ephexin2, Ephexin3, and Ephexin4 are expressed in the lungs, intestine and kidney 
(Sahin et al., 2005).  Ephexin5 is the only other member highly enriched in the brain, but is also 
expressed in the heart, kidney, lungs, and endothelial cells (Okita et al., 2003; Sahin et al., 2005; 
Takase et al., 2012).  The Ephexins are characterized by a tandem DH/PH/SH3 domain and are 
intimately tied to Eph receptor signaling through known Eph dependent phosphorylation and 
interaction (Sahin et al., 2005; Xie et al., 2005; Fu et al., 2007; Yohe et al., 2008).  Therefore, the 
Ephexin family could link upstream Eph receptor signaling, and perhaps receptor tyrosine 
kinases in general, to downstream actin-mediated cell morphogenesis.  In addition, variability in 
the length and primary sequence of the N-terminus may dictate specificity to a particular receptor 
subclass, or it may dictate differential intramolecular regulation of GEF activity.  Thus while 
initial studies of the Ephexin family of GEFs have given basic mechanistic insight into how they 
function, further study of the Ephexin subfamily is needed to understand possible mechanisms 
and functions for this diverse and important subfamily of GEFs. 
Ephexin1/NGEF 
 Ephexin1 (human homolog called NGEF) is a central mediator that links EphA signaling 
to actin dynamics (Shi et al., 2010).   Ephexin1/Ngef was first characterized and cloned from an 
adult mouse brain cDNA library (Rodrigues et al., 2000).  It was found to be highly enriched in  
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Figure 1.5:  The murine Ephexin family of RhoGEFs  
Ephexin family contains tandem DH/PH/SH3 domains and N-termini of variable length. Dbl-
homology = DH,  Pleckstrin homology = PH, Src-homology 3 = SH3.  Pink bar indicates 
conserved tyrosine phosphorylation site (Sahin et al., 2005).  
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the brain, specifically in the caudate nucleus, hippocampus, and amygdala.  In preliminary 
experiments, Rodrigues et al. demonstrated that Ephexin1 has transformation potential in 
NIH3T3 fibroblasts presumably via its DH/PH domain.   
A better understanding of Ephexin1 signaling came when it was identified in a systematic 
yeast-two hybrid screen searching for cytosolic interacting partners with the EphA4 receptor 
tyrosine kinase (Shamah et al., 2001).  EphA4 signaling induces growth cone collapse in 
developing neurons,  which is important for proper guidance of axonal tracts during development 
(Frisen et al., 1999).  Under baseline conditions, Ephexin1 can activate RhoA, Rac1, and Cdc42.  
However, upon EphA4-induced tyrosine phosphorylation, Ephexin1 increases its activation 
towards RhoA and decreases its preference for Rac1/Cdc42 (Shamah et al., 2001; Sahin et al., 
2005).  In this way, Ephexin1 links upstream EphA4 signaling to downstream RhoA-mediated 
actin dynamics and axonal pathfinding.   
A similar mechanism occurs during synapse development both in the hippocampus and 
neuromuscular junction (NMJ).  EphA4-mediated dendritic spine retraction in the hippocampus 
requires Ephexin1 (Fu et al., 2007).  Specifically, EphA4 induces the tyrosine phosphorylation 
and recruitment of cyclin-dependent kinase 5 (Cdk5), a process that enhances Cdk5’s kinase 
activity (Zukerberg et al., 2000).  In turn, the EphA4/Cdk5 complex enhances the GEF activity 
of Ephexin1 via Cdk5-dependent phosphorylation (Fu et al., 2007).   
 At the NMJ, post-synaptic Ephexin1 induces RhoA-mediated dissociation and 
disassembly of acetylcholine receptor clusters from the actin cytoskeleton (Shi et al., 2010).  
This process can be stimulated by EphA receptors and it requires Ephexin1 phosphorylation.  In 
support of this finding, Ephexin1 knockout mice have altered NMJ morphology, impaired NMJ 
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synaptic transmission, and exhibit severe muscle weakness.(Shi et al., 2010).  At the Drosophila 
NMJ, pre-synaptic Ephexin modulates homeostatic vesicle release by activating Cdc42 
downstream of pre-synaptic Eph receptors (Frank et al, 2009).  In the latter case, the mechanism 
is difficult to discern because there is only one Ephexin family member in Drosophila and there 
is no distinction between EphB or EphA receptor subclasses.  Nonetheless, it suggests that the 
link to Eph receptor signaling may be conserved across species. 
Ephexin2/WGEF/Arhgef19 
 Ephexin2 (human homolog called WGEF) has GEF activity towards RhoA and Cdc42, 
and can induce stress-fiber and filopodial formation, respectively (Wang et al., 2004; Smith et 
al., 2005).  Similar to Ephexin1, the RhoA activity of WGEF can be induced by Src- and EphA4-
mediated phosphorylation (Yohe et al., 2008).  The literature on WGEF/Ephexin2 is sparse, but 
it suggests that WGEF may play a role earlier in development than other Ephexin members, 
perhaps during cell differentiation.  For example, it was shown to complex with Dishelleved and 
Frizzled-7 receptor in the Wnt-mediated planar cell polarity pathway during notochord 
development in Xenopus embryos (Tanegashima et al., 2008).  In addition, the genomic locus of 
WGEF was shown to be de-methylated during adipocyte differentiation, but its role in this 
process is unclear (Horii et al., 2009).   
Ephexin3/TIM/Arhgef5 
 Ephexin3 (human homolog called TIM) was isolated from a human mammary epithelial 
cell cDNA library that was screening for novel oncogenes with transforming activity in NIH3T3 
cells (Chan et al., 1994).  TIM only activates the RhoA subfamily of GTPases (RhoA, RhoB, 
RhoC) in vitro, but seems to also have some activity towards Cdc42 and Rac1 when 
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overexpressed in vivo in a mammalian cell line (Yohe et al., 2007; Xie et al., 2005; Debily et al., 
2004).  Interestingly, five truncating isoforms of TIM are specifically upregulated in breast 
carcinoma cell lines.  Some of these variants seem to only have GEF activity towards 
Cdc42/Rac1, and do not seem to activate RhoA-induced stress fibers in these cells (Debily et al., 
2004).  It is possible that the discrepancy over which GTPases TIM can activate may be due to 
the specific isoform of TIM being expressed in each experiment and/or cell-type specific 
signaling of the cell line used in each experiment.   
Ephexin4/Neuroblastoma/Arhgef16 
 Ephexin4 (human homolog known as Neuroblastoma or Arhgef16) activates Cdc42, but 
not Rac1 or RhoA in vitro (Oliver et al., 2011).  Interestingly, Ephexin4 is the only member that 
does not activate RhoA in vitro or in a cell-line.  In addition, unlike TIM, Ephexin4 activates 
RhoG, a Rac subfamily GTPase that acts upstream of Rac1 (Hiramoto-Yamaki et al., 2010).  
Ephexin4 complexes with EphA2 in breast-cancer cells and activates RhoG,  This process 
recruits a Dock-family GEF, DOCK4, that is capable of activating Rac1 (Hiramoto-Yamaki et 
al., 2010; Harada et al., 2011).  Through this mechanism, Ephexin4 is thought to be a central 
mediator of EphA2-dependent cell migration in breast cancer cells. 
Ephexin5/Arhgef15/VsmRhoGEF 
 Aside from Ephexin1, Ephexin5 (human homolog known as Arhgef15 or VsmRhogef) is 
the only other Ephexin member highly expressed in the brain (Sahin et al., 2005).  VsmRhoGEF 
is necessary for EphA4-mediated RhoA activation and stress fiber formation (Ogita et al., 2003).  
ARHGEF15/Ephexin5 was also shown to be required for VEGF-induced Cdc42 activation, 
although these effects were modest (Kusuhara et al., 2012).  At the initiation of my dissertation 
work, the biological roles and underlying mechanisms of Ephexin5 were not well understood.  
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Bimodal regulation by N-terminal autoinhibition and tyrosine phosphorylation  
The activity of the ephexin family of GEFs towards RhoA and Cdc42 GTPases can be 
activated by Eph and Src family tyrosine kinases.  How might tyrosine phosphorylation modulate 
the Ephexins?  EphA4 phosphorylation of Ephexin1 at tyrosine 87 (Y87) enhanced its activity 
towards RhoA (Sahin et al., 2005).  Interestingly, truncating Ephexin1’s N-terminus (including 
Y87) activated RhoA to a similar extent as a phosphorylated, full-length Ephexin1.  This 
suggested that the N-terminus of Ephexin1 serves as an auto-inhibitory constraint on its GEF 
activity and tyrosine phosphorylation might be one way to relieve this constraint.  This tyrosine 
residue is conserved amongst all Ephexins, suggesting a common regulatory mechanism (see 
Figure 1.5).   
Yohe et al provide additional insight into this process by studying two intramolecular 
motifs on the N-terminus of TIM (Yohe et al., 2007; Yohe et al., 2008).  Similar to Ephexin1, 
they find that truncating or mutating the first 22 amino acids (Δ22) on the N-terminus can 
increase TIM’s RhoA activity.  They find that tyrosine phosphorylation at the conserved tyrosine 
residue (Y19) is responsible for relieving the constraint on TIM’s RhoA activity.  Interestingly, 
they were able to inhibit the activities of both Ngef/Ephexin1 and Wgef/Ephexin2 by adding an 
unphosphorylated peptide consisting of TIM’s first 22 amino acids.  This suggests that even 
though there is low conservation between the N-termini of Ephexins, a short, conserved N-
terminal motif may be a common way to inhibit DH-PH function. 
A second mode of N-terminal regulation has also been suggested.  
VsmRhoGEF/Ephexin5, Ephexin1/NGEF and Ephexin2/WGEF all have conserved polyproline 
rich regions proximal to their DH-PH domains.   Intramolecular binding between this polyproline 
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rich region and the C-terminal SH3 domain autoinhibits TIM, NGEF, and WGEF activity (Yohe 
et al., 2008).  This finding suggests a mechanism where binding of an unknown poly-proline rich 
protein with high affinity for the SH3 domain may activate the protein by competing with the N-
terminus for binding.  This unknown protein could be Src itself, which can then tyrosine 
phosphorylate the conserved residue and relieve repression.   
 Taken together, a sequential stepwise relief model of Ephexin activation has been 
proposed (Figure 1.6).  Initially, an N-terminal inhibitory helix (amino acid 1-22) is bound to the 
DH domain and an N-terminal polyproline region is bound to the SH3 domain.  Unknown 
protein X binds to the SH3 domain, which effectively out-competes the N-terminal poly-proline 
region.  Subsequently, this opens the N-terminus to phosphorylation at the conserved tyrosine 
residue and relieves a secondary constraint on GEF activity.  In this way, bimodal regulation of 
the Ephexins could tightly regulate their activity within the cell.  Additional mechanisms of 
inhibition may also exist.  For instance, Cdk5 is able to phosphorylate Ephexin1 at four 
serine/threonine residues on its N-terminus (Fu et al., 2007).  It is possible that this also relieves 
N-terminal inhibition, adding additional complexity to the regulation of Ephexin1. At the outset 
of this dissertation nothing was known about Ephexin5 
 
 
 
40 
 
 
Figure 1.6: Model for bimodal inhibition of Ephexins by N-terminal repression 
Initially, an N-terminal inhibitory helix is bound to the DH domain, and an N-terminal poly-
proline region to the SH3 domain.  Unknown protein X binds to the SH3 domain, which 
effectively out-competes the N-terminal poly-proline region.  Subsequently this opens up the N-
terminus to phosphorylation at the conserved tyrosine residue allowing activation of downstream 
GTPases. 
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1.6  Summary of Dissertation 
The mechanisms that promote excitatory synapse formation have been extensively study, 
and several well understood models have been described.  In contrast, although molecules that 
restrict the synapse have been identified, specific molecular mechanisms are not well understood.  
We were interested in identifying novel mechanisms that restrict the synapse.  One restrictive 
pathway is through RhoA, which has been shown to negatively regulate many aspects of cellular 
morphogenesis including dendritic spine and synapse formation.  Since the Ephexin family 
activates RhoA, and since Ephexin5 is expressed in the brain, at the outset of this dissertation we 
sought to explore its role during synapse development.   
In Chapter 2, we describe efforts to elucidate a role for Ephexin5 during Eph-dependent 
synapse development.  We find that Ephexin5 activates RhoA both in a mammalian cell-line and 
in vivo.  It restricts excitatory synapse number through its GEF activity and serves to limit EphB-
dependent synapse formation.  Upon EphB2 activation, Ephexin5 is tyrosine phosphorylated at 
the analogous tyrosine residue found in Ephexin1 (Y361).  Unlike Ephexin1 and other Ephexins 
however, EphB2-dependent phosphorylation leads to the degradation of Ephexin5 protein.  
Degradation of Ephexin5 requires the E3 ubiquitin ligase, UBE3A, and ube3A knockout mice 
show increased levels of Ephexin5. Loss of UBE3A activity in the brain leads to Angelman 
syndrome is a neurodevelopmental disorder characterized by profound speech impairments, 
severe intellectual disability, motor dysfunction, frequent seizures, and a prevalence of autism-
related behavior (Williams et al., 2005). Thus this finding suggests that the misregulation of 
Ephexin5 in the Angelman syndrome brain may contribute to the eitiology of the disease. 
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In Chapter 3 we find that Ephexin5/Arhgef15 is mutated in a form of infantile epileptic 
encephalopathy at Arg.604.Cys (R604C).  This R604C mutation resides at a critical residue in 
the DH-PH linker domain, and this linker region is thought to provide structural rigidity 
necessary for proper GEF activity.  Indeed, R604C and the homologous mouse mutation, R612C, 
lead to a 45% reduction in GEF activity.  We also demonstrate that an Ephexin5 
happloinsuffiency mouse model (Ephexin +/-) has increased susceptibility to audiogenic seizures 
and increased anxiety.  We currently screening for additional Ephexin5 mutations in epilepsy 
that may help clarify Ephexin5’s role in vivo and its role in epilepsy disorders. 
In Chapter 4, we identified a number of novel serine/threonine phosphorylation sites on 
the N-terminus of Ephexin5 that are critical for restricting excitatory synapse density in 
dissociated hippocampal cultures.  Two of these phosphorylation sites, serine-107/109, are 
drastically reduced during postnatal development at the height of synapse formation.  We suggest 
that phosphoregulation of Ephexin5 may be another critical mechanism underlying Ephexin5-
mediated excitatory synapse restriction during early brain development.    
Taken together, the studies described in this dissertation demonstrate an important 
biological function for Ephexin5 in excitatory synapse formation and normal brain development. 
The mechanisms described in this dissertation not only provide a molecular model for the 
function of Ephexin5 but also provide insight into how this function may be disrupted in 
neurodevelopmental disease.  
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Chapter 2 
EphB-mediated degradation of the RhoA GEF Ephexin5 relieves a 
developmental brake on excitatory synapse formation 
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2.1   Abstract 
The mechanisms that promote excitatory synapse formation and maturation have been 
extensively studied. However, the molecular events that limit excitatory synapse development so 
that synapses form at the right time and place and in the correct numbers are less well 
understood. We have identified a RhoA guanine nucleotide exchange factor, Ephexin5, which 
negatively regulates excitatory synapse development until EphrinB binding to the EphB receptor 
tyrosine kinase triggers Ephexin5 phosphorylation, ubiquitination, and degradation. The 
degradation of Ephexin5 promotes EphB-dependent excitatory synapse development and is 
mediated by Ube3A, a ubiquitin ligase that is mutated in the human cognitive disorder Angelman 
syndrome and duplicated in some forms of Autism Spectrum Disorders (ASDs). These findings 
suggest that aberrant EphB/Ephexin5 signaling during the development of synapses may 
contribute to the abnormal cognitive function that occurs in Angelman syndrome and, possibly, 
ASDs. 
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2.2   Background and Significance 
A crucial early step in the formation of excitatory synapses is the physical interaction 
between the developing presynaptic specialization and the postsynaptic dendrite (Jontes et al., 
2000; Ziv and Smith, 1996). This step in excitatory synapse development is thought to be 
mediated by cell surface membrane proteins expressed by the developing axon and dendrite and 
appears to be independent of the release of the excitatory neurotransmitter glutamate (reviewed 
in Dalva et al., 2007).  Several recent studies have revealed an important role for Ephrin cell 
surface-associated ligands and Eph receptor tyrosine kinases in this early cell-cell contact phase 
that is critical for excitatory synapse formation (Dalva et al., 2000; Ethell et al., 2001; 
Henkemeyer et al., 2003; Kayser et al., 2006; Kayser et al., 2008; Lai and Ip, 2009; Murai et al., 
2003).  
Ephs can be divided into two classes, EphA and EphB, based on their ability to bind the 
ligands EphrinA and EphrinB, respectively (reviewed in Flanagan and Vanderhaeghen, 1998). 
EphBs are expressed postsynaptically on the surface of developing dendrites, while their cognate 
ligands, the EphrinBs, are expressed on both the developing axon and dendrite (Grunwald et al., 
2004; Grunwald et al., 2001; Lim et al., 2008). When an EphrinB encounters an EphB on the 
developing dendrite, EphB becomes autophosphorylated, thus increasing its catalytic kinase 
activity (reviewed in Flanagan and Vanderhaeghen, 1998). This leads to a cascade of signaling 
events including the activation of guanine nucleotide exchange factors (GEFs) Tiam, Kalirin, and 
Intersectin, culminating in actin cytoskeleton remodeling that is critical for excitatory synapse 
development (reviewed in Klein, 2009). Consistent with a role for EphBs in excitatory synapse 
development, EphB1/EphB2/EphB3 triple knockout mice have fewer mature excitatory synapses 
in vivo in the cortex, and hippocampus (Henkemeyer et al., 2003; Kayser et al., 2006). In 
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addition, the disruption of EphB function postsynaptically in dissociated hippocampal neurons 
leads to defects in spine morphogenesis and a decrease in excitatory synapse number (Ethell et 
al., 2001; Kayser et al., 2006). Conversely, activation of EphBs in hippocampal neurons leads to 
an increase in the number of dendritic spines and functional excitatory synapses (Henkemeyer et 
al., 2003; Penzes et al., 2003).  These findings indicate that EphBs are positive regulators of 
excitatory synapse development. 
While there has been considerable progress in characterizing the mechanisms by which 
EphBs promote excitatory synapse development, it is not known if there are EphB-associated 
factors that restrict the timing and extent of excitatory synapse development.  We hypothesized 
that neurons might have evolved mechanisms which act as checkpoints to restrict EphB-
mediated synapse formation, and that the release from such synapse formation checkpoints might 
be required if synapses are to form at the correct time and place and in appropriate numbers. 
We considered the possibility that likely candidates to mediate the EphB-dependent 
restriction of excitatory synapse formation might be regulators of RhoA, a small G protein that 
functions to antagonize the effects of Rac (Tashiro et al., 2000).  In previous studies we 
identified a RhoA GEF, Ephexin1, which interacts with EphA4 (Fu et al., 2007; Sahin et al., 
2005; Shamah et al., 2001).  Ephexin1 is phosphorylated by EphA4 and is required for the 
EphrinA-dependent retraction of axonal growth cones and dendritic spines (Fu et al., 2007; Sahin 
et al., 2005).  While Ephexin1 does not appear to interact with EphB, Ephexin1 is a member of a 
family of five closely related GEFs. Of these GEFs, Ephexin5 (in addition to Ephexin1) is highly 
expressed in the nervous system.  Therefore, we hypothesized that Ephexin5 might function to 
restrict the EphB-dependent development of excitatory synapses by activating RhoA. 
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In this study we report that EphB interacts with Ephexin5, that Ephexin5 suppresses 
excitatory synapse development by activating RhoA, and that this suppression is relieved by 
EphrinB activation of EphB during synapse development. Upon binding EphrinB, EphB 
catalyzes the tyrosine phosphorylation of Ephexin5 which triggers Ephexin5 degradation.  We 
identify Ube3A as the ubiquitin ligase that mediates Ephexin5 degradation, thus allowing 
synapse formation to proceed.  As UBE3A is mutated in Angelman syndrome and duplicated in 
some forms of Autism Spectrum Disorders (ASDs), these findings suggest a possible mechanism 
by which the mutation of Ube3A might lead to cognitive dysfunction (Jiang et al., 1998; Kishino 
et al., 1997).  Specifically, we provide evidence that in the absence of Ube3A, the level of 
Ephexin5 is elevated and propose that this may lead to the enhanced suppression of EphB-
mediated excitatory synapse formation, thereby contributing to Angelman syndrome and, 
possibly, ASDs. 
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2.3   Results  
Ephexin5 interacts with EphB2 
To identify mechanisms that restrict the ability of EphBs to promote an increase in 
excitatory synapse number, we searched for RhoA guanine nucleotide exchange factors (GEFs) 
that specifically activate RhoA signaling, are expressed in the same population of neurons that 
express EphB, are expressed at the same time during development as EphB, and interact with 
EphB.  Structure-function studies of GEFs  identified amino acid residues in the activation 
domain of Rho family GEFs that specifically identify the GEFs as activators of RhoA rather than 
Rac or Cdc42. Applying this criterion, fourteen GEFs were identified that specifically activate 
RhoA (Rossman et al., 2005). Of these GEFs we found by in situ hybridization that Ephexin5 
has a similar expression pattern to EphB in the hippocampus (Figure 2.1A).  These findings 
raised the possibility that Ephexin5 might mediate the effect of EphB on developing synapses. 
We asked if Ephexin5 interacts physically with EphB.  We transfected HEK293T (293) 
cells with plasmids encoding Myc-tagged Ephexin5, Ephexin1, or a vector control together with 
Flag-tagged EphB2 or EphA4 and asked if these proteins co-immunoprecipitate.  Extracts were 
prepared from the transfected 293 cells and EphA4 or EphB2 immunoprecipitated with Flag 
antibodies.  The immunoprecipitates were subjected to SDS polyacrylamide gel electrophoresis 
(SDS-PAGE) and blotted with anti-Myc antibody (α-Myc).  We found that Ephexin5 co-
immunoprecipitates with EphB2 but not with EphA4 (Figure 2.1B).  The relatively weak 
Ephexin5 interaction with EphA4 is consistent with published experiments (Ogita et al., 2003).  
By contrast, Ephexin1 is co-immunoprecipitated by EphA4 but not EphB2 (Shamah et al., 2001).  
These findings suggest that Ephexin5 interacts preferentially with EphB2. 
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Figure 2.1:  Ephexin5 interacts with EphB2 
A) Ephexin5 and EphB2 are expressed in the CA1 region and dentate gyrus (DG) of the 
hippocampus at P12.  Adjacent 100 nm mouse brain sections were stained for Ephexin5 or 
EphB2 using digoxigenin-labeled RNA probes to the anti-sense strand or sense strand as a 
control (top).  Lower panels show nuclear staining with DAPI.   
B) Immunoprecipitation with α-Flag from 293 cell lysates previously transfected with various 
combinations of overexpressing plasmids containing Ephexin1-Myc, Ephexin5-Myc, Flag-
EphB2, and Flag-EphA4, followed by immunoblotting with α-Myc or α-Flag.  Input protein 
levels shown (bottom). 
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Figure 2.1 (continued): 
C) Immunoprecipitation of mouse cortical lysates with IgG or α-C-E5, followed by 
immunoblotting with α-EphB2 or α-N-E5 (left).  Input protein levels shown (right).   
D) Dissociated rat hippocampal neurons were stained using α-N-E5 (Blue) and α-EphB2 (Red). 
A representative image of overlapped EphB2 and Ephexin5 is shown (left). Arrows indicate 
example locations of EphB2/Ephexin5 co-localization.  In three independent experiments, 
quantification of overlapped EphB2/Ephexin5 puncta was determined at DIV2, DIV4 and DIV8 
and is represented as percent of EphB2 overlapped with Ephexin5 (right).  Error bars ± SEM; *p 
<0.05, non-significant (n.s.). 
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To extend this analysis we investigated whether EphB2 interacts with Ephexin5 in 
neurons.  Neurons from embryonic day 16 (E16) mouse brains were lysed in RIPA buffer and 
the lysates incubated with affinity purified anti-C-terminal Ephexin5 (α-C-E5) or control (IgG) 
antibodies.  The immunoprecipitates were then resolved by SDS-PAGE and immunoblotted with 
affinity purified anti-N-terminal Ephexin5 (α-N-E5) or EphB2 (α-EphB2) antibodies (Figure 
2.1C).  This analysis revealed that endogenous, neuronal EphB2 is immunoprecipitated by α-C-
E5 but not IgG.   
As an independent means of assessing if EphB and Ephexin5 interact with one another, 
we used immunofluorescence microscopy to determine if these two proteins co-localize in 
neurons.  Cultured mouse hippocampal neurons were transfected with a plasmid expressing 
green fluorescent protein (GFP).  The GFP-expressing neurons were imaged and quantified for 
the co-localization of EphB2 and Ephexin5 puncta by staining with α-C-E5 and α-EphB2.  This 
analysis revealed that EphB2 and Ephexin5 co-localize along dendrites (Figure 2.1D). We find 
that 40% of EphB staining overlaps with α-C-E5 staining early during the development of 
excitatory synapses.  After eight days in vitro (DIV) the overlap of EphB with Ephexin5 within 
neuronal dendrites decreases to below the level that would be detected by random chance.  This 
change suggests that EphB interacts with Ephexin5 early during development, possibly to inhibit 
EphB synapse formation.   
Ephexin5 is a guanine nucleotide exchange factor that activates RhoA  
To determine if Ephexin5 activates RhoA, we transfected 293 cells with a control 
plasmid or a plasmid that drives the expression of Myc-tagged mouse Ephexin5.  We prepared 
extracts from the transfected cells and incubated the extracts with a GST-fusion protein that 
52 
 
 
Figure 2.2:  Generation of Ephexin5 knockout mice and validation 
A) Scheme used to generate the Ephexin5
-/-
 and Ephexin5
fl/fl
 mice 
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Figure 2.2 (continued):  
B) Southern blot showing the successful removal of exons 4 through 8 in the Ephexin5 gene in 
mouse ES cells. Genomic DNA was digested with HindIII and hybridized with a 5’ probe shown 
in A).   
C) PCR analysis of genomic tail DNA showing that the Ephexin5 gene is correctly recombined 
in Ephexin5
-/-
 and Ephexin5
fl/fl
 mice.   
D) Western blot showing that Ephexin5 protein is absent in Ephexin5
−/−
 mice. EphB2 and  -
βactin serve as a loading control. 
E) Immunocytochemistry of dissociated hippocampal cultures from Ephexin5
+/-
 and Ephexin5
-/-
 
mice reveals specific staining of Ephexin5.  
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Figure 2.2 (continued): 
F) Ephexin5 is enriched in dendrites of hippocampal neurons.  Cultured hippocampal neurons 
were transfected with GFP at DIV8 and fixed and stained two days later for endogenous 
Ephexin5 expression (red) and the dendritic marker Map2 (Blue).  Overlapped Map2/GFP 
staining indicates dendrites.  Subtraction of Map2-positive processes from GFP-labeled neuronal 
staining indicates location of axons.  To measure Ephexin5 density, the number of Ephexin5 
puncta were divided by the area of the GFP dendritic or axonal field.  Quantification was done 
using MetaMorph. 
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includes the Rhotekin-Binding Domain (GST-RBD), a protein domain that selectively interacts 
with active (GTP-bound) but not inactive (GDP-bound) RhoA.  Following SDS-PAGE of the 
proteins in the extract that bind to GST-RBD, RhoA binding to GST-RBD was measured by 
immunoblotting with anti-RhoA antibodies. We found that cells expressing Ephexin5 exhibited 
higher levels of activated RhoA compared to cells transfected with a control plasmid, indicating 
that Ephexin5 activates RhoA (Figure 2.3A). 
When a similar series of experiments were performed using a GST-fusion Pak-Binding 
Domain (GST-PBD) which specifically interacts with active forms of two other Rho GTPases, 
Rac1 and Cdc42, we found that Ephexin5 does not induce the binding of GST-PBD to Rac1 or 
Cdc42.  In contrast, Ephexin1-expressing cells displayed enhanced binding of Rac1 and Cdc42 
to GST-PBD. We conclude that Ephexin5 activates RhoA but not Rac1 or Cdc42 (Figure 2.3B).  
To determine whether Ephexin5 activation of RhoA requires the GEF activity of 
Ephexin5, we generated a mutant form of Ephexin5 in which its guanine nucleotide exchange 
activity is impaired. To identify the residues required for Ephexin5 guanine nucleotide exchange 
activity we compared its Dbl-homology (DH) domain to the DH domain of other RhoA GEFs 
(Figure 2.3C) (Snyder et al., 2002).  We identified within the α5 helix of Ephexin5’s DH 
domain three amino acids that are conserved in other GEFs that like Ephexin5, preferentially 
activate RhoA.  To generate a form of Ephexin5 predicted to be inactive as a GEF, we mutated 
these three conserved amino acids to alanine (i.e., L562, Q566, and R567 (Ephexin5-LQR)).  
Using the GST-RBD pull down assay we found that although Ephexin5-WT and Ephexin5-LQR 
are expressed at similar levels, the Ephexin5-LQR mutant is significantly impaired relative to 
WT in its ability to activate RhoA (Figure 2.3D).  As a control, we mutated other conserved 
residues within the α5 DH region to alanine (Q547, S548, R554, and L555).  When we tested this 
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Figure 2.3: Ephexin5 is a guanine nucleotide exchange factor that activates RhoA 
A) Lysates from 293 cells transfected with empty vector (Control) or Ephexin5-Myc 
overexpressing vector were assayed for endogenous RhoA activity using the RBD pulldown 
assay and analyzed by immunoblotting with an antibody to RhoA (top panel). GTPγS lane is a 
positive control for inducing RhoA activity.  Increased endogenous RhoA activity is 
demonstrated by presence of anti-RhoA signal in RBD pulldown lanes. Input protein levels and 
β-actin loading control are shown (Bottom).   
B) Lysates from 293 cells transfected with empty vector (Control), Ephexin5-Myc, or Ephexin1-
Myc were assayed for activated Rac1 and Cdc42 using the PBD pulldown assay. Pulldown lanes 
were immunoblotted with mouse anti-Rac1 and re-probed with rabbit anti-Cdc42 (top two 
panels). GTPγS lane is a positive control for inducing Rac1 and Cdc42 activity. Increased 
endogenous Rac1 or Cdc42 activity is demonstrated by presence of anti-Rac1 or anti-Cdc42 
signal in PBD pulldown lanes. Input protein levels and β-actin loading control are shown 
(Bottom). 
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Figure 2.3 (continued): 
C) Sequence alignment of the α5 helix loop of the Ephexin5-DH domain to known RhoA GEFs. 
Asterisks highlight residues important for GEF activity.   
D) Lysates from 293 cells transfected with empty vector (Control), LQR mutant of Ephexin5-
Myc (LQR) or Ephexin5-Myc (WT) were assessed for RhoA activity as measured by RBD assay 
described in part (A).  Input protein levels and β-actin  loading control are shown (Bottom).   
E) Presence of Ephexin5 is critical for wild type levels of endogenous RhoA signaling in vivo. 
P3 mouse whole brain lysates from wild type (WT) or E5
-/-
 (KO) littermates were subjected to 
RBD pulldown assays as described in part (A). A representative immunoblot is shown (left).  
From three experiments, blinded to condition, the quantification of α-RhoA signal was 
normalized to input RhoA signal (Right).  Error bars ± SEM; *p<0.05 
 
. 
58 
 
mutant we observed no defect in RhoA activation, suggesting that the Ephexin5-LQR mutation 
specifically disrupts the GEF activity of Ephexin5 and that the inability of the LQR mutant to 
activate RhoA is not a general consequence of disrupting the α5 region of Ephexin5 (Figure 
2.4).  Taken together, these findings indicate that Ephexin5 requires an intact conserved GEF 
domain to promote RhoA activity in 293 cells, suggesting that Ephexin5 functions as a RhoA 
GEF. 
We next asked if Ephexin5 expression affects RhoA activity in the brain.  We lysed P3 
whole brains from wild type or Ephexin5
-/-
 mice and performed a GST-RBD pull down assay.  
This analysis revealed a significant decrease in RhoA activation in brain extracts from Ephexin5
-
/-
 mice compared to wild type mice, suggesting that Ephexin5 is required to maintain wild type 
levels of RhoA activity in the brain (Figure 2.3E). 
Ephexin5 negatively regulates excitatory synapse number 
Our findings indicate that Ephexin5 interacts with EphB2, a key regulator of excitatory 
synapse development.  Thus, we asked whether Ephexin5 plays a role in the development of 
excitatory synapses.  We generated two short hairpin RNA constructs that each knocks down 
Ephexin5 protein levels when expressed in 293 cells or cultured hippocampal neurons (Figure 
2.5A-2.5B).  These shRNAs were introduced into cultured hippocampal neurons together with a 
plasmid that drives expression of green fluorescent protein (GFP) to allow detection of the 
transfected cells.  We found by staining with α-N-E5 antibodies that the Ephexin5 shRNAs (E5-
shRNA), but not scrambled hairpin control shRNAs (ctrl-shRNA), efficiently knocked down 
Ephexin5 expression in the transfected neurons (Figure 2.5C). 
By staining with antibodies that recognize pre- and post- synaptic proteins or by  
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Figure 2.4: QSRL mutant does not affect GEF activity 
Lysates from HEK293T cells transfected with empty vector, Ephexin5-Myc (WT), Ephexin5-
LQR-Myc (LQR), or Ephexin5-QSRL-Myc (QSRL) were assayed for activated RhoA using 
RBD pulldown assay as described in Figure 2. Total protein levels were assessed by 
immunoblotting for Ephexin-Myc and β-Actin (Input panels). 
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Figure 2.5 Ephexin5 knockdown by shRNA    
A) Genomic structure of the Ephexin5 gene. The genomic location and shRNA sequence used 
for Ephexin5 knockdown are shown. 
B) Western blot showing that exogenously expressed Ephexin5 protein can be knocked down in 
HEK293T cells in the presence of shRNA constructs. Only two of the three shRNA constructs 
were capable of knocking down Ephexin5 protein expression. 
C) Rat hippocampal neurons were transfected with GFP and shRNA targeted to Ephexin5 gene 
at DIV10. At DIV14, neurons were fixed and stained for endogenous Ephexin5 protein. 
Immunocytochemistry shows that Ephexin5 shRNA-expressing neurons have a dramatic 
decrease in endogenously expressed Ephexin5. 
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Figure 2.5 (continued): 
D) Loss of Ephexin5 function does not affect dendritic spine morphology. 10 ng of Ephexin5 
shRNA (E5 shRNA) or scrambled shRNA (scr shRNA) was co-transfected with GFP into rat 
hippocampal neurons at DIV14. At DIV18, transfected neurons were fixed and spines quantified 
for spine length and head width. Data are plotted as cumulative distribution to identify 
populations of spines that have changed in length or width. All error bars are SEM; *p < 0.002. 
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visualizing dendritic spines in GFP transfected neurons we observed a significant increase in the 
number of excitatory synapses and dendritic spines that are present on the E5-shRNA-expressing 
neurons compared to neurons expressing ctrl-shRNAs (Figure 2.6A-2.6B).  By contrast, we 
failed to detect a significant change in dendritic spine length or width under these conditions 
(Figure 2.5D).  These findings suggest that Ephexin5 functions to restrict spine/excitatory 
synapse number but has no significant effect on spine morphology.  Consistent with these 
conclusions, we found that overexpression of Ephexin5 in hippocampal neurons leads to a 
decrease in the number of excitatory synapses that are present on the Ephexin5-overexpressing 
neurons (Figure 2.6C).  This ability of Ephexin5 to negatively regulate excitatory synapse 
number requires its RhoA GEF activity, as overexpression of Ephexin5-LQR had no effect on 
synapse number (Figure 2.6D). 
To assess the effect of reducing Ephexin5 levels on the functional properties of excitatory 
synapses, we recorded miniature excitatory postsynaptic currents (mEPSCs) from cultured 
hippocampal neurons transfected with E5-shRNA or ctrl-shRNA.  We observed an increase in 
the frequency and amplitude of mEPSCs on neurons expressing E5-shRNA compared to ctrl-
shRNA (Figure 2.6E). This suggests that Ephexin5 can act postsynaptically to restrict excitatory 
synapse function. Indeed, the increase in mEPSC frequency could be due to an increase in 
presynaptic vesicle release onto the transfected neuron or an increase in the number of excitatory 
synapses that are present on the transfected neuron.  We favor the latter possibility since our 
transfection protocol selectively reduces Ephexin5 levels postsynaptically and also because the 
increase in synapse number is most consistent with the increase in co-staining of pre- and post-
synaptic markers that we observe when the level of Ephexin5 is reduced.  The possibility that 
Ephexin5 functions postsynaptically is further supported by immunofluorescence staining 
63 
 
 
 
 
 
 
 
 
 
 
Figure 2.6:  Ephexin5 negatively regulates excitatory synapse number 
A) 10 ng of E5-shRNA or Ctrl-shRNA was co-transfected with GFP into rat hippocampal 
neurons at DIV14.  At DIV18 dendritic spines were measured as described in methods. 
Representative image illustrates quantified dendritic spines. N indicates number of neurons 
assessed.  Error bars ± SEM; **p < 0.01, ANOVA. 
B) 10 ng or 20 ng of two different E5-shRNA or Ctrl-shRNA constructs was co-transfected with 
GFP into rat hippocampal neurons at DIV10.  At DIV14 excitatory synapses were measured as 
described in methods.  Representative image illustrates quantified synapse puncta (White). Error 
bars ± SEM; **p < 0.01, ***p<0.005, ANOVA. 
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Figure 2.6 (continued): 
C) DIV10 rat hippocampal neurons were co-transfected with GFP and increasing concentrations 
of Ephexin5-Myc or control plasmid. At DIV 14 excitatory synapses (gray bars) and exogenous 
Ephexin5 expression (blue bars) were measured as described in methods. Representative image 
illustrates localization of Ephexin5-Myc on transfected neuron (Red). Error bars ± SEM; **p <  
D) Neurons were transfected with Ephexin5-Myc (Ephexin5-WT) or Ephexin5-LQR-Myc 
(Ephexin5-LQR) and quantified similar to (C).  Error bars ± SEM; **p < 0.01, ANOVA 
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Figure 2.6 (continued): 
E) Quantification of mEPSC inter-event interval and amplitude from hippocampal neurons 
transfected as in (B) with 20 ng of shRNA.  Cumulative distribution plots, bar graphs and 
representative traces are shown. Error bars are standard deviation of the mean, ***p<0.005, 
*p<0.05.  
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experiments demonstrating that Ephexin5 is enriched in dendrites relative to axons (Figure 
2.2F). 
As an independent means of assessing the importance of Ephexin5 in the control of 
excitatory synapse number, we cultured hippocampal neurons from Ephexin5
-/-
 mice or their wild 
type littermates for 10 days in vitro and then, following transfection of a GFP-expressing 
plasmid into these neurons, quantified the number of excitatory synapses present on the 
transfected neuron at DIV14.  We observed a three-fold increase in the number of synapses that 
are present on Ephexin5
-/-
 neurons compared to Ephexin5
+/-
 neurons (Figure 2.7A).  Taken 
together with the E5-shRNA knockdown and Ephexin5 overexpression analyses, these findings 
suggest that Ephexin5 acts postsynaptically to reduce excitatory synapse number. 
We next asked if Ephexin5 regulates synapse number in the context of an intact 
developing neuronal circuit using conditional Ephexin5 (Ephexin5
fl/fl
) animals (Figure 2.2). 
Upon introduction of Cre recombinase into Ephexin5
fl/fl
 cells, exons 4-8 of the Ephexin5 gene are 
excised resulting in a cell that no longer produces Ephexin5 protein (data not shown).  
Organotypic slices were prepared from the hippocampus of the Ephexin5
fl/fl
 mice or their wild 
type littermates. Using the biolistic transfection method, a plasmid expressing Cre recombinase 
was introduced into a low percentage of neurons in the slices. We found that introduction of a 
Cre-expressing plasmid into Ephexin5
fl/fl
 neurons in the hippocampal slice led to a significant 
increase in the density of dendritic spines present on the Cre-expressing neurons (Figure 2.7B).  
By contrast, expression of Cre in neurons of a wild type hippocampal slice has no effect on 
dendritic spine density.   
To assess the role of Ephexin5 in hippocampal circuit development in vivo, we performed  
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Figure 2.7: Ephexin5 negatively regulates synapses in vivo and restricts EphB2 control of 
excitatory synapse formation   
A) E16 hippocampi from E5
+/-
 or E5
-/-
 mice were dissected and dissociated for culture.  At 
DIV10 dissociated neurons were transfected with GFP.  At DIV14 neurons were fixed, stained 
and, excitatory synapses were measured as described in methods. Error bars ± SEM; ***p < 
0.005, ANOVA. 
B) Organotypic slices from WT or E5
fl/fl
 mice were biolistically transfected with Cre-
recombinase (Cre) and dendritic spines were quantified as described in methods.  Representative 
images are shown (left).  Error bars ± SEM; ***p < 0.005, KS test. 
C) Quantification of mEPSC inter-event interval and amplitude from acute hippocampal brain 
slices prepared from P12-P14 WT or E5
-/-
 mice.  Error bars are standard deviation of the mean; 
***p<0.005, *p<0.05. 
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Figure 2.7 (continued): 
D) Hippocampi from three independent littermate pairs consisting of P12 WT and E5
-/-
 mice 
were prepared as described in methods for quantification of synapses, Synapsin1 and PSD-95 
using array tomography.  Error bars ± SEM; *p < 0.05, Mann-Whitney U-Test. 
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acute slice physiology experiments in the CA1 region of the hippocampus from wild type or  
Ephexin5
-/-
 mice.  We find that relative to wild type neurons, in Ephexin5 knockout CA1 
pyramidal neurons there are more frequent excitatory events that have larger amplitude (Figure 
2.7C).  A possible explanation for these findings is that when Ephexin5 function is disrupted 
during in vivo development more excitatory synapses form resulting in more excitatory post-
synaptic events.  To test this possibility, we used array tomography to quantify the number of 
excitatory synapses that form in the CA1 stratum radiatum of wild type and Ephexin5
-/-
 mice.  
We observed a ~2-fold increase in the number of excitatory synapses within the CA1 region of 
the Ephexin5
-/-
 hippocampus compared to wild type mice (Figure 2.7D).  Specifically, the 
number of juxtaposed synapsin and PSD-95 puncta was quantified and considered a 
measurement of the number of excitatory synapses that form within the CA1 region of the 
hippocampus in vivo.  This analysis revealed a significant increase in the number of PSD-95 
puncta but no change in the number of synapsin puncta density (Figure 2.7D).  This suggests 
that the increase in excitatory synapse number in the stratum radiatum of Ephexin5
-/-
 mice is 
likely due to the absence of Ephexin5 post-synaptically and that when Ephexin5 is present within 
dendrites it functions to negatively regulate synapse number in vivo.  On the basis of these 
results, we conclude that a key function of Ephexin5 is to restrict excitatory synapse number 
during the development of neuronal circuits. 
Ephexin5 restricts EphB2 control of excitatory synapse formation 
We next considered the possibility that the ability of Ephexin5 to restrict excitatory synapse 
number might be controlled by EphB2 signaling.  To test this idea, we asked whether reducing 
EphB2 signaling eliminates the increase in excitatory synapse number detected when Ephexin5 
levels are knocked down by expression of E5-shRNA. To block EphB2 activation, we introduced 
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into neurons a kinase dead version of EphB2 (EphB2-KD) which has been previously shown to 
block EphB2 signaling (Dalva et al., 2000).  As described above, expression of E5-shRNA in 
neurons leads to a significant increase in the number of synapses that are present on the E5-
shRNA-expressing neuron.  However, this increase was reversed if the E5-shRNA was co-
transfected with a plasmid that drives expression of EphB2-KD, but was not affected by co-
transfection of a control plasmid (Figure 2.8A).  These findings suggest that the increase in 
excitatory synapse number that occurs when Ephexin5 levels are reduced requires EphB 
signaling.  Consistent with this conclusion, we find that if we overexpress wild type EphB2 in 
neurons more synapses are present on the EphB-expressing neuron. However, this effect is 
reduced if Ephexin5 is overexpressed in neurons together with EphB (Figure 2.8B).  It is 
possible that the ability of overexpressed Ephexin5 to suppress the synapse-promoting effect of 
EphB2 reflects independent actions of these two signaling molecules.  However, given that 
EphB2 and Ephexin5 interact with one another in neurons, the most likely interpretation of these 
results is that Ephexin5 functions directly to restrict the synapse-promoting effects of EphB2.  If 
this were the case, we would predict that for EphB2 to positively regulate excitatory synapse 
development it would be necessary to inactivate and/or degrade Ephexin5. 
EphB mediates phosphorylation of Ephexin5 at tyrosine-361 
Since EphB2 is a tyrosine kinase, we considered the possibility that it might inhibit the 
guanine nucleotide exchange activity or expression of the Ephexin5 protein by catalyzing the 
tyrosine phosphorylation of Ephexin5.  In support of this possibility, stimulation of dissociated 
mouse hippocampal neurons with EphrinB1 for 15 minutes led to an increase in the level of 
Ephexin5 tyrosine phosphorylation as detected by probing immunoprecipitated Ephexin5 with 
the pan-anti-phosphotyrosine antibody, 4G10 (Figure 2.9A). 
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Figure 2.8: Ephexin5 restricts EphB2 control of synapse formation 
A) Increase in excitatory synapse number following loss of Ephexin5 requires EphB2 signaling. 
At DIV10, control plasmid (-) or EphB2KD plasmid (+) were co-expressed in dissociated mouse 
hippocampal neurons with GFP and either Ctrl-shRNA or E5-shRNA. At DIV14 excitatory 
synapses were measured as described in methods. Error bars ± SEM; **p < 0.01, ***p<0.005, 
ANOVA. 
B) Ephexin5 can suppress an EphB2-mediated increase in excitatory synapse number. At DIV10, 
control plasmid (-) or EphB2-expressing plasmid (+) were co-expressed in dissociated mouse 
hippocampal neurons with GFP and either control (Ctrl) plasmid or Ephexin5-Myc plasmid. At 
DIV14 excitatory synapses were measured as described in methods. Error bars ± SEM; **p < 
0.01, ***p<0.005, ANOVA. 
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Figure 2.9:  EphB2 phosphorylates Ephexin5 at tyrosine-361 
A) Dissociated mouse hippocampal neurons were stimulated with either anti-Fc IgG (Ctrl) or 
pre-clustered Fc-EphrinB1 (EB1) for 15 minutes. Neuronal lysates were immunoprecipitated 
with α-N-E5, followed by immunoblotting for pan-phosphotyrosine (α-pTyr) and Ephexin5 with 
α-N-E5. EphrinB1 stimulation was determined by immunoblotting neuronal lysates for phospho-
Eph (pEph).  Input protein levels and β-Actin loading control are shown (Bottom). 
B) Ephexin5-Y361 is a conserved residue with Ephexin1-Y87 (Sahin et al., 2005). 
C) Immunoprecipitation with α-Myc from 293 cell lysates previously transfected with various 
combinations of overexpressing plasmids containing Ephexin5-Myc or Ephexin5 (Y361F)-Myc 
and EphB2-Flag, followed by immunoblotting with α-pTyr or α -pY361. Input EphB2 levels are 
shown (bottom). 
D) Dissociated mouse hippocampal neurons were stimulated with either anti-Fc IgG (Ctrl) for 15 
minutes or pre-clustered Fc-EphrinB1 (EB1) for 5 or 15 minutes. Neuronal lysates were 
immunoprecipitated with α-N-E5, followed by immunoblotting with α-pY361 and α-N-E5.  
Representative immunoblot with input pEph levels is shown (top).  Quantification of three 
independent experiments are shown as a percent increase in pY361 over Ctrl stimulation 
(bottom).  Error bars ± SEM; *p<0.05 
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Figure 2.9 (continued): 
E) Ephexin5 is phosphorylated at Y361 along developing dendrites. Dissociated rat hippocampal 
neurons were transfected with GFP (gray outline) and stimulated with either anti-Fc IgG (Ctrl) or 
pre-clustered Fc-EphrinB1 (EB1) for 15 minutes, followed by fixing and staining for endogenous 
phosphorylated Ephexin5 using α -pY361 (Red). Representative image shown (left).  Four 
independent experiments were imaged and analyzed for Ephexin5-Y361 (bar graph).  Error bars 
± SEM; *p<0.05. 
F) Lysates from 293 cells transfected with empty vector (-) or increasing concentrations of 
Ephexin5-Myc with or without Flag-EphB2 were assessed for endogenous RhoA activity by 
RBD assay (previously described). GTPγS lane is a positive control for inducing RhoA.  Input 
protein levels and β-Actin loading control are shown (Bottom). 
G) WT and EphB2
-/-
 (B2
-/-
) brain lysates were immunoblotted with α -N-E5 and α -pY361 
according to methods (left).  Quantification of α -N-E5 signal from three independent 
experiments is normalized to β-Actin and represented as fold change compared to wild type.  
Error bars ± SEM; *p<0.05. 
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We have previously shown that EphrinA1 stimulation of cultured neurons leads to the 
tyrosine phosphorylation of Ephexin1 at tyrosine 87 (Sahin et al., 2005).  On the basis of this 
finding we hypothesized that exposure of neurons to EphrinB1 might promote the 
phosphorylation of the analogous tyrosine residue (Y361) on Ephexin5 (Figure 2.9B) and that 
phosphorylation at this site might lead to Ephexin5 inactivation.  To address test this, we 
overexpressed EphB2 in 293 cells together with wild type Ephexin5 or a mutant form of 
Ephexin5 in which Y361 is converted to a phenylalanine (Ephexin5-Y361F).  Lysates were 
prepared from the transfected cells and after SDS-PAGE were immunoblotted with the pan 
tyrosine antibody 4G10 (Figure 2.9C).  We found that in the presence of EphB2, Ephexin5-WT, 
but not Ephexin5-Y361F, becomes tyrosine phosphorylated. These findings suggest that EphB2 
catalyzes the tyrosine phosphorylation of Ephexin5 primarily at Y361. 
To show definitively that Ephexin5 Y361 is tyrosine phosphorylated, we generated 
Ephexin5 phospho-Y361 antibodies (α-pY361).  To demonstrate that these antibodies 
specifically recognizes the Y361-phosphorylated form of Ephexin5, we immunoblotted cell 
lysates prepared from 293 cells that express EphB2 and either Ephexin5-WT or Ephexin5-Y361F 
with α-pY361.  This analysis demonstrated that the α-pY361 recognizes wild type Ephexin5 but 
not Ephexin5-Y361F (Figure 2.9C).  Furthermore, using α-pY361 we found that when wild type 
EphB2, but not a kinase dead or cytoplasmic truncated version of EphB2, is expressed in 293 
cells together with Ephexin5, Ephexin5 becomes tyrosine phosphorylated at Y361 (Figure 
2.10A).  In contrast, when EphA4 or EphA2 were expressed in 293 cells we detected little to no 
phosphorylation of Ephexin5 at Y361 (Figure 2.10B).  These findings suggest that EphB2, but 
not EphAs, promote Ephexin5 Y361 phosphorylation.   
We also found by immunoblotting with the α-pY361 that Ephexin5 is phosphorylated at  
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Figure 2.10:  Specificity of EphB-mediated phosphorylation at tyrosine-361  
A) Both the EphB2 cytoplasmic domain and kinase domain are necessary for Ephexin5 
phosphorylation, but only the EphB2 cytoplasmic domain is required for the EphB2  interaction 
with Ephexin5. HEK293T cell lysates from transfected cells with Ephexin5-Myc with either 
Flag-EphB2, Flag-EphB2-kinase dead (KD), or Flag-EphB2-Δcyto were immunoprecipitated 
with Flag antibody followed by immunoblotting with Flag or with Myc antibodies to assay for 
immunoprecipitated Ephs and Ephexin5, respectively. Cell lysates were immunoblotted for Myc 
and pY361. 
B) Ephexin5 is preferentially phosphorylated by EphB2. HEK293T cell lysates from cells 
transfected with the indicated Ephs, with or without Ephexin5-Myc were immunoblotted with 
antibodies to Ephexin5-pY361, Myc, and Actin. 
C) Ephexin5 is phosphorylated in mouse brain at Y361. Whole brain lysates from P3 wild type 
(WT) and Ephexin5
-/-
 (KO) littermates were lysed and immunoblotted with α-pY361, α-
Ephexin5 (α-N-E5) and α-β-Actin. 
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Y361 in the hippocampus of wild type but not Ephexin5 knockout mice (Figure 2.10C), and that 
EphrinB1 stimulation of cultured hippocampal neurons leads to Ephexin5 Y361 phosphorylation 
(Figure 2.9D).  By immunofluorescence microscopy we detect punctate α-pY361 staining along 
the dendrites of EphrinB1-treated wild type neurons, but less staining in untreated neurons 
(Figure 2.9E).  This result suggests that Ephexin5 becomes phosphorylated at Y361 upon 
exposure of hippocampal neurons to EphrinB1. 
EphB2-mediated degradation of Ephexin5 is kinase and proteasome dependent 
We asked if EphrinB1 stimulation of Ephexin5 Y361 phosphorylation leads to a change 
in Ephexin5 activity or expression.  To investigate this possibility we asked if EphB suppresses 
Ephexin5-dependent RhoA activation in a phosphorylation-dependent manner.  We transfected 
293 cells with Ephexin5 in the presence or absence of EphB2 and measured RhoA activity using 
the RBD pull down assay (Figure 2.9F).  We found that Ephexin5-dependent RhoA activation 
was reduced in 293 cells expressing EphB2 and Ephexin5 compared to cells expressing 
Ephexin5 alone.  These findings are consistent with the possibility that EphB2-mediated tyrosine 
phosphorylation of Ephexin5 either leads to a suppression of Ephexin5’s ability to activate 
RhoA, or alternatively might trigger a decrease in Ephexin5 protein expression resulting in a 
decrease in RhoA activation.  We found this latter possibility to be the case (Figure 2.9F, 
Ephexin5 loading control).  Furthermore, when we compared lysates from the brains of wild type 
or EphB2
-/- 
mice, we observed that Ephexin5 phosphorylation at Y361 is decreased while the 
levels of Ephexin5 expression are increased in the lysates from EphB2
-/-
 mice (Figure 2.9G). 
These data suggest that EphB2 functions to phosphorylate and degrade Ephexin5.  Consistent 
with the idea that Ephexin5 expression is destabilized in the presence of EphB2, we observed 
that in the dendrites of cultured hippocampal neurons overexpressing EphB2, endogenous 
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Ephexin5 expression levels are reduced compared to control transfected neurons or neurons 
transfected with a kinase dead version of EphB2 (Figure 2.11A and 2.12).  When neurons were 
exposed to EphrinB1 compared to EphrinA1 for 60 minutes, we found by immunoblotting of 
neuronal extracts, or immunofluorescence staining with α-N-E5, that exposure to EphrinB1 leads 
to a decrease in Ephexin5 expression (Figure 2.11B).  The lack of complete loss of Ephexin5 
expression by western blot may be due to the fact that EphrinB1 stimulation leads to dendritic 
and not somatic loss of Ephexin5 expression.  Moreover, immunofluorescence staining revealed 
a loss of Ephexin5 puncta specifically within the dendrites of EphrinB1-stimulated neurons, 
consistent with the possibility that EphrinB1/EphB-mediated degradation of Ephexin5 relieves 
an inhibitory constraint that suppresses excitatory synapse formation on dendrites. In support of 
this idea, we find by immunoblotting of extracts from mouse hippocampi with α-N-E5 that 
endogenous Ephexin5 protein levels are highest at postnatal day 3 prior to the time of maximal 
synapse formation and then decrease as synapse formation peaks in the postnatal period (Figure 
2.11C). Northern blotting revealed that this decrease in Ephexin5 protein is not due to a change 
in the level of Ephexin5 mRNA expression (Figure 2.11C).  Given that Ephexin5 protein levels 
decrease dramatically during the time period P7-P21 when synapse formation is maximal, these 
findings suggest that Ephexin5 may need to be degraded prior to synapse formation.  
We asked whether EphB-mediated degradation of Ephexin5 could be reconstituted in 
heterologous cells.  When EphB and myc-tagged Ephexin5 were co-expressed in 293 cells we 
observed a significant decrease in Ephexin5 protein expression in the presence of EphB2.  The 
presence of EphB2 had no effect on the level of expression of a related GEF, Ephexin1 
(Figure2.11D).  We asked whether EphB-mediated degradation of Ephexin5 depends upon 
Y361 phosphorylation.  We found that in 293 cells overexpressing myc-tagged Ephexin5, the  
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Figure 2.11: EphB2-mediated degradation of Ephexin5 is kinase and proteasome 
dependent  
A) Dissociated mouse hippocampal neurons were co-transfected at DIV10 with GFP (gray) and 
an overexpressing plasmid containing EphB2-Flag. At DIV14 neurons were fixed and stained for 
endogenous Ephexin5 (α-N-E5, Red) and EphB2-Flag (α-Flag, Blue). Representative images 
show transfected neurons (left). Three independent experiments were quantified for dendritic and 
somatic endogenous Ephexin5 as described in methods (right). Error bars ± SEM; *p<0.05. 
B) Dissociated mouse hippocampal neurons were incubated with pre-clustered Fc, Fc-EphrinB1 
(EB1) or Fc-EphrinA1 (EA1) for 60 minutes, lysed, and immunoprecipitated with α-C-E5 
followed by immunoblotting with α-N-E5.  Input protein levels and α -βactin loading control are 
shown. Western is one representative image and quantification is of three separate experiments 
with samples normalized to α-βactin (left). Right, dissociated mouse hippocampal neurons were 
transfected with GFP (gray) and stimulated with either pre-clustered Fc (Ctrl) or Fc-EphrinB1 
(EB1) for 30 minutes, followed by fixing and staining for endogenous Ephexin5 using α-N-E5 
(Red).  Error bars ± SEM; *p<0.05. 
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Figure 2.11 (continued): 
C) Whole brain lysates from wild type mice of indicated ages were assessed for Ephexin5 
protein expression by immunoblot with α-N-E5 (top).  Immunoblot of brain lysates from WT and 
E5
-/-
 mice is shown.  α-βactin was used as loading control.  Levels of Ephexin5 RNA from wild 
type mice of indicated ages were assessed by northern analysis using an Ephexin5 specific probe.  
Schematic of Ephexin5 genomic locus shows location of northern probe (Bottom). 
D) Lysates from 293 cells previously transfected with various combinations of overexpressing 
plasmids containing Ephexin5-Myc, Ephexin1-Myc and Flag-EphB2 were immunoblotted with α 
-Myc, α -Flag, and α -βactin (loading control).  
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Figure 2.11 (continued): 
E) Lysates from 293 cells previously transfected with various combinations of overexpressing 
plasmids containing Flag-EphB2, Flag-EphB2KD and Ephexin5-Myc were immunoblotted with 
α -Myc, α -Flag, and α -βactin (loading control).  
F) Lysates from 293 cells previously transfected with various combinations of overexpressing 
plasmids.  Representative immunoblot is shown from 3 independent experiments 
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Figure 2.11 (continued): 
G) 293 cells transfected with Ephexin5-Myc were treated with proteasome inhibitor lactacystin 
(+) or vehicle control (-).  Lysates from transfected 293 cells were immunoprecipitated with α -
Myc, followed by immunoblotting with α-N-E5 or ubiquitin (α-ub) (left).  Similar experiment 
was repeated in the presence or absence of co-transfected Flag-EphB2 (right). 
H) Dissociated mouse hippocampal neurons transfected with GFP (gray) were stimulated similar 
to part (B) in the presence or absence of lactacystin and immunostained with α-N-E5. 
I) WT and E5
-/-
 brains were lysed and immunoprecipitated with α-C-E5 followed by 
immunoblotting with α-N-E5 and α-ub. 
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Figure 2.12:  EphB2-mediated degradation of endogenous Ephexin5 is kinase dependent 
Overexpression of EphB2 or EphB2-KD in neurons at DIV10 leads to a decrease in endogenous 
Ephexin5 expression by DIV14 in transfected neurons as measured by immunocytochemistry. 
Images were quantified by MetaMorph. The data represents three independent experiments. 
 
 
 
 
 
 
 
 
 
83 
 
co-expression of EphB2, but not EphB2-KD, resulted in a significant decrease in Ephexin5 
levels (Figure 2.11E).  This suggests that EphB tyrosine kinase activity is required for Ephexin5 
degradation.  The EphB-mediated reduction in Ephexin5 levels is partially dependent on Y361 
phosphorylation, as the Ephexin5-Y361F levels were suppressed when cotransfected with EphB2 
in 293T cells (Figure 2.11F). Taken together, this data suggests that EphB-mediated tyrosine 
phosphorylation is required to degrade Ephexin5. 
We considered the possibility that the Y361 phosphorylation-dependent decrease in 
Ephexin5 protein levels might be due to EphB-dependent stimulation of Ephexin5 proteasomal 
degradation.  Consistent with this possibility we found that addition of the proteasome inhibitor 
lactacystin to 293 cells leads to a reversal of the EphB-dependent decrease in Ephexin5 protein 
levels, as measured by an increase in total ubiquitinated Ephexin5 (Figure 2.11G). In addition, 
in neuronal cultures the EphrinB1 induced decrease in Ephexin5 protein expression is blocked if 
the proteasome inhibitor lactacystin is added prior to EphrinB1 addition (Figure 2.11H).  
Notably, in the presence of lactacystin, Ephexin5 is ubiquitinated, further supporting the idea that 
Ephexin5 is degraded by the proteasome. 
To test whether Ephexin5 is ubiquitinated in the brain, we incubated wild type or 
Ephexin5
-/- 
brain lysates with α-C-E5 and after immunoprecipitation and SDS-PAGE, probed 
with anti-ubiquitin antibodies. This analysis detected the presence of ubiquitinated species in α-
C-E5 immunoprecipitates prepared from wild type but not Ephexin5
-/-
 brain lysates (Figure 
2.11I).  These findings indicate that Ephexin5 is ubiquitinated in the brain. 
We also found by yeast two-hybrid analysis that Ephexin5 binds Ubiquitin-B and 
Ubiquitin-C proteins as well as several ubiquitin E2 family members (data not shown).  
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Moreover, the results of a recent unbiased screen for targets of the proteasome identified 
Ephexin5 as one of several GEFs targeted by the ubiquitin proteasome (Yen et al., 2008).  These 
findings, taken together with the observations that Ephexin5 is ubiquitinated, and that lactacystin 
treatment blocks the EphrinB1-induced decrease in Ephexin5 expression, suggests that EphB 
induction of Ephexin5 Y361 phosphorylation triggers Ephexin5 degradation via the proteasome.  
Given the role that Ephexin5 plays in suppressing excitatory synapse development, we next 
sought to determine the mechanism by which EphrinB1/EphB-mediated Ephexin5 Y361 
phosphorylation triggers Ephexin5 degradation. 
EphB2-mediated degradation of Ephexin5 requires Ube3A 
During proteasome-dependent degradation of proteins, specificity is conferred by E3 
ligases or E2 conjugating enzymes that recognize the substrate to be degraded. The E3 ligase 
binds to the substrate and catalyzes the addition of polyubiquitin side chains to the substrate 
thereby promoting degradation via the proteasome (Hershko and Ciechanover, 1998).  We 
considered several E3 ligases that have recently been implicated in synapse development as 
candidates that catalyze Ephexin5 degradation.  One of these E3 ligases, Cbl-b, has previously 
been implicated in the degradation of EphAs and EphBs (Fasen et al., 2008; Sharfe et al., 2003).  
A second E3 ligase, Ube3A, has been shown to regulate synapse number.  To determine if 
Ube3A and/or Cbl-b catalyze Ephexin5 degradation we first asked if either of these E3 ligases 
interacts with and degrades Ephexin5 in 293 cells.  When these E3 ligases were epitope-tagged 
and expressed in 293 cells together with Ephexin5 we found that Ephexin5 co-
immunoprecipitates with Ube3A but not with Cbl-b (Figure 2.13A).  The co-
immunoprecipitation of Ube3A with Ephexin5 was specific in that Ube3A was not co-
immunoprecipitated with two other neuronal proteins, Ephexin1 or the transcription factor 
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MEF2.  In a previous study we have shown that Ube3A binds to substrates via a Ube3A binding 
domain (hereafter referred to as UBD (Greer et al., 2010). Using protein sequence alignment 
programs, ClustalW and ModBase, we identified a UBD in Ephexin5, providing further support 
for the idea that Ephexin5 might be a substrate of Ube3A (Figure 2.14).  Consistent with this 
hypothesis, we found that the level of Ephexin5 expression is reduced in 293 cells co-transfected 
with Ube3A compared to cells co-transfected with Cbl-b (Figure 2.13B). 
We asked if EphrinB1/EphB-mediated Ephexin5 degradation in neurons is catalyzed by 
Ube3A.  To inhibit Ube3A activity we introduced into neurons a dominant interfering form of 
Ube3A (dnUbe3A) that contains a mutation in the ubiquitin ligase domain rendering Ube3A 
inactive.  We have previously shown that even though dnUbe3A is catalytically inactive it still 
binds to E2 ligases and to its substrates and functions in a dominant negative manner to block the 
ability of wild type Ube3A to ubiquitinate its substrates (Greer et al., 2010).  We found that when 
introduced into 293 cells dnUbe3A binds to Ephexin5 (Figure 2.13A).  We also found by 
immunofluorescence microscopy that when overexpressed in neurons, dnUbe3A, but not WT 
Ube3A, blocks EphrinB1/EphB stimulation of Ephexin5 degradation (Figure 2.13C).  
EphrinB1/EphB stimulation of Ephexin5 degradation was also attenuated when Ube3A 
expression was knocked down by a shRNA that specifically targets the Ube3A mRNA (Figure 
2.13D) (Greer et al., 2010)).  Notably, the presence of the dnUbe3A did not affect Ephexin5 
expression in neurons in the absence of EphrinB stimulation, suggesting that EphrinB 
stimulation of Ephexin5 Y361 phosphorylation may be required for Ube3A-mediated 
degradation of Ephexin5 (Figure 2.13D). 
To determine if Ube3A-dependent degradation of Ephexin5 might be relevant to the 
etiology of Angelman syndrome we asked if the absence of Ube3A in a mouse model of 
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Figure 2.13:  EphB2-mediated degradation of Ephexin5 requires Ube3A 
A) Immunoprecipitation with α-HA from 293 cell lysates previously transfected with various 
combinations of overexpressing plasmids containing Ephexin1-Myc, Ephexin5-Myc, HA-
DNUbe3A, HA-MEF2A, HA-Cbl-b, and HA-Ube3A, followed by immunoblotting with α-HA or 
α -Myc. Input protein levels and α-βactin loading control are shown (Bottom). 
B) Lysates from 293 cells previously transfected with various combinations of overexpressing 
plasmids containing Ephexin5-Myc, HA-Ube3A and HA-Cbl-b were immunoblotted with α-
Myc, α-HA, and α-βactin (loading control). 
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Figure 2.13 (continued): 
C) Hippocampal mouse neurons were co-transfected with GFP and control, HA-DNUbe3A or 
Ube3A-shRNA at DIV10.  At DIV14, neurons were incubated with clustered Fc (-) or Fc-
EphrinB1 (+) for 30 minutes. Neurons were fixed and stained for Ephexin5 with α-N-E5 and 
quantified according to methods.  Quantification is of Ephexin5 staining intensity normalized to 
Fc control.  Error bars ± SEM; **p < 0.01, ANOVA. 
D) Hippocampal mouse neurons were co-transfected with GFP and control, HA-Ube3A or HA-
DNUbe3A at DIV10.  At DIV14 Neurons were fixed and stained for Ephexin5 and quantified 
according to methods. Quantification is of Ephexin5 staining intensity normalized to control. 
Error bars ± SEM; **p < 0.01, ANOVA. 
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Figure 2.13 (continued): 
E) Ube3A wild type and maternal-deficient (Ube3A
-m/+p
) mouse brains were lysed and 
immunoblotted with α-N-E5, α-EphB2, α-MEF2, α-Actin (loading control), and α-Ube3A (Top).  
Samples were normalized to α-Actin and quantified as described in methods (bottom).  Error 
bars ± SEM; *p<0.05, Mann-Whitney. 
F) Brain lysates from WT and Ube3A
-m/+p
 were collected and treated similar to part E, 
immunoprecipitated with α-C-E5 and immunoblotted with α-N-E5 and α-ub.  Input protein levels 
are shown (right). 
G) Neurons from WT and Ube3A
-m/+p
 mice were dissociated, cultured and transfected with GFP 
at DIV10.  At DIV14, neurons were incubated with pre-clustered Fc or Fc-EphrinB1 (EB1) for 
30 minutes. Neurons were fixed and stained for Ephexin5 with α-N-E5 and quantified according 
to methods.  Error bars ± SEM; **p<0.01. 
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Figure 2.14:  Structure and alignment of Ephexin5 UBD 
Schematic  of  Ephexin5  showing  Dbl-homology  (GEF)  domain,  PH domain,  SH3 domain,  
and  Y361  phosphorylation  site  followed  by  location  of  predicted  UBD.   Comparing   
Ephexin5  to  HHR23A  through  protein  sequence  alignment programs, ClustalW 
(http://www.ebi.ac.uk/Tools/clustalw2/index.html) and ModBase 
(http://modbase.compbio.ucsf.edu/modbase-cgi/search_form.cgi), we identified a UBD in 
Ephexin5, consistent with its predicted tertiary structure. 
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Angelman syndrome affects the level of Ephexin5 expression in the brain.  We compared the 
level of Ephexin5 protein expression in the brains of wild type mice to that expressed in the 
brains of mice in which the maternally inherited Ube3A was disrupted (Ube3A
m-/p+
).  Because 
the paternally inherited copy of Ube3A is silenced in the brain due to imprinting, the level of 
Ube3A expression in Ube3A
m-/p+
 neurons is very low.  We found that the level of Ephexin5 
expression in the brains of Ube3A
m-/p+
 mice was significantly higher than that detected in the 
brains of wild type mice (Figure 2.13E).  Moreover, the level of ubiquitinated Ephexin5 in 
brains of Ube3A
m-/p+ 
mice was significantly reduced compared to the brains of littermate controls 
(Figure 2.13F).  In addition we found that when neurons from wild type and Ube3A
m-/p+ 
brains 
were cultured and then treated with EphrinB1 the level of Ephexin5 protein was reduced upon 
EphrinB1 treatment in wild type but not in Ube3A
m-/p+ 
neurons (Figure 2.13G).  Taken together, 
these findings suggest that in response to EphrinB treatment Ephexin5 is tyrosine phosphorylated 
by an EphB-dependent mechanism, and that this leads to Ephexin5 degradation by a Ube3A-
dependent mechanism. If Ephexin5 degradation is disrupted due to a loss of Ube3A as occurs in 
Angelman syndrome the result is an increase in Ephexin5 expression and a disruption of the 
proper control of excitatory synapse number during brain development. 
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2.4   Discussion 
Previous studies have revealed a role for EphrinB/EphB signaling in the development of 
excitatory synapses (Klein, 2009).  However, the regulatory constraints that temper EphB-
dependent synapse development so that excitatory synapses form at the right time and place, and 
in the correct number were not known.  In this study we identify a RhoA GEF, Ephexin5, which 
functions to restrict EphB-dependent excitatory synapse development.  Ephexin5 interacts with 
EphB prior to EphrinB binding, and by activating RhoA serves to inhibit synapse development.  
The binding of EphrinB to EphB as synapses form triggers the phosphorylation and degradation 
of Ephexin5 by a Ube3A-dependent mechanism.  The reduction in Ephexin5 expression may 
allow EphB to promote excitatory synapse development by activating Rac and other proteins at 
the synapse (Figure 2.15). 
The findings that Ephexin5 functions to restrict excitatory synapse number suggests that, 
even though EphBs promote excitatory synapse development, there are constraints on the 
activity of EphB so that synapse number is effectively controlled.  There are several steps in the 
process of synapse development where Ephexin5 may function to restrict synapse number.  One 
possibility is that Ephexin5 functions early in development as a barrier to excitatory synapse 
formation by activating RhoA and restricting the motility or growth of dendritic filopodia that 
are the sites of contact by the presynaptic neuron.  For example, by inhibiting dendritic filopodia 
formation or motility, Ephexin5 may decrease the number of contacts the filopodia make with 
the presynaptic neuron, thus resulting in the formation of fewer synapses.  An alternative 
possibility is that Ephexin5 functions to restrict synapse number later in development perhaps to 
counterbalance the positive effects of EphB on Rac that promote dendritic spine development.   
92 
 
 
Figure 2.15:  Model of EphB and Ephexin5-dependent synapse formation 
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Figure 2.15 (continued): 
A)  Ephexin5, via its RhoA GEF activity, restricts early spine and synapse formation along the 
developing dendrite prior to the EphB-dependent phase of synapse development. 
B) Presynaptic EphrinB on the incoming axon contacts postsynaptic EphB receptor tyrosine 
kinases along the developing dendrite.  Subsequent autophosphorylation of EphBs leads to the 
tyrosine phosphorylation and the Ube3a-dependent degradation of Ephexin5 at nascent synaptic 
sites.  This allows EphB-mediated synapse formation to ensue, in part, through the recruitment 
and activation of Rac GEFs. 
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An additional possibility is that Ephexin5 functions after excitatory synapse development as a 
regulator of synapse elimination. 
Our analyses of Ephexin5 function are most consistent with the possibility that Ephexin5 
functions early in the process of synapse development. First, we find that Ephexin5 is expressed, 
active, and bound to EphB prior to synapse formation.  Second, the interaction of EphrinB with 
EphB, a process that is thought to be an early step in excitatory synapse development, triggers 
the degradation of Ephexin5.  Third, our preliminary time-lapse imaging studies suggest that 
Ephexin5 is localized to newly formed filopodia prior to synapse development where it appears 
to restrict filopodia motility and growth (Margolis et al. unpublished).  Thus, Ephexin5 might 
function as an initial barrier to synapse formation until it is degraded upon EphrinB binding to 
EphB. 
It is possible that through its interaction with EphB, Ephexin5 marks the sites where 
synapses will form, and that the degradation of Ephexin5 is a critical early step in excitatory 
synapse development.  While the mechanisms by which Ephexin5 is degraded are not fully 
understood, our studies suggest that the phosphorylation of the N-terminus of Ephexin5 at Y361 
triggers the Ube3A-mediated proteasomal degradation of Ephexin5.  One possibility is that prior 
to Y361 phosphorylation the N- and C-terminal portions of Ephexin5 interact, thereby protecting 
Ephexin5 from degradation. The phosphorylation of Ephexin5 at Y361 may relieve this 
inhibitory constraint allowing for Ephexin5 ubiquitination and degradation.  A similar 
mechanism has been shown to regulate the activation of the Rac GEF Vav, (Aghazadeh et al., 
2000)).  During EphrinA/EphA signaling it has been proposed that Vav-mediated endocytosis of 
the EphrinA/EphA complex may allow the conversion of the initial adhesive interaction between 
EphrinA and EphA-expressing cells into a repulsive interaction that result in growth cone 
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collapse and axon repulsion.  It is possible that Ephexin5 has a related function during EphB 
signaling at synapses.  Typically the EphrinB/EphB interaction is thought to be repulsive.  This 
has been documented in studies of EphB’s role in the process of axon guidance (Egea and Klein, 
2007; Flanagan and Vanderhaeghen, 1998).  However, during synapse development the 
EphrinB/EphB interaction is thought to result in synapse formation, a process that requires an 
interaction between the developing pre- and post-synaptic specialization.  One possibility is that 
when EphrinB and EphB mediate the interaction between the incoming axon and the developing 
dendrite, the interaction is facilitated by the degradation of Ephexin5.  Since Ephexin5 is a RhoA 
GEF, its presence might initially lead to repulsion between the incoming axon and the dendrite. 
However, the EphB-dependent degradation of Ephexin5 might convert this initial repulsive 
interaction into an attractive one. 
The finding that Ube3A is the ubiquitin ligase that controls EphB-mediated Ephexin5 
degradation is of interest given the role of Ube3A in human cognitive disorders such as 
Angelman syndrome and autism.  The absence of Ube3A function in Angelman syndrome would 
be predicted to result in an increase in Ephexin5 protein expression, and thus a decrease in 
EphB-dependent synapse formation.  Consistent with this possibility, we find in a mouse model 
for Angelman syndrome that the level of Ephexin5 protein expression is elevated and that in 
response to EphrinB treatment, Ephexin5 is not degraded.  Likewise, several studies have 
indicated that synapse development and function is disrupted in these mice (Cooper et al., 2004; 
Dindot et al., 2008; Jiang et al., 1998; Yashiro et al., 2009). 
The recent finding that the Ube3A gene lies within a region of chromosome 15 that is 
sometimes duplicated in autism raises the possibility that altered levels of Ephexin5 and the 
resulting defects in excitatory synapse restriction might also be a mechanism relevant to the 
96 
 
etiology of autism (Glessner et al., 2009).  If this is the case, a possible therapy for treating 
autism might be to reduce the level of Ube3A activity, and thus increase the level of Ephexin5 
expression.  It is important to consider that in addition to Ephexin5, Ube3A regulates the 
abundance of other synaptic proteins.  Therefore, the ultimate effect of the aberrant expression of 
Ephexin5 and other Ube3A substrates on synapse development and function will require further 
study.  It seems likely that such studies will provide further understanding of the development of 
human cognitive function and new insights into how this process goes awry in disorders such as 
Angelman syndrome and autism. 
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2.6   Materials and Methods 
DNA Constructs 
The full-length mouse Ephexin5 was generated by RT-PCR from RNA isolated from 
mouse E16 cortical neurons at 7 days in vitro and subcloned into EcoRI/XhoI sites of the pEF1-
Myc-HisA vector (Invitrogen).  Ephexin5 GEF and phosphorylation mutants (LQR, QSRL, and 
Y361F) were generated using the QuickChange site-directed mutagenesis kit (Stratagene). All 
constructs were verified by DNA sequencing. The following plasmid constructs have been 
described previously: Flag-EphB2, Flag-EphB2KD, Flag-EphB2 Cyto (Dalva et al., 2000), 
Ephexin1-Myc (Sahin et al., 2005), HA-Ube3A (Greer et al, 2010), HA-Mef2 (Flavell et al., 
2006), HA-Cbl-b (Cowan et al., 2005), eGFP (Paradis et al., 2007), Cre-recombinase (Lin et al., 
2008).  The pLenti-Lox-Ephexin5 RNAi constructs were designed as previously described. 
Briefly, the following oligonucleotides were annealed with their complimentary sequence and 
inserted into the BglII site of pLenti-Lox vector: TAGCCGCCTTATGGATACAAA and 
TCCGAAAGCACTTCCTCAAAT (Figure S2). These regions were not homologous to 
Ephexin1 or any other known genes as indicated by Blast search. 
Generation of Ephexin5
−/−
 Mice 
An Ephexin5 targeting vector was electroporated into 129 J1 ES cells, and positive clones 
were identified by Southern hybridization with two separate probes. To obtain constitutive 
deletion of the Ephexin5 exons, a Cre-recombinase expressing plasmid (pOG231Cre or pMC-
CreN) was electroporated into ES cells carrying the homologous recombination. Constitutive 
knockout and conditional floxed ES cells were identified by replicate plating for G418 sensitivity 
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followed by Southern hybridization and genomic PCR. Positive clones were grown without 
G418 and expanded for genotyping. 
Antibodies 
The following rabbit polyclonal antibodies were generated against the indicated amino 
acids of mouse Ephexin5 and then affinity purified: α-N-E5 was raised against a GST-fusion 
protein containing amino acids 1-418. α-C-E5 was raised against a C-terminal peptide sequence 
corresponding to amino acids 720-732 (EHERRKHLRQHUK). -α-p361 was raised against a 
peptide sequence corresponding to amino acids 354-368 (PLQDEPLpYQTYRAAV), in which 
tyrosine residue 361 was phosphorylated (denoted as pY in peptide sequence). The specificity of 
the Ephexin5 antibodies was tested by western blotting using brain lysates from WT and 
Ephexin5 knockout littermates. Rabbit polyclonal α-EphB2) and anti-phospho-Eph (α-pEph) 
were used as previously described (Dalva et al., 2000). The following antibodies are 
commercially available and used according to manufacturer’s suggestions for western blotting, 
immunocytochemistry and immunoprecipitations: α-Myc (Abcam), α-Flag (Sigma), α-RhoA 
(Santa Cruz Biotechnology), goat α-EphB2 (Santa Cruz), α-Rac1 (Millipore), α-Cdc42 
(Millipore), α-β-actin (Abcam), α-PSD95 (ABR Affinity Bioreagents), αSynapsin (Chemicon), 
α-HA (Santa Cruz Biotechnology), α-pan-phosphotyrosine 4G10 (Millipore), α-ubiquitin 
(Biomol International), and α-E6AP (Ube3A) (Biomol). 
Mice, Cell culture, Transfections, and Ephrin stimulations 
Ube3a knockout mice were obtained from The Jackson Laboratory, strain 129- 
Ube3a
tm1Alb
/J, from stock number 004477.  HEK293T cells were cultured in DMEM 
supplemented with 10% fetal bovine serum, 2 mM glutamine (Sigma), and 
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penicillin/streptomycin (100 U/mL and 100 µg/mL, respectively; Sigma). Rat hippocampal 
neurons were prepared from E18 Long-Evans rat embryos (Charles River) as previously 
described (Xia et al., 1996). Mouse hippocampal neurons were prepared from E16 C57/B6 
mouse embryos as previously described (Tolias et al., 2005). Hippocampal neurons were 
maintained in Neurobasal Medium (Invitrogen) supplemented with 2% B27 (Invitrogen), 
penicillin/streptomycin (100 U/mL and 100 µg/mL, respectively), and 2 mM glutamine. For 
synapse assays using immunofluorescence staining, hippocampal neurons were plated on glia 
isolated as previously described (Flavell et al., 2006). Organotypic hippocampal slice cultures 
were prepared from P6 Ephexin5 conditional mice as previously described (Stoppini et al., 
1991). Slices were biolistically transfected with a Helios Gene Gun (Biorad) after 2 days. Bullets 
for the gene gun were 1.6-μm gold particles coated with 15 μg eGFP and 30 μg Cre. Empty 
vector plasmid was added to bring the total DNA to 60 μg in each case. Cultures were fixed, 
stained, and quantified for spine number at DIV6. HEK293T cells were transfected for 24 or 48 
hours using the calcium phosphate method as previously described (Lois et al., 2002).  
Dissociated neurons were transfected using the Lipofectamine method (Invitrogen) 
according to the manufacturer’s suggestions. For Ephrin stimulations in dissociated cultured 
neurons, mouse EphrinB1-FC (1µg/µL; R & D Systems) was pre-clustered with goat anti-human 
IgG FC (1.3 µg/µL; Jackson Immunoresearch) at room temperature in 1x PBS in a 1:3 ratio prior 
to stimulation. Pre-clustered EphrinB1-FC was added to Neurobasal/B27 medium at 5 µg/mL 
and applied to cultured neurons. For controls, clustered goat anti-human IgG FC in 
Neurobasal/B27 was applied to neurons. 
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Cell lysis, immunoprecipitations, GEF pulldown assays and western blots 
Whole rat or mouse brains or cultured cells were collected and homogenized in RIPA 
buffer (50 mM Tris pH 8.0, 150 mM NaCl, 1% Triton X-100, 0.5% Sodium Deoxycholate, 0.1% 
SDS, 5 mM EDTA, 10 mM NaF, complete protease inhibitor cocktail tablet (Roche), 1 mM 
sodium orthovanadate, 1 mM β-glycerophosphate). For time course studies, hippocampus was 
freshly dissected out of whole brain and homogenized as described above. For 
immunoprecipitations, cells were lysed in RIPA buffer and centrifuged at 50,000 x g. 
Supernatants were incubated with appropriate antibody (1-3 µg) for 2 hours at 4 °C, followed by 
addition of Protein-A or Protein-G beads (Santa Cruz Biotechnology) for 1 hour, and washed 
three times with ice-cold RIPA buffer. For the phosphotyrosine detection experiment in 
HEK293T cells, samples were boiled for 10 minutes in 1% SDS buffer to disrupt the 
Ephexin5/EphB2 interaction and diluted 1:5 in 1.25X RIPA buffer prior to immunoprecipitation 
of Ephexin5-Myc.  RBD and PBD pulldown assays were conducted according to the 
manufacture’s suggestions (Upstate Cell Signaling Solutions). Briefly, HEK293T cells were 
grown to ~60% confluence, transfected with plasmids for 48 hours, lysed in Mg
2+
/lysis buffer 
(25 mM HEPES pH 7.5, 125 mM NaCl, 1% NP-40, 10 mM MgCl2, 1mM EDTA, and 10% 
glycerol supplemented with complete protease inhibitor tablets from Roche), and incubated with 
either RBD or PBD agarose for 45 minutes at 4 degrees. For western blots, samples were boiled 
for 5 minutes in SDS sample buffer, resolved by SDS PAGE, transferred to nitrocellulose, and 
immunoblotted. 
 
 
101 
 
In situ hybridization 
To generate probes for in situ hybridization, mouse Ephexin5 and EphB2 cDNA were 
subcloned into pBluescript II SK (+).  Bluescript plasmids containing Ephexin5 or EphB2 cDNA 
were linearized using the restriction enzyme BssHII.  Sense and antisense probes were generated 
using DIG RNA labeling mix (Roche) according to manufacturer’s instructions.  Full-length 
DIG-labeled probes were subjected to alkaline hydrolysis as previously described (Wiemers and 
Gerfin-Moser, 1993).  Probe sizes were checked by running non-hydrolyzed and hydrolyzed 
probes on a 1% formaldehyde agarose gel.  In situ hybridization was performed as previously 
described (Schaeren-Wiemers and Gerfin-Moser, 1993).  Briefly, P10 whole brains were 
embedded in Tissue-Tec and kept at -20 °C.  Tissue sections 14 µm-thick were sectioned onto 
Superfrost Plus Slides (Merck), fixed for 10 minutes with 4% paraformaldehyde in PBS, and 
subsequently washed 3 times in PBS.  Acetylation of tissue sections was performed for 10 
minutes with constant stirring in glass staining jars, and subsequently washed 3x with PBS.  
Slides were incubated with pre-hybridization solution (50% formamide, 5x SSC, 5x Denhardts 
solution (Sigma), Yeast tRNA) at room temperature for 6 hours to overnight.  DIG-labeled 
probes were hydrolyzed in an alkaline hydrolysis buffer as previously described (Schaeren-
Wiemers and Gerfin-Moser, 1993).  Probes were diluted in pre-hybridization buffer at a 
concentration of 200 ng/mL and denatured for 5 minutes at 85 °C prior to hybridization.  Slides 
were incubated in 100 µL, covered by plastic coverslips (Invitrogen), and hybridization was 
performed overnight at 72 °C.  Color reaction was performed as previously described (Schaeren-
Wiemers and Gerfin-Moser, 1993), except a BCIP/NBT mixture (Roche) was used according to 
manufacturer’s instructions.  Slides were mounted in Slowfade Gold antifade reagent with DAPI 
(Invitrogen) and covered with Glass Coverslides (Fisher).  Sections were imaged using a Zeiss 
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Imager.Z1 microscope with a Photometrics CoolSNAP HQ2 camera on a PLAN APO 63x/1.4 
objective.   
Immunocytochemistry 
Neurons were fixed for 8 minutes at 25 °C with 4% paraformaldehyde/4% sucrose in 
PBS. For synapse density measurement, fixed neurons were incubated with α-PSD-95 and α-
Synapsin antibodies (1:200 each) in 1× GDB (30 mM phosphate buffer [pH 7.4] containing 0.2% 
gelatin, 0.3% Triton X-100, and 0.8 M NaCl) overnight at 4 °C. Goat α-mouse Cy3 and goat α-
rabbit Cy5 (1:200 each in 1× GDB for 1 hour at 25 °C) antibodies were used to visualize the 
primary antibodies. For protein co-localization experiments fixed neurons were similarly treated 
using α-EphB2 antibodies raised in goat (1:200) and the rabbit anti-N-terminal Ephexin5 
antibodies (1:200) or α-pY361-Ephexin5. For over-expression studies, transfected neurons were 
fixed and stained as described above using α-Myc and α-N-terminal Ephexin5 antibodies to 
visualize overexpressed Ephexin5 protein in the context of the GFP-labeled neurons to visualize 
the localization of Ephexin5 protein. Samples on coverslips were mounted on glass slides using 
Fluoromount-G (Southern Biotech). Neurons were imaged using a laser scanning Zeiss Pascal 
microscope. 
Synapse Assays 
Our method for introducing shRNAs results in the transfection of a low percentage of the 
neurons, thus facilitating quantification of the number of synapses/dendritic spines that are 
present on the transfected neuron (Paradis et al., 2007).  The number of dendritic spines that are 
present on a shRNA-expressing neuron was quantified by first marking each dendritic spine 
found on the developing dendrites of the transfected neuron and then using MetaMorph analysis 
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tools to tally the number of marked spines that were present on a given length of dendrite.  The 
number of excitatory synapses that are present on a shRNA-expressing neuron were determined 
by staining with the postsynaptic excitatory synaptic marker PSD-95 and the presynaptic 
excitatory synaptic marker Synapsin.  Using MetaMorph analysis tools, we quantified the 
number of overlapping pre- and post-synaptic puncta on the transfected green fluorescing neuron 
to determine excitatory synapse density.   
Image analysis and quantification  
For dissociated neurons, images were obtained using a Zeiss Pascal confocal microscope, 
using a 63× objective with sequential acquisition settings at 1024 × 1024 pixel resolution. 
Images for the colocalization analysis were taken with the same exposure parameters. On 
average, 5 stacks at 0.5 µm were taken for each neuron image. Images were collected from 10 to 
15 neurons per coverslip, with two coverslips required for each condition. Synapse density was 
measured using Metamorph software as previously described (Universal Imaging Corporation) 
(Paradis et al., 2007). Because synapse density and immunostaining vary significantly between 
experiments, it was necessary to normalize each experiment before combining the data from 
individual experiments. Normalization and error propagation were performed as previously 
described (Paradis et al., 2007). The number of overlapping red and blue puncta greater than 2 
pixels in size and localized to the transfected neuron was divided by the total dendritic area being 
measured. For Ephexin5 levels, the total intensity of Ephexin5 puncta over the area of the neuron 
was used to determine the density of Ephexin5 expression in the neuron. Statistical significance 
was determined by Student’s t test. 
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For dendritic spine assays, a z series projection of each neuron was made using 
approximately six sections (0.45 μm/section), each averaged four times. To measure spine 
density, an experimenter blinded to the condition measured at least three dendritic segments 
totaling at least 200 μm of dendritic length/neuron, and the number of spines was counted. 
Between eight and ten transfected neurons were chosen randomly for quantification per 
experiment, and several pairs of littermates were quantified individually. For quantification of 
spine size, images blinded to the experimenter were analyzed using Metamorph (Universal 
Imaging Corporation) by manually tracing the length for at least 1000 spines per animal (Pak et 
al., 2001). Statistical significance was calculated using Student’s t test or ANOVA.  For 
densitometry measurements we analyzed western blots in the linear range using ImageJ.  Each 
western lane is normalized to loading controls. 
Array Tomography  
Array tomography was performed as described previously (Micheva and Smith, 2007).  
In summary, acute hippocampal slices (300 μm thick) were fixed in 4% paraformaldehyde for 1 
hour at room temperature and embedded in LR White resin using the benchtop protocol.  
Ribbons of between 30-50 serial 100 nm-thick wild type sections prepared from wild type and 
Ephexin5 mutant mice were mounted side by side on subbed glass coverslips.  Coverslips were 
immunostained with α-synapsin1 (ms, Chemicon, 1:100) and α-PSD95 (Rb, ABR Affinity 
Bioreagents, 1:100) antibodies as described.  Serial sections were imaged using a Zeiss 
Imager.Z1 microscope with a Photometrics CoolSNAP HQ2 camera on a PLAN APO 63x/1.4 
objective.  Tissue volumes were aligned using ImageJ (NIH) with the multistackreg plugin (Brad 
Busse).  Reconstructed tissue volumes were cropped to include only stratum radiatum of CA1; 
and, three dimensional models of the synaptic puncta were built using Bitplane Imaris and 
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analyzed using custom software to count synapses.  This software computes the distance from 
the center of every synapsin puncta to the center of every PSD-95 puncta, and a synapse was 
counted if the distance between the centers was equal to or less than the sum of the radii of the 
two puncta plus an empirically determined scaling factor of 0.15 μm.  All experiments were 
carried out and analyzed blinded to genotype. 
Electrophysiology 
Whole-cell voltage clamp recordings were obtained using an Axopatch 200B amplifier at 
25 °C. Rat hippocampal neurons were transfected with 250 ng of eGFP and 25 ng of shRNA to 
Ephexin5 or scrambled shRNA as a control.  Four days after transfection, neurons were perfused 
with artificial cerebrospinal fluid containing 127 mM NaCl, 25 mM NaHCO3, 1.25 mM 
Na2HPO4, 2.5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 25 mM glucose, and saturated with 95% O2, 
5% CO2. The internal solution for mEPSC analysis contained 120 mM cesium methane 
sulfonate, 10 mM HEPES, 4 mM MgCl2, 4 mM Na2ATP, 0.4 mM Na2GTP, 10 mM sodium 
phosphocreatine and 1 mM EGTA. Osmolarity and pH were adjusted to 300 mOsm and 7.3 with 
Millipore water and CsOH, respectively. 
The mEPSCs were isolated by exposing neurons to 0.5 µM tetrodotoxin, 50 µM 
picrotoxin (Tocris Bioscience), and 10 µM cyclothiazide. Cells with series resistance larger than 
25 MΩ during the recordings were discarded. Data were analyzed in IgorPro (Wavemetrics) 
using custom-written macros. For each trace, the event threshold was set at 1.5 times the root-
mean-square current. Currents were counted as events if they crossed the event threshold, had a 
rapid rise time (1.5 pA ms
-1
) and had an exponential decay (τ <50 ms for mEPSC). 
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Statistical significance was determined by two methods. First, 50 random points selected 
from each cell were concatenated to describe the cumulative distributions of events in each 
condition and then compared by a Kolmogorov–Smirnov test. Second, a Monte Carlo simulation 
was performed in which points were randomly sampled from each condition and the mean of 
these samples compared at least 1,000 times. P<0.05 from both tests was considered significant. 
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Chapter 3  
Human ArhGEF15/Ephexin5 mutations in epileptic encephalopathy 
 
 
 
 
 
 
 
 
 
 
 
 
 
108 
 
3.1   Abstract 
 Infantile seizures are often the most difficult to control and can be associated with 
cognitive impairments and motor deficits.  Whole exome sequencing has proven to be a useful 
and efficient tool to identify de novo mutations in protein coding exons from individuals with 
infantile epileptic encephalopathies.  Our collaborators identified a mutation in the human 
homolog of Ephexin5 (Arhgef15) at Arg.604.Cys (R604C).  Clinical features of this individual, 
known as Proband G, include infantile spasms, epileptic encephalopathy, motor delay and 
emotional lability.  Overexpression of human ArhGEF15-R604C cDNA, and the homologous 
mutation in mouse, Ephexin5-R612C, results in a 45-50% reduction in guanine nucleotide 
exchange activity (GEF) towards RhoA.  Since R604C is a de novo human mutation that only 
affects one allele, and since the major protein function of Ephexin5 is its GEF activity, we 
reasoned that Ephexin5 heterozygote mice (Ephexin5 +/-) would be a useful model for epilepsy 
associated with the Arhgef15 mutation.  Indeed, Ephexin5 +/- mice are more susceptible to 
audiogenic seizures.  We also find that Ephexin5 +/- mice have increased anxiety in both the 
light dark box and the elevated plus maze, consistent with comorbid clinical features such as 
emotional lability.  Taken together, we suggest that studying Ephexin5 signaling will be a useful 
tool for understanding the wide array of synaptic deficits associated with epilepsy.   
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3.2  Background and Rationale 
Epilepsy is a disorder characterized by recurring seizures of heterogenous origin.  
Approximately one quarter of all seizures are caused by brain lesions coming from hypoxic 
injury, trauma, tumors, or drug misuse (Meisler et al., 2010).  It is estimated that the majority of 
seizures have a genetic origin (Meisler et al., 2010).  Despite the identification of some of these 
genes, in many cases the underlying genetic perturbations are still unknown.  Two major goals of 
epilepsy research are to identify all candidate genes in order to create a rapid screening platform 
for diagnosis, and to elucidate the mechanisms of how these genes contribute to underlying 
cellular processes (Bamshad et al., 2011; The Epi4K Consortium, 2012). 
Next generation sequencing has made it possible to identify candidate genetic loci that 
contribute to epileptic disorders.  323 genes have been identified that are mutated in epilepsy as 
the primary phenotype or as a phenotype associated with other neurological diseases (Lemke et 
al., 2012).  Because of this heterogeneous genetic contribution, epilepsies are often associated 
with cognitive impairment, ataxia, or autism as comorbid phenotypic features.   
The most common genetic cause of de novo and inherited epilepsy are mutations in the 
voltage-gated sodium channel gene, SCN1A (Meisler et al., 2010).  SCN1A protein is highly 
enriched in GABAergic interneurons, and mutations in these neurons are hypothesized to disrupt 
action-potential firing properties by reducing the sodium conductance, which increases overall 
net excitation (Meisler et al., 2010).  More than 80% of SCN1A mutations are found in 
individuals with Dravet Syndrome, a disorder characterized by severe intractable seizures 
starting in infancy.  Comorbid features of Dravet syndrome include sleeplessness, ataxia, delayed 
language, and cognitive impairments (Marini et al., 2011).  Mouse models of Dravet syndrome 
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(i.e., Scn1a heterozygotes) have spontaneous seizures and autistic-like features consistent with 
the human disorder (Han et al., 2012; Marini et al., 2011).  Similar to Scn1a, it is hypothesized 
that most genes implicated in epilepsy alter the balance of neuronal excitation/inhibition (E/I), 
resulting in a hyperexcitable neuronal circuit (Meisler et al., 2010).     
Scn1a is one of 30 known protein-coding genes mutated in a phenotypic class of epilepsy 
known as infantile epileptic encephalopathies (Meisler et al., 2010; Lemke et al., 2012).  These 
genes include transcriptional regulators such as FoxG1, Pnkp andMeCP2, cell-adhesion 
molecules such as neurexin1 and Cntnap2, the presynaptic-release machinery molecule Stxbp1, 
and cytosolic enzymes such as ArhGEF9, Ube3a, and Mapk10 (Lemke et al., 2012).  Recently, 
our collaborators identified three new genes mutated in infantile epilepsy (Veeramah et al., 
2013). 
Here we report the identification and analysis of a mutation in the guanine-nucleotide 
exchange factor (GEF) ARHGEF15/Ephexin5, a negative regulator of synapse development.  
We find that this mutation leads to a reduction in RhoA GEF activity, without altering protein 
stability.   Ephexin5 heterozygote mice display increased susceptibility to seizures and increased 
anxiety-like behaviors.  Taken together, we suggest that studying Ephexin5 signaling in more 
detail will be important for understanding the wide array of synaptic deficits associated with 
epilepsy.     
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3.3   Analysis of a de novo mutation in human Ephexin5      
Our collaborators at the University of Arizona employed whole exome sequencing to 
screen individuals with intractable infantile epilepsies (Probands A-J) and their unaffected 
parents (Veeramah et al, 2013).  A de novo mutation in Arhgef15, the human homolog of 
Ephexin5, was identified.  This individual, known as Proband G, had complex, infantile seizures 
that were difficult to control with drug interventions.  Comorbid clinical features include 
infantile spasms, mild motor and speech delay, emotional lability, and compulsive behavior 
(Table 3.1). 
Proband G possesses a de novo non-synonymous mutation in the gene Rho Guanine 
Nucleotide Exchange Factor 15 (ARHGEF15), a human homolog of mouse Ephexin5, resulting 
in an Arg604Cys substitution in the protein.  Ar604 is conserved in the mouse genome at 
Arg.612 and a number of other closely related species (Figure 3.1).  While an Ephexin5 
mutation has not previously been associated with a human disease, Ephexin5 is highly expressed 
in the brain (Sahin et al., 2005) and was recently shown to negatively regulate excitatory synapse 
formation during development (Margolis et al., 2010).  In particular, Ephexin5 suppresses the 
function of EPH receptor B2 (EphB2), a mechanism believed to limit uncontrolled synapse 
formation.  When EphB2 encounters its ligand Ephrin-B1/2, Ephexin5 is phosphorylated, 
ubiquitinated and finally degraded, allowing synapse formation to occur.  The process of 
degradation is mediated by ubiquitin protein ligase E3A (UBE3A).  Interestingly, 90% of patients 
diagnosed with Angelman Syndrome, which is highly associated with seizures, lack expression 
of UBE3A (Dan, 2009). It has been suggested from studying Angelman Syndrome mouse 
models that one mechanism of the disorder is due to a lack of degradation of Ephexin5 by  
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Table 3.1: Clinical summary of Proband G with ArhGEF15 mutation 
113 
 
 
 
 
 
Figure 3.1:  Human Ephexin5 protein alignment reveals conserved site at Arg.604 
ClustalW protein alignment reveals conservation across multiple species of amino acid position 
Arg.604 (red rectangle) in human Ephexin5 protein.    
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UBE3A, which leads to a decrease in synaptic formation (Margolis et al., 2010).   
Ephexin5’s GEF exchange activity is required to restrict synapse formation (Margolis et 
al., 2010; Chapter 2).  Since Ephexin5 was previously shown to promote the activation of the 
small GTPase RhoA, we hypothesized that a de novo mutation in Ephexin5 may disrupt its GEF 
exchange activity towards RhoA.  To test this we cloned an Ephexin5 human cDNA containing 
the p.Arg604Cys substitution (R604C).  We transfected 293 cells with a control plasmid, a 
plasmid driving the expression of wild-type (WT) human Ephexin5, or a plasmid driving the 
expression of mutant R604C.  We prepared extracts from transfected cells, and subjected them to 
a calorimetric-based G-LISA RhoA activation assay.  We find that RhoA activation by R604C is 
reduced by ~46% compared to WT-Ephexin5 (Figure 3.2A).  We also find that the homologous 
amino acid substitution in mouse Ephexin5 at Arg612Cys (R612C) shows a ~47% reduction as 
compared to mouse WT-Ephexin5 protein (Figure 3.2B).  As an alternative approach, we lysed 
293 cells transfected with control plasmid, WT-Ephexin5 plasmid, or R612C plasmid, and 
incubated the lysates with GST-Rhotekin-binding-domain (RBD) agarose.  Active RhoA was 
determined by immunoblotting the RBD pulldowns with an antibody to RhoA.  Lysates from 
overexpressed R612C had reduced RhoA activity compared to WT-Ephexin5 (Figure 3.3)   
Importantly, we did not detect differences in mutant protein expression compared to the WT 
protein in these 293 cell lysates (Figure 3.2C and 3.2D), suggesting that the de novo mutation 
causes a deficit in GEF exchange activity, and not protein stability. Taken together, we conclude 
that the human R604C mutation may lead to decreased Ephexin5 GEF activity resulting in an 
increase in excitatory synapse number in the brain which could be an underlying cause of the 
seizures observed in Proband G. It is important to note that Proband G also possesses a 
frameshift de novo mutation in the gene HADHB, which is known to cause mitochondria 
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Figure 3.2: De novo Arg to Cys mutations in Ephexin5 reduce RhoA GEF activity 
A) Lysates from 293 cells transfected with control plasmid, human WT-Ephexin5, and R604C 
were subjected to the G-LISA activation assay.  Error bars indicate SEM (n=4) *p < .01, 
Student’s T-test.   
B) Mouse WT-Ephexin5 and R612C were assayed for RhoA activation similar to A).  Error bars 
indicate SEM (n=3) *p < .05, Student’s T-test.   
C) Representative quantitative Western Blot using LiCor Odyssey IR software from lysates used 
in A) and B).  Protein samples were run on an SDS-PAGE gel and Ephexin5 protein was 
detected using a rabbit polyclonal antibody raised against the N-terminus.   
D) Western Blot quantification for all samples.  Error bars indicate SEM (n=4 per human 
conditions; n=3 per mouse conditions), p > .05, Student’s T-test 
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Figure 3.3: Ephexin5-R612C has reduced RhoA GEF activity by RBD pulldown.   
A)  HEK 293 cells were transfected with control, WT-Ephexin5, or R612C plasmids.  Cell 
lysates were incubated with GST-RBD agarose.  RBD pulldowns were immunoblotted with α-
RhoA.  Total levels of transfected Ephexin5, and RhoA were assessed with α- N-E5, and α-
RhoA, respectively.  Representative image.   
B)  Quantification of A from 3 independent experiments expressed as fold-change over control.  
Immunoblot signals were quantified by densitometry and normalized to total RhoA levels.  p < 
.01, Student’s T-test. 
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trifunctional protein (MTP) deficiency when found in simple homozygous or compound 
heterozygous form (Park et al., 2009). However, there were no other variants found in this trio in 
HADHB, suggesting that this is not a causative mutation. 
We have begun to search for additional rare and pathogenic Arhgef15/Ephexin5 variants 
in individuals with epileptic encephalopathies in collaboration with Dr. Poduri at Children’s 
Hospital Boston.  Poduri and colleagues have access to a list of sequenced genomes from 
individuals with epileptic encephalopathies both at Children’s Hospital and part of the Epi4K 
consortium, whose stated goal is to sequence at least 500 individuals.  Thus far, we have 
identified two additional putative Ephexin5 variants (verified by Sanger sequencing) in cases 
where the genetic etiology was unknown.   One rare variant at Arg.546Pro (R546P) is mutated in 
an individual with migrating partial epilepsy.  It is a highly conserved amino acid, and predicted 
to be deleterious using SIFT software (Poduri, personal communication).  It is not clear whether 
this variant is a sporadic, de novo mutation because the parental DNA has not been sequenced.  
R546P is in the RhoGEF domain and in fact, is the amino acid adjacent to the CR3 domain 
predicted to be important for all GTPase interactions (see Section 1.5).  This variant is a rare 
SNP (<.1% of the control population), however this individual has no other obvious alternate 
explanations in known disease-causing genes.  The second variant at Arg.105.Gln (R105Q) is 
from a girl with autism and early onset epilepsy that resolved.  In this case, the variant was 
paternally inherited, but given the patient’s mild presentation, the possibility of this variant being 
a causative mutation remains open.  Interestingly, R105Q lies two amino acids upstream of a 
novel, developmentally regulated phosphorylation site at serine-107 (see Chapter 4).  
Phosphorylation at S107 is predicted to be a recognition site for the basophilic kinase protein 
kinase A (PKA) and mutating this critical Arg residue would inhibit phosphorylation.  Therefore, 
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it is worth investigating whether the R105Q variant works in concert with Ephexin5 serine 
phosphorylation to regulate aspects of GEF activity and synapse development.   
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3.4  Behavioral mouse model of epilepsy and comorbidity: analysis 
of Ephexin5 +/- mice  
R604C is a de novo human mutation that only affects a single allele, and since the major 
protein function of Ephexin5 is its GEF activity, we reasoned that Ephexin5 heterozygote mice 
(Ephexin5 +/-) would be a useful model for epilepsy associated with the Arhgef15 mutation.  
Similar haploinsuffiency mouse models have proven useful in elucidating mechanisms in Scn1a 
+/- mice (Han et al., 2012; Marini et al., 2011). 
First, we sought to determine if Ephexin5 +/- mice are susceptible to seizures.  
Audiogenic-induced seizures (AGS) were conducted on P30 Ephexin5 +/- mice and their wild-
type (WT) littermates.  Ephexin5 +/- mice take approximately 2.5x longer to recover from AGS 
than their WT littermates (Figure 3.4), suggesting that Ephexin5 +/- mice have an increased 
susceptibility to seizures. 
 We were also interested in the comorbid features associated with the Arg.604.Cys 
Arhgef15 mutation.  In particular, Proband G displayed emotional lability, language and speech 
delay, and poor coordination.  Emotional lability has previously been related to anxiety-related 
behaviors in mouse models (Wei et al., 2004).  Ephexin5 +/- mice display an increase in the time 
spent in the open arms (Figure 3.5A) compared to WT littermate controls.  They also display an 
increase in number of open arm entries compared to WT littermate controls (Figure 3.5B).  
Next, as an independent means of assessing anxiety, Ephexin5 +/- were assayed in the light/dark 
box.  Ephexin5 +/- display a reduction in the time spent in the light compared to their WT 
littermates (Figure 3.5C).  Taken together, these data suggest that Ephexin5 +/- have increased 
anxiety-related phenotypes that model emotionally labile behaviors observed in Proband G.  
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Figure 3.4: Ephexin5 mouse model has enhanced audiogenic seizure susceptibility. 
Ephexin5 heterozygote (E5 +/-) males and littermate wild-type controls (WT) were subjected to 
audiogenic stimulation (see Materials and Methods), and time to recovery was assessed.  p=.053, 
Student’s T-test. 
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Figure 3.5: Increased anxiety in Ephexin5 mouse model 
A) Elevated plus maze for Ephexin5 +/- (n=11) and WT (n=8) littermate controls.  Total time 
spent in open arms is displayed, Student’s T-test, *p < .05 
B) Same as A) except the number of open arm entries was assessed, Student’s T-test, *p < .05 
C) Light/Dark Box for Ephexin5 +/- (n=10) and WT (n=9) littermate controls. Total time spent 
in light was assessed, *p<.05, Student’s T-test
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3.5  Discussion 
 We have analyzed a mutation found in an individual with infantile epileptic 
encephalopathy.  This mutation resides in the RhoGEF domain of Arhgef15/Ephexin5 and 
reduces guanine nucleotide exchange activity towards the small G-protein RhoA.  An Ephexin5 
happloinsufficiency mouse model (Ephexin5 +/-) has increased susceptibility to audiogenic 
seizures.  In addition, similar to comorbid phenotypes associated with Scn1a happloinsuffiency 
mouse models and human epilepsy disorders, we find that Ephexin5 /- mice have increased 
anxiety behaviors.   
In the future we will take two approaches to determine the robustness of our Ephexin5 
epilepsy model.  First, in collaboration with Dr. Poduri and colleagues at Children’s Hospital 
Boston, we identified two variants at R105Q and R546P that need to be tested for their ability to 
activate RhoA GEF activity and to regulate excitatory synapse development.  We will continue 
screening for rare variants in individuals with epileptic encephalopathies.  Second, we will 
screen Ephexin5 +/- mice for additional seizure phenotypes by electroencephalography 
recordings (EEGs) or by pentylenetetrazol (PTZ)/kainic acid-induced seizures.  Screening for 
additional seizure phenotypes is important because it is possible that our audiogenic-induced 
seizures are a consequence of specific alterations in the underlying brain stem/auditory pathway 
in Ephexin5 +/- mice, and not due to a bona fide alteration in the circuitry underlying 
generalizable seizures.   
How might seizures arise in the Ephexin5 happloinsuffiency model?  Ephexin5 
negatively regulates the density of excitatory synapses in the CA1 stratum radiatum subregion of 
the hippocampus (Chapter 2).  An increase in the number of excitatory synapse density could 
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lead to enhanced excitation and seizure activity.  The hippocampal circuit is often involved in 
epileptic activity, particularly in temporal lobe epilepsy (TLE) (Avoli, 2007).  Two major circuit 
pathways have been proposed to underly recurrent seizure activity in TLE. The first is an 
enthorinal cortex -> dentate gyrus -> CA3 -> CA1 -> subiculum -> entorhinal cortex pathway, 
and the second is a direct entorhinal cortex -> CA1 pathway (Avoli, 2007; Ang et al., 2006).  In 
future studies, stimulating epileptiform activity in Ephexin5 +/- acute slices containing the intact 
cortical/hippocampal circuit may help distinguish between these possible circuit mechanisms. 
Ephexin5 is also highly expressed in the cortex (Sahin et al., 2005; Salogiannis, 
unpublished observations) and could function to restrict excitatory synapse density in cortical 
neurons.  Increased synapse number in the cortex has been shown to lead to an increase in 
seizure susceptibility.  For instance, the immune response protein C1q is a potent negative 
regulator of excitatory synapses (Stevens et al., 2007), and C1q KO mice exhibit seizures due to 
an increase in neocortical synapse number (Chu et al., 2010).  Alternatively, it is plausible that 
the seizures in our Ephexin5 +/- model arise from deficits in axon guidance or deficits in 
inhibitory synapses.  Indeed, Ephexin1 has been shown to regulate axon guidance (Shamah et al., 
2001; Sahin et al., 2005; also see Section 1.5).  Additionally, an overwhelming number of genes 
mutated in human forms of epilepsy exhibit deficits in either inhibitory synapse number or in 
inhibitory neurotransmission.  The role of Ephexin5 in inhibitory synaptic function has not been 
tested.  Preliminary data from the Greenberg lab suggests that Ephexin5 is expressed in 
inhibitory neurons in vivo (Spiegel, personal communication).    
The R604C (mouse R612C) reduces RhoA GEF activity by 45-50%.  We previously 
demonstrated that amino acid substitutions at key residues in the GEF/GTPase interaction pocket 
lead to a reduction in the GEF activity of Ephexin5.  R604 resides in a region of the DH-PH 
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domain outside of the GEF interaction pocket.  Specifically, R604C is in a linker region between 
the DH and PH domains.  This region can provide structural rigidity critical for PH-domain 
anchoring to the plasma membrane, as well as for PH-domain autoinhibition during GEF 
exchange (Cherfils & Zeghouf, 2013).   Studying the R604C mutation in more detail will help 
elucidate biophysical mechanisms underlying the GEF activity of Ephexin5.   
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3.6  Materials and Methods 
DNA constructs 
 pCMV-SPORT6-ARHGEF15 was purchased (OpenBiosystems).  Ephexin5 mouse 
cDNA was previously described (Margolis et al., 2010 and Section 2.5).  Human Ephexin5 
R604C and mouse R612C were cloned using QuikChange Site Directed Mutagenesis 
(Stratagene).  All plasmids were sequenced for correct cDNA.  N-terminal Ephexin5 antibody 
was described previously (Margolis et al., 2010 and Chapter 2 Materials and Methods).   
RhoA activation assays and Ephexin5 protein levels 
For RhoA/RBD assays, HEK 293 cells were cultured in DMEM supplemented with 10% 
fetal bovine serum, 2 mM glutamine (Sigma), and penicillin/streptomycin (100 U/mL and 100 
µg/mL, respectively; Sigma). 293 cells were transfected in a 6-well dish (2 mL of media) for 36 
hours with 1 ug of indicated plasmids using the calcium phosphate method.  For the quantitative 
G-LISA RhoA activation assays, 150 ug of protein lysates were subjected to the colorimetric-
format G-LISA RhoA Activation Assay Kit (Cytoskeleton, Inc; Cat# BK124) as per the 
manufacturer’s instructions.  All lysate samples were run in duplicate and the GloMax Multi-
plate Detection System was used for colorimetric readings.  Final values for RhoA activation 
were calculated as a fold-change over the plasmid control transfection.  For the RBD pulldown 
assay, 500 ug of total protein lysates from overexpressed cells was subjected to GST-Rhotekin 
pulldown and analyzed by Western Blot.  Quantification of active RhoA/Total RhoA was 
conducted using Image imaging software to measure densitometry of the immunosignal.  To 
quantify levels of Ephexin5 protein, LiCor Biosciences Odyssey Infrared detection software was 
used on a Western Blot.          
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Audiogenic Seizures 
 Male Ephexin5 heterozygotes and WT littermate controls were generated by crossing a 
pure C57/Bl6 WT males to a 129J backcrossed (at least 10 generations) Ephexin5 +/- female to 
create 50:50 (129J:C57/Bl6) hybrid progeny.  Protocol for audiogenic seizures was adapted from 
a previously described protocol (Jiang et al., 1999).  Male mice were placed in a clear, plastic tub 
10 inches (?) in diameter and 12 inches in height. After a 5 minute habituation period, audiogenic 
seizures were induced by raking a pen for 45 seconds over a cage-top situated above the plastic 
tub similar to a previously established protocol (Jiang et al., 1998).  Time to recovery was 
measured as a step movement of any forelimb or hindlimb.  We set a test maximum of 480 
seconds.  All animals were tested between 2-6pm and genotypes were blinded to the 
experimenter. 
Elevated Plus Maze and Light/Dark Box 
 6 to 8 week old 129J Ephexin5 males (backcrossed at least 5 generations) were used for 
testing.  All animals tested were progeny of an Ephexin5 +/-  X  Ephexin5 +/-  male/female 
cross.  All behavioral testing was performed between 2pm-6pm at the TUFTS Neuroscience 
Behavioral Core with an inverse light/dark cycle; therefore, anxiety tests were performed in the 
mice’s nocturnal cycle.  A lux lighting level of 100 was used for all experiments.  All animals 
were habituated at least 30 minutes before testing began to the behavioral testing room.  Each 
test was 10 minutes.  Experimenters were blinded to genotype.  For elevated plus maze, the 
automated KinderScientific Elevated Plus Maze (http://www.kinderscientific.net/plusmaze.html) 
was used.  Arms were raised 50 cm off the floor.  Open arms were 25 x 5 x 0.5cm and closed 
arms were 25 x 5 x 16cm.  Closed arm height borders were black.  Animals were placed in a 5 x 
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5 x 0.5 cm center platform facing open arms at the beginning of test.  Automated beam breaks 
(16 beams per arm) were used with MotorMonitor software to analyze mouse movements.  The 
light/dark box was approximately 44 x 20 x 15 cm.  Each compartment (light and dark) took up 
1/2 the box.  Animals were placed in the middle of the light compartment to start the test.  
Animals were able to move between compartments with a 5 x 5 cm hole.  No shadows were 
allowed at the hole-opening (from experimental lighting) in order to minimize and discourage 
crouching behavior near the border between compartments.  Each animal was assessed manually 
with a stop watch for time spent in open area, and the number of transitions between 
compartments was recorded manually by two independent experimenters.        
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Chapter 4 
Phospho-regulation of Ephexin5 during brain development 
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4.1   Abstract 
 The specific molecular mechanisms that restrict excitatory synapse formation are not well 
understood.  We previously identified the RhoGEF Ephexin5 as a critical negative regulator of 
excitatory synapse formation in early brain development.  We extend these findings and 
demonstrate that Ephexin5 knockout mice have a normal density of dendritic spines in 
adulthood.  We searched for additional mechanisms that may underlie the preferentially early 
developmental deficits associated with Ephexin5.  Using mass spectrometry, we identified novel 
serine/threonine phosphorylation sites on the N-terminus of Ephexin5 that are critical for 
restricting excitatory synapse density in dissociated hippocampal cultures.  Two of these 
phosphorylation sites, serine-107/109, are drastically reduced during postnatal development at 
the height of synapse formation.  We conclude that phosphoregulation of Ephexin5 may be 
another critical mechanism underlying Ephexin5-mediated excitatory synapse restriction during 
early brain development.     
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4.2   Identification and analysis of Ephexin5 phosphorylation 
Reduction of Ephexin5 phosphorylation during postnatal brain development  
To uncover novel mechanisms of early synapse restriction in vivo, we first sought to 
determine the time point in development when Ephexin5 knockout mice had the most drastic 
effects on dendritic spine development.  A negative regulator of synapse development could 
function during early activity independent phases, during later activity-dependent phases, or 
perhaps during maintenance and elimination phases.  Our results thus far, suggest that Ephexin5 
must at least have a role in early synapse development.   
To address this, Ephexin5 knockout mice (KOs) and their WT littermates were prepared 
for Golgi staining at postnatal day 15 and 90 (P15 vs. P90) (Figure 4.1A).  We analyzed 
dendritic segments in the stratum radiatum of CA1 hippocampus similar to our previous study.  
As expected (although previously not tested) Ephexin5 KOs have an approximate 40% increase 
in dendritic spine density at P15 compared to their WT littermate controls (Figure 4.1B).  
Interestingly, no differences were detected in dendritic spine density at P90 (Figure 4.1C).  This 
is consistent with Ephexin5 have a prominent role in restricting synapse number early in 
development.  To analyze the effects in the adult another way, we utilized the Thy1-GFPm line 
(Fang et al., 2000), where there is expression of GFP in a sparse subset of CA1 pyramidal 
neurons (Figure 4.1D).  No differences were found between Ephexin5 KOs and their littermate 
controls at P60.   
Since we determined that Ephexin5-mediated synapse restriction was more severe during 
postnatal development (~2 weeks) as compared to early adulthood (~6-9 weeks), we were 
particularly interested in Ephexin5 protein expression that spans these time points.  To address 
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Figure 4.1: Ephexin5 knockout mouse have increased spine density at P15 but not in 
adulthood 
A) Representative image using to quantify Golgi staining.  Image of an apical dendritic segment 
in CA1 of the hippocampus at P90 used for Neurolucida tracings (see Materials and Methods). 
B)  Quantification of dendritic protrusion density in apical region of hippocampal CA1 
pyramidal neurons from Ephexin5 knockout (KO) mice (n= 10) versus wild-type (WT) littermate 
controls (n=11) at postnatal day 15 (P15) from 2 brains per condition, *p < .05, Student’s T-test 
C)  Quantification of dendritic protrusion density in apical region of hippocampal CA1 
pyramidal neurons from Ephexin5 KO mice (n= 27) versus WT littermate controls (n=26) at 
postnatal day 90 (P90) from 3 brains per condition, Student’s T-test n.s. p > 0.5 
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Figure 4.1 (continued): 
D)  Representative images (left panel) apical dendritic segments of hippocampal CA1 pyramidal 
neurons from theThy1-GFPm.  Quantification of  dendritic protrusion density (right panel) of 
Ephexin5 KO mice (n=22) versus WT littermate controls (n=11) at postnatal day 60 (right 
panel), not-signficant (p > 0.5) by Student’s T-test 
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this, whole brains were lysed at postnatal day (P) 15, 30, and 60, and RNA was extracted and 
reverse transcribed.  There were no differences in the level of Ephexin5 mRNA during 
development by quantitative PCR by two independent primer sets (Figure 4.2A and data not 
shown; see Materials and Methods).  Next, whole brains were lysed at the same time points 
(P15,P30,P60) and lysates were run on SDS-PAGE and immunoblotted with an antibody raised 
against the N-terminus of Ephexin5.  We detected the presence of a higher molecular weight 
band that is drastically reduced between P15 and P30, with no apparent difference in the slightly 
lower molecular weight band (Figure 4.2B).  We hypothesized that this developmentally 
regulated higher molecular weight band is phosphorylated Ephexin5.  To test this, P3 whole 
brain lysates were treated with alkaline phosphatase and immunoblotted for Ephexin5.  The 
higher molecular weight band collapsed to a single band by Western blot only in the brain 
samples treated with phosphatase (Figure 4.2C).  This suggests that Ephexin5 is phosphorylated 
in the brain and this phosphorylation might be dynamically regulated during brain development 
in vivo. 
Identification of Ephexin5 phosphorylation sites 
We sought to identify the sites of Ephexin5 phosphorylation.  Since Ephexin5 protein has 
a similar higher molecular weight band when overexpressed in HEK 293 (293) cells, we 
reasoned that we can use this system to identify the developmentally regulated phosphorylation 
site(s).   To accomplish this, HEK 293 cells were transfected with myc-tagged Ephexin5 
plasmid, lysed, and incubated with a myc antibody to immunoprecipitate Ephexin5 protein.  
Lysates were run on an SDS-PAGE gel and stained with Coomassie dye (Figure 4.3A).  We cut 
out the region around a ~110 kDa band, corresponding to the molecular weight of Ephexin5, and  
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Figure 4.2:  Reduction of Ephexin5 phosphorylation during postnatal brain development 
A)  Quantitative PCR from whole brain lysates at indicated time points.  Two distinct, non-
overlapping primer sets were used.  Ephexin5 knockouts at P15 (KO(P15)) were used to 
demonstrate specificity of primer sets.  n=3 per condition.     
B)  Western blot from whole brain lysates at indicated time points.  Arrows indicate Ephexin5 
immunosignal.  Top band (*) is non-specific.  An antibody to βactin was used as a loading 
control. 
C)  Western blot from increasing concentrations of P3 whole brain lysates treated with or 
without alkaline phosphatase (AP).  Arrows indicate Ephexin5 immunosignal.  Top band (*) is 
non-specific and persists in the KO of all ages (data not shown) 
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Figure 4.3: Identification of Ephexin5 phosphorylation sites by mass spectrometry 
A) 293 cell lysates from Ephexin5-myc transfection was clarified on an SDS-PAGE gel. The 
~110 kDa band was cut out and sent for mass spectrometry.  Representative image from 3 
independent experiments. 
B) Mass spectrometry amino acid coverage = 96.3%.  Yellow indicates amino acid sequence not 
covered.  High-confidence sites at S33, S90, S107, S109, S116, and S244 (red); lower 
confidence sites at S84, T97, S99, S101 (green); not conserved in human at S83, S166, S169 
(light blue) 
C) 293 cells overexpressed with indicated WT-Ephexin5 and various phospho-mutant plasmids.  
Displayed is a Western blot for α-C-Ephexin5.  
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performed mass spectrometry to search for posttranslational modifications.  Our analysis 
revealed 12 phosphorylation sites, 10 of which are conserved in humans, and five that were 
deemed high-confidence (Figure 4.3B; see Materials and Methods).  Interestingly, all 12 
phosphorylation sites were located on the N-terminus of Ephexin5.  In addition, eight were 
clustered within a 32-amino acid stretch spanning from serine-84 to serine-116. non-specific.  
Mef2a is used as a control to demonstrate efficiency of alkaline phosphatase (Flavell et al., 
2006).     
To identify the Ephexin5 phosphorylation sites that contribute to the developmentally 
regulated phosphorylation in the brain, we overexpressed a series of serine to alanine point 
mutations in 293 cells, ran cell lysates on an SDS-PAGE gel and monitored the higher molecular 
weight band by immunoblotting for Ephexin5.  A serine to alanine point mutation at both S107 
and S109 (S107A and S109A, respectively), but not the other mutations, were able to collapse 
the higher molecular weight band into a single lower band (Figure 4.3C and data not shown).  
To determine if these phosphorylation sites are the same sites developmentally regulated in vivo, 
we generated phospho-specific rabbit polyclonal antibody raised against pS107/109 (α-
pS107/109).  293 cells were overexpressed with WT-Ephexin5, S107A-Ephexin5, or S109A-
Ephexin5 plasmids, lysed, and immunoblotted with α-pS107/109.  We observe an immunosignal 
in the WT-Ephexin5 lane, but not S107A or S109A (Figure 4.4A), suggesting that α-pS107/109 
specifically recognizes these serine sites.  Antibodies raised against the single pS107 and pS109 
were unable to recognize wild-type Ephexin5 (data not shown).  This observation raises the 
possibility that these sites are phosphorylated in tandem.  To determine if the α-pS107/109 
immunosignal was specific to phosphorylation, 293 cell lysates from a WT- 
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Figure 4.4: Validation of p.S107/109 antibody 
A)  293 cells transfected with either WT-Ephexin5 (WT), S107A, or S109A plasmids.  Western 
Blot with  α-pS107/109.  Lysates from Figure 4.2C. 
B)  293 cells overexpressing WT-Ephexin5 with (+) or without (-) alkaline phosphatase 
treatment were run on a Western blot with α-pS107/109.   
C)  Whole brain lysates from C57/Bl6 mice at P3 (WT1,KO1) or P14 (WT2, KO2) probed with 
either α-pS107/109 or α-Ephexin5 (total).  Arrows indicate higher and lower migrating bands. 
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Ephexin5 transfection were treated with alkaline phosphatase.  Western blotting detected a α-
pS107/109 signal in phosphatase-untreated but not treated samples (Figure 4.4B). These data 
suggest that the antibody is phospho-specific to S107/109, and not an inability to recognize 
S107A and S109A due to the alanine mutation.  
To determine if phosphorylation of Ephexin5 at serine-107/109 is indeed the higher 
molecular weight band we detect in early brain development, we ran an SDS-PAGE gel with 
whole brain lysates from wild-type and Ephexin5 KO brains at P3 and P15.  An α-pS107/109 
signal was detected in WT, but not KO lysates (Figure 4.4C).  Importantly, the α-pS107/109 
immunosignal co-migrated with the higher molecular weight Ephexin5 band, but not the lower 
band (Figure 4.4C, arrows).  Finally, we blotted whole brain lysates at P5, P15, P30, and P60 
with α-pS107/109 (Figure 4.5A).  Similar to the higher molecular weight band, the 
phosphorylation at serine 107/109 is drastically reduced between P15 and P30 (Figure 4.5B).  
Taken together, our data suggests that Ephexin5 is specifically phosphorylated at serine-107/109 
and these sites are drastically reduced in the brain during early postnatal development.  
Phosphorylation is important for the restriction of excitatory synapses 
 We hypothesized that phosphorylation of Ephexin5 at these sites could protein stability, 
protein localization, EphB-dependent signaling, RhoA activity, and/or excitatory synapse 
development.  Previously, we found that EphB2 receptors can phosphorylate and degrade 
Ephexin5.  We asked whether the serine/threonine phosphorylation sites we identified play a role 
in EphB2/Ephexin5 binding, phosphorylation, and degradation.  To accomplish this we 
constructed a plasmid with cDNA of Ephexin5- that contains alanine  
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Figure 4.5: Serine-107/109 is reduced during postnatal brain development  
A)  Whole brain lysates at indicated times were lysed and run on a Western blot for α-
pS(107/109) and α-βactin (loading control).  Representative image displayed. 
B)  Western blot quantification using ImageJ densitometry for P15, P30, and P60 (n=3 per 
condition).  α-pS(107/109) signal normalized to βactin loading control.     
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mutations at the eight phosphorylation sites (see Figure 4.3B) clustered on the N-terminus 
within a 32-amino acid stretch (Ephexin5-8pMut).  Ephexin5-8pMut or Ephexin5-WT was 
expressed in 293 cells with or without EphB2.  There was no difference in the ability for 
Ephexin5 WT or 8pMut to bind to EphB2 (Figure 4.6A).  In addition, cell lysates (Inputs) were 
immunoblotted for α-pY361 and α-Ephexin5 to assess both EphB2-mediated phosphorylation at 
Y361 and degradation of Ephexin5 protein, respectively.  No differences between WT and 
8pMut were observed in either case.  Taken together, we conclude that serine/threonine 
phosphorylation of Ephexin5 is not mechanistically linked to EphB signaling. 
We next asked if Ephexin5 serine/threonine phosphorylation regulates hippocampal 
excitatory synapse development.  Dissociated mouse hippocampal neurons were sparsely 
transfected with a control, Ephexin5-WT or Ephexin5-8pMut plasmid along with a plasmid 
expressing GFP and neurons were fixed at DIV10.  The number of excitatory synapses was 
determined by immunostaining for the postsynaptic excitatory synaptic marker PSD-95 and the 
presynaptic excitatory synaptic marker Synapsin, as well as α-GFP to visualize transfected 
neurons.  Excitatory synapse density was assayed as the colocalization of PSD-95 and Synapsin 
along the length of a GFP-transfected dendrite (Figure 4.6B).  Similar to our previous study, we 
find that Ephexin5-WT reduces excitatory synapse density as compared to a control plasmid 
(Figure 4.6C; Margolis et al., 2010).  In contrast, Ephexin5-8pMut was unable to restrict 
synapse density.  We also find that dendritic arborization, localization and expression were 
similar across all conditions (Figure 4.6D-4.6F).  Taken together, these data suggest that 
Ephexin5 serine/threonine phosphorylation is required for excitatory synapse restriction via a 
yet, unidentified, mechanism. 
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Figure 4.6: Ephexin5 serine/threonine phosphorylation is critical for synapse restriction  
A) 293 cells were cotransfected with Ephexin5-WT with either pCS2-empty control or Flg-
EphB2.  Lysates with immunoprecipitated with Flag-beads (Sigma).  Immunoprecipitations (IP) 
and Inputs were immunoblotted (IB) with α-Ephexin5, and α-Flag.  Inputs were also blotted for 
α-pY361-Ephexin5 and α-tubulin for a loading control. 
B) Mouse dissociated hippocampal neurons were cotransfected with GFP and either pCS2-empty 
control (n=25 neurons), WT-Ephexin5 (WT) (n=28 neurons), or 8pMut-Ephexin5 (8pMut) (n=20 
neurons).  2 coverslips per condition.  Excitatory synapse density was measured as the 
colocalization of PSD95 (ms anti-PSD95), Synapsin (rb anti-synapsin) and GFP (chicken anti-
GFP).  p < .05, Student’s T-test 
C) Representative 63x images for B) of GFP dendritic branch (green), Synapsin (yellow, 
pseudocolored), and PSD95 (red). 
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Figure 4.6 (continued): 
D) Mouse hippocampal neurons were cotransfected at DIV10 with GFP and either myc-tagged 
WT-Ephexin5 or myc-tagged 8pMut-Ephexin5.  Neurons were fixed and stained at at DIV14 for 
myc (anti-myc, red). Imaged at 40x.  n= 10 neurons per condition.  DAPI staining is also in this 
field of view (Blue). 
E) Expression levels of total Ephexin5 levels (minus cell body) from D). 
F) Mouse hippocampal neurons were transfected at DIV6 similar to B) and analyzed at DIV 10 
at 20x objective.  n = 30 neurons per condition 
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4.3   Discussion 
We find that Ephexin5 knockout mice have defects in early but not late spine 
development.  This is consistent with our previously published data (Margolis et al., 2010 and 
see Chapter 2).  We find that S107/109 is phosphorylated in the brain and reduced in adulthood.  
S107/109 are two of eight phosphorylation sites clustered on the N-terminus of Ephexin5.  We 
mutated these sites and found that Ephexin5 was not able to restrict excitatory synapse number in 
dissociated hippocampal culture, suggesting that Ephexin5 phosphorylation at these sites is 
critical for synapse restriction.  A crucial next step is to deconvolve each phosphorylation site 
and determine which ones are required for the suppression of synapse restriction.   
In Chapter 2 we demonstrated that Ephexin5 knockout mice had an increased number of 
functional excitatory synapses onto CA1 pyramidal neurons in the hippocampus at P15.  We 
extend that in vivo analysis here by demonstrating that Ephexin5 knockout mice display an 
increased number of spines at P15.  These data are consistent with Ephexin5 playing a role in 
early synaptic development.  It is still a formal possibility that Ephexin5 regulates some aspect of 
synapse maturation or elimination processes during later stages of development.  There is data 
suggesting that spine abnormalities during critical points in development (usually around 2-3 
postnatal weeks) can have consequences on behavioral learning in the adult (Lendvia et al., 
2000; Majewska et al., 2003; Clement et al., 2012; see Chapter 1).  For example, SynGAP1, a 
negative regulator of synapse development mutated in Intellectual Disability, plays a role in 
accelerating mature spine growth during an early developmental time window (Clement et al., 
2012).  The conclusions from these studies is that although there are no changes in spine number 
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in the adult, rearrangements in how the spines incorporated into a functional neuronal circuit 
may have been affected.   
 We identified novel serine/threonine phosphorylation sites that may contribute to 
Ephexin5’s ability to restrict early synaptic development.  It has yet to be determined whether the 
additional sites we mutated (8pMut) are developmentally regulated in addition to S107/109.  We 
would like to test the idea that these sites are determinants for an active Ephexin5 protein.  In the 
future, we will deconvolve these sites to find the critical residues required for suppression of 
synapse restriction and determine if these sites are also developmentally regulated.  In addition, 
our findings raise the possibility that Ephexin5 is either being de-phosphorylated at these 
residues during development, or a kinase is being shut down in later stages of postnatal 
development.  One possible phosphatase is the developmentally regulated spinophilin/neurabin 
complex.  It has previously been shown to regulate the RhoA-specific Lfc during activity-
dependent spine restriction (Ryan et al., 2005; Kang et al., 2009). 
 In addition to identifying developmentally regulated kinases/phosphatases, we would like 
to understand the biochemical consequences of this phosphorylation.  A likely mechanism is 
through its RhoA GEF activity, which was shown in Chapter 2 to be critical for synaptic 
restriction.  The eight phosphorylation sites clustered around the N-terminus is reminiscent of 
Vav acidic residues that are phosphorylated to relieve N-terminal autoinhibition on GEF activity 
(Aghazadeh et al., 2000; also see Chapter 1 for discussion).  Moreover, the Ephexin family 
members have robust N-terminal inhibition mechanisms that are relieved via phosphorylation.  
We are currently testing this model in an in vitro cell-free system.  Interestingly, our preliminary 
data suggests that although it activates RhoA in vitro, activation in mammalian cells (293 cells) 
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is more robust.  We are in the process of truncating the N-terminus to look for hyperactivation as 
well as identifying kinases that can phosphorylate Ephexin5 in vitro. 
 Taken together, the data presented in Chapter 4 suggests the intriguing possibility that 
constitutive phosphorylation during development activates Ephexin5 protein, an event that is 
turned off in adulthood.  Finding the possible mechanisms that shutoff these phosphorylation 
events, either through autoinhibition or dephosphorylation is a critical next step to understanding 
additional mechanisms of synapse restriction in early postnatal development. 
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4.4   Materials and Methods 
DNA constructs 
 pEF-Ephexin5-WT-myc construct was previously described in Materials and Methods 
Section 2.5.  We used QuikChange Site Directed Mutagenesis (Stratagene) as per the 
manufacturer’s instructions for all single phosphorylation mutants (S90A, S107A, S109A, 
S116,S244A) using the pEF-Ephexin5-WT-myc as a template.  To construct the pEF-Ephexin5-
8pMut-myc plasmid, we synthesized complementary oligos spanning 179-380 of WT-Ephexin5 
cDNA with mutations corresponding to S(84,90,T97,S99,S101,S107,S109,S116)A.  Oligos were 
hybridized and BbsI and PflmI were used to create 5’ and 3’ overhang, respectively.  Digested 
oligos were subcloned into pEF-Ephexin5 swapping out the WT sites for the 8 phospho 
mutations 
Mass spectrometry for post-translation modifications 
 4 10cm
2
 dishes of 293T cells were transfected with 5ug Ephexin5-WT-myc plasmid at 
~50% confluency.  Cells were lysed after 48 hours in RIPA buffer (see below for recipe) with 
Phosphatase inhibitor cocktail 2 and 3 (Sigma).  Myc antibody (9E10 from abcam) was used to 
immunoprecipitate Ephexin5.  10-well format 4-12% Bis/Tris gradient gel (Invitrogen) was used 
to run samples and band corresponding to Ephexin5 was cut out, placed in an eppendorf in 
sterile, distilled water, and sent to Taplan Mass Spectrometry Facility at Harvard Medical School 
for analysis.  High-confidence targets were deemed as targets whose peptide phosphorylation 
sites were easily determined. 
Whole brain and HEK 293 cell lysis and CIP treatment 
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 Whole brains or HEK293 cells were collected and homogenized in RIPA buffer (50 mM 
Tris pH 8.0, 150 mM NaCl, 1% Triton X-100, 0.5% Sodium Deoxycholate, 0.1% SDS, 5 mM 
EDTA, 10 mM NaF, complete protease inhibitor cocktail tablet (Roche), 1 mM sodium 
orthovanadate, 1 mM β-glycerophosphate).  For CIP with P3 whole brain lysates, 40 or 160 ug of 
protein (measured by the Bradford method) per condition (no CIP vs. CIP) was diluted in 1x 
NEB Buffer 4.  10 units CIP (NEB) added to CIP conditions and all conditions were incubated at 
37 deg for 1 hr.  For CIP using 293T cell, 6-well dishes at 50% confluency were transfected with 
.5 ug of Ephexin5 protein.  24 hours later, cells were lysed in RIPA (see above) and 50 uL of 
total lysate was diluted to 1x NEB and processed similar to whole brain lysates.   
qPCR 
 For developmental Ephexin5 mRNA analysis, two sets of exon spanning qPCR primers 
(100-125 bps) were constructed by IDT as follows: 
Ephexin5 primer Set 1 (Exon spanning 1-2): 
F 5’ GAAGGGAGGAGGAAGGATTG 
R 5’ CAGCTCCTCTGACAGCACAG 
Ephexin5 Primer Set 2: 
F 5’ TGACCGACACCTTCGTCCTGAG 
R 5’GGAACGAACACGAGACAGCAGT 
 Each qPCR primer set was validated for one melting curve peak as well as efficacy of 
amplification within the dilution range used for each sample.  For qPCR, brains were 
homogenized in Trizol using a Polytron automated homogenizer (at setting 10 for 10 seconds), 
settled on ice for 10 minutes, and supernatant taken and flash frozen for at least 30 minutes (or -
80 for longer).  Trizol/homogenized brain mixture is subsequently thawed at room temp for 5 
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minutes, and 200 uL choloform is added for every mL of Trizol.  Solution is vigorously mixed 
for 20 seconds, and spun at 4 deg for 15 mins.  For each sample, 2ug of total RNA was isolated 
using the RNAse easy kit (Qiagen) and RNA was on-column digested with DNAseI (Qiagen). 
RNA was reverse-transcribed using OligodT amplification using SuperScriptIII reverse 
transcriptase (Invitrogen).  For transcripts of interest, 1/80
th
 of result cDNA was assessed by 
quantitative real-time PCR using SYBR green detection method (Applied Biosystems).  
Antibodies and Western Blots  
 All antibodies were described in Section 2.5 with the exception of anti-S107/109.  The 
polyclonal antibody that recognizes S107/109 of Ephexin5 was generated by injecting New 
Zealand white rabbits (Convance) with the peptide C- PSPVSRRpSIpSPEPAPC.  The antiserum 
was affinity-purified by application of a column conjugated with unphosphorylated Ephexin5 
peptide.  The flow-through was then applied to a column conjugated with phosphorylated 
Ephexin5 peptide and the affinity-purified anti-S107/109 antibody was eluted. 
 For Western Blots, all gels were 8% SDS-PAGE gels.  They were run at 70 V through 
stacking gel, 120 V through resolving gel and transferred on ice onto nitrocellulose for 2 hrs at 
200 mA.  Transferred blots were blocked in 5% milk for 1 hr shaking at RT and incubated with 
indicated primary antibodies in 5% milk overnight at 4 deg.  The following antibody dilutions 
were used: rb anti-S107/109 at 1:1000; rb anti-Ephexin at 1:500 in whole brain and 1:10,000 in 
293T cells (Margolis et al., 2010); anti-tubulin (abcam) at 1:25,000; ms anti-actin (abcam at 
1:2000.  Blots were washed 3x in 1x TBST (.05% Tween).  Secondary-HRP antibodies were 
diluted at 1:15,000 in 5% milk and washed 3x in 1x TBST.  Immunosignals were processed on 
Kodak Film using the ECL method.  For endogenous total Ephexin5, Western Blots were run on 
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a 6% SDS-PAGE gel and transferred overnight for 12 hrs at 60 mA.  Primary antibodies were 
incubated for 2 hrs shaking at room temp.  All other steps were similar.  
EphB2/Ephexin5 coprecipitation experiments 
 Each well of a 6-well dish was transfected with 500 ng Ephexin5 plasmid and either a 
pCS2-empty vector or pCS2-Flg-EphB2 (Soskis et al., 2012).  Cells were lysed in RIPA buffer 
(see above) in 300 ul per well, and two-wells per condition were combined.  Lysates were rotated 
half-end at 4 deg for 5-10 minutes and subsequently spun at 13K RPM for 10 mins on a table-top 
centrifuge at 4 deg.  350 uL of each supernatant was added to 40 uL Flg beads (Sigma) (beads 
pre-washed in RIPA 3x) for 2 hrs at 4 deg with full rotation.  Beads/antibody/lysate mixture was 
washed 3x with 5 mins rotation in between a 3K RPM spin for 3 mins and 30 uL 2x Sample 
Buffer was added after last spin.  Samples were boiled for 3 mins, spun down at max speed for 1 
min, and run for Western Blot analysis. 
Synapse and Sholl assays in dissociated culture 
 Excitatory synapse assays, imaging and analysis were conducted similar to Materials and 
Methods section 2.5 with the following exceptions:  Neurons were plated at a density of 100K 
per well (24-well plate) on a confluent rat glial monolayer (plated 3 days prior).  Neurons were 
transfected at DIV6 and stained at DIV10.  In addition to PSD95 and synapsin antibodies, 
neurons were also stained with chicken anti-GFP (Aves Labs) to visualize transfected neurons.  
250 ng of eGFP plasmid was transfected.  500 ng of Ephexin5 plasmids or pCS2 control 
plasmids was transfected using the Lipofectamine method (Invitrogen). 
 For Sholl analysis, we used a Zeiss Pascal confocal microscope at 20× objective with 
sequential acquisition settings at 1024 × 1024 pixel resolution.  On average, 5 stacks at 2 µm 
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each were taken for each neuron image.  Images were collected from 8-12 neurons per coverslip 
with four coverslips per condition from two independent biological replicates.  Images were 
exported to ImageJ NIH software, and max projections were converted to gray where they were 
traced using NeuronJ software and calculated using the Sholl analysis software PlugIn.   
Golgi staining and GFPm (spine imaging and analysis) 
Animals were deeply anesthetized using isoflourane. Golgi–Cox staining was performed 
using the FD Rapid Golgi Stain Kit (FD NeuroTechnologies, Inc., Ellicott City, MD). Brains 
were removed, rinsed with water, and placed directly in a mixture of 1 part Solution A and 1 part 
Solution B from the kit (see manufacturer's instructions for solution contents) for 10 days at 
room temperature in the dark. The solution was replaced and brains were then moved into 
Solution C for 24 hours at 4 °C in the dark. Brains were snap frozen in an isobutanol bath cooled 
to −70 °C and embedded in Tissue Freezing Medium (Triangle Biomedical Sciences, Durham, 
NC). Brains were coronally sectioned in a cryostat at −25 °C at a thickness of 100 μm and 
mounted on superfrost slides. Sections were dried in the dark overnight at room temperature for 
1 day before staining. Sections were visualized using a Nikon 80i upright microscope under 
bright field at 100X magnification. Spines were manually traced and reconstructed using 
Neurolucida 10.3 (MBF Bioscience, MicroBrightField, Inc., Williston, VT).  Only secondary 
dendrites from a visible primary apical tuft in CA1 hippocampus were analyzed for spine 
number.  Dendritic lengths were traced and reconstructed with live Bright-field images.  All 
visible protrusions emanating off the dendritic branch was considered a spine.  At least two 
dendritic lengths were taken per neuron and dendritic segments length were added together and 
total number of spines were divided by dendritic segment to obtain a neuronal protrusion density 
calculation.  
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Thy1-GFPm animals (129 background) were obtained from Jackson labs and described 
previously (Fang et al., 2000).  Thy1-GFPm brains were processed as previously described 
(Wills et al., 2012).  Briefly, Ephexin5 +/- females were mated with Thy1GFPm 
+/+;Ephexin5+/- males so all progeny contain one allele of GFP. Animals were anesthetized with 
Ketamine and perfused with 4% PFA in PBS. Following perfusion, brains were post fixed for 1 
hour, followed by a 1 hour incubation in 10% sucrose and then submersed in 20% sucrose 
overnight at 4 degrees (or until tissue sinks in solution). Brains were mounted with Tissue 
Freezing Medium and sectioned coronally at -20 degrees in a cryostat in 100uM slices. Sections 
were stained using a floating sections technique, using a 12 well dish with mesh buckets for easy 
tissue transfer. Following sectioning, tissue was placed in Block (1X PBS, .025% Triton, Goat 
Serum) for 1 hour and then placed in antibody (GFP antibody: Conjugated 488 anti-rb, 
Invitrogen) overnight at 4 degrees. Sections were washed 5x in 1xPBS over an hour, mounted on 
superfrost slides and coverslipped with Permount. Sections containing dorsal hippocampus were 
used for analysis.  For Imaging of GFPm, Pascal Confocal was used at 63x objective zoom 2 at 
1024 x 1024 resolution with 2-4 times averaging.  488 laser set to 5%, gain with an excitation of 
800 and 0 offset. Pinhole was set to 1 airy unit.  Z slice was set to 0.5 um per slice with 
anywhere between 5-15 slices per dendrite.  2 proximal secondary dendrites coming off main 
apical branch (within ~100um of cell body) from each CA1 pyramidal neuron was imaged.  
Neurons were taken from at least 3 animals per condition.  Spines were analyzed using 
Metamorph software similar to Section 2.5.  
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Chapter 5 
 
Conclusion 
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The precise balance between promoting and restricting the synapse is critical to ensure 
that synapses form in the proper time, number and place during development.  The mechanisms 
that promote excitatory synapse formation in the central nervous system are well understood, but 
the mechanisms that restrict/negatively regulate excitatory synapse number are largely unknown.  
A literature search for negative regulators of spine and synapse formation reveals approximately 
15 proteins including SynGAP1 (Vasquez et al., 2004; Clement et al., 2012), MEF2A/D (Flavell 
et al., 2006), C1q (Stevens et al., 2007), δ-catenin (Arikkath et al., 2009), RhoA (Nakayama et 
al., 2000; Tashiro et al., 2000), Ephexin1 (Fu et al., 2007), EphA4 (Murai et al., 2003) and 
Sema3F (Tran et al., 2009); only a subset of these has attributed mechanisms.  The findings 
within this dissertation suggest that Ephexin5 restricts excitatory synapse formation in early 
postnatal development and we provide two potential mechanisms for how this may occur.   
During the first two weeks of postnatal development, Ephexin5 knockouts (Chapters 2 & 
4) and heterozygotes (data not shown) display an increased density of dendritic spines compared 
to wild-type littermates.  Interestingly, this increase in spine density does not persist into 
adulthood suggesting that Ephexin5 protein is only critical for the early phase of excitatory 
synapse development.  This is reminiscent of the phenotype in SynGAP1 mutant mice, where the 
maturation of dendritic spines are prematurely accelerated during early postnatal development, 
but seem to have no discernible differences in adulthood (Clement et al., 2012; Vasquez et al., 
2004).  Since both Ephexin5 and SynGAP1 mutant mice display behavioral deficits in adulthood 
it is possible that premature acceleration of synapses alters the proper wiring and incorporation 
of synapse into a mature neural circuit.  Consistent with this, miswiring of spines during early 
phases of synapses formation leads to deficits in critical period plasticity and learning in 
adulthood (Lendvai et al., 2000; Majewska et al., 2003). 
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Our data is most consistent with Ephexin5 playing a role in regulating the total number of 
dendritic protrusions, and not a particular type of spine.  This is based on a few observations: 
First, Ephexin5 knockdown does not yield differences in the length or width of dendritic spines.  
Second, overexpression of constitutively active RhoA in early organotypic slice culture leads to a 
reduction in dendritic protrusions (Nakayama et al., 2000; Tashiro et al., 2000).  Third, 
knockdown of Ephexin5 in early dissociated hippocampal culture (DIV2 to DIV 6) leads to a 
striking increase in excitatory synapse number suggesting that it serves as a barrier to the overall 
number of synapses.   
In Chapter 2, we demonstrate that Ephexin5 can bind to the EphB2 receptor tyrosine 
kinase and is tyrosine phosphorylated at Y361.  Tyrosine phosphorylation leads to the 
degradation of Ephexin5 protein in heterologous cells and along the dendrite.  Protein 
degradation of Ephexin5 is dependent on the E3 ubiquitin ligase, Ube3a.  A few questions 
regarding this mechanism still remain unclear: First, what are the specific mechanisms 
underlying Ephexin5 Y361 phosphorylation and degradation?  Second, can the synaptic 
EphB2/Ephexin5 interaction be explained by tyrosine-kinase independent mechanisms?  
Overexpression of WT-EphB2, but not a kinase-dead version, reduces the amount of 
Ephexin5 protein in heterologous cells and in neurons.  Ephexin5 tyrosine-361 is a major site of 
EphB-dependent phosphorylation.  However, mutating this site to phenylalanine only partially 
suppressed EphB2-mediated degradation in heterologous cells.  This suggests that additional 
sites on Ephexin5 may be required for its degradation.  Alternate routes of degradation could be 
explained by either other tyrosine residues or by other residues downstream of EphB-dependent 
signaling events independent of receptor tyrosine kinase activation.  Our data is most consistent 
with the second possibility, since Ephexin5 Y361 is the major site of tyrosine phosphorylation in 
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vitro (unpublished observations) and in heterologous cells (Chapter 2).  In addition, there is 
evidence suggesting that the receptor tyrosine kinase domain of EphB2 is dispensable for proper 
synapse formation (Soskis et al., 2012).  Since knockdown of EphBs drastically reduces the 
number of excitatory synapses, this suggests that EphBs may require other functional domains at 
the synapse.   
Upon binding of EphrinB, EphBs multimerization results in the recruitment and 
clustering of molecules at the synapse including NMDAR’s, Src-family kinases, and RacGEFs 
such as Tiam and Kalirin (Dalva et al., 2000; Klein et al., 2009).  Our preliminary in vitro data 
demonstrates that Ephexin5 is tyrosine phosphorylated in response to Src stimulation.  Src-
family kinases can be activated by EphBs and NMDARs through calcium-dependent signaling 
(Klein et al., 2009), suggesting that Ephexin5 could be degraded through EphB-kinase 
independent processes at the synapse.  In support of this, unpublished data from Karen Zito and 
colleagues suggests that treating organotypic cultures with bicucilline (ie, increased synaptic 
activity) reduces dendritic expression of Ephexin5 protein.  Conversely, treating cells with 
tetrodotoxin increases Ephexin5 expression (unpublished observations).  Future experiments 
elucidating the role of neuronal activity on Ephexin5 protein levels should shed insight into the 
interplay between receptor tyrosine kinase and calcium-dependent processes. 
In Chapter 4, we demonstrated that Ephexin5 is serine/threonine phosphorylated in the 
brain during early postnatal development.  These sites are required for restricting excitatory 
synapse number in dissociated culture, suggesting that dephosphorylation of Ephexin5 may be a 
critical event to reduce its activity.  These phosphorylation events seem to be independent of 
EphB signaling in heterologous cells.  Whether this is the case in neurons has yet to be 
determined.  As outlined in the Chapter 4 Discussion Section, the priority of future experiments 
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will be to determine the kinases/phosphatases that regulate these phosphorylation events and to 
determine whether other serine/threonine sites are developmentally regulated.  
Taken together, the results within this dissertation suggest that Ephexin5 serves as a 
brake during early synapse development and that precise control of Ephexin5 activity via 
degradation and phosphorylation are critical mechanisms to ensure that synapses form in the 
correct number, time, and place.  Ephexin5 has been linked to early developmental disorders 
such as epilepsy (Chapter 3) and Angelman syndrome (Chapter 2).  Future studies focusing on its 
role in early brain development may be critical for understanding the etiology of 
neurodevelopmental disorders and normal cognitive function. 
 
 
 
 
 
 
 
 
 
157 
 
Bibliography 
 
 
 
158 
 
 
(2012). "Epi4K: gene discovery in 4,000 genomes." Epilepsia 53(8): 1457-1467. 
 
Abe, K., K. L. Rossman, et al. (2000). "Vav2 is an activator of Cdc42, Rac1, and RhoA." J Biol 
Chem 275(14): 10141-10149. 
 
Abe, K., I. P. Whitehead, et al. (1999). "Involvement of NH(2)-terminal sequences in the 
negative regulation of Vav signaling and transforming activity." J Biol Chem 274(43): 
30410-30418. 
 
Aghazadeh, B., W. E. Lowry, et al. (2000). "Structural basis for relief of autoinhibition of the 
Dbl homology domain of proto-oncogene Vav by tyrosine phosphorylation." Cell 102(5): 
625-633. 
 
Aghazadeh, B., K. Zhu, et al. (1998). "Structure and mutagenesis of the Dbl homology domain." 
Nat Struct Biol 5(12): 1098-1107. 
 
Ahmari, S. E., J. Buchanan, et al. (2000). "Assembly of presynaptic active zones from 
cytoplasmic transport packets." Nat Neurosci 3(5): 445-451. 
 
Ang, C. W., G. C. Carlson, et al. (2006). "Massive and specific dysregulation of direct cortical 
input to the hippocampus in temporal lobe epilepsy." J Neurosci 26(46): 11850-11856. 
 
Avoli, M. (2007). "The epileptic hippocampus revisited: back to the future." Epilepsy Curr 7(4): 
116-118. 
 
Bamshad, M. J., S. B. Ng, et al. (2011). "Exome sequencing as a tool for Mendelian disease gene 
discovery." Nat Rev Genet 12(11): 745-755. 
 
Berglund, K. and G. J. Augustine (2008). "Calcium helps neurons identify synaptic targets 
during development." Neuron 59(2): 186-187. 
 
Bos, J. L., H. Rehmann, et al. (2007). "GEFs and GAPs: critical elements in the control of small 
G proteins." Cell 129(5): 865-877. 
 
Bresler, T., M. Shapira, et al. (2004). "Postsynaptic density assembly is fundamentally different 
from presynaptic active zone assembly." J Neurosci 24(6): 1507-1520. 
 
Brose, N. (2009). "Synaptogenic proteins and synaptic organizers: "many hands make light 
work"." Neuron 61(5): 650-652. 
 
Bustelo, X. R. (2001). "Vav proteins, adaptors and cell signaling." Oncogene 20(44): 6372-6381. 
 
Cahill, M. E., Z. Xie, et al. (2009). “Kalirin regulates cortical spine morphogenesis and disease-       
related behavioral phenotypes.” Proc Natl Acad Sci U.S.A. 106(31): 13058-13063. 
 
159 
 
Chan, A. M., E. S. McGovern, et al. (1994). "Expression cDNA cloning of a novel oncogene 
with sequence similarity to regulators of small GTP-binding proteins." Oncogene 9(4): 
1057-1063. 
 
Chen, C. and W. G. Regehr (2000). "Developmental remodeling of the retinogeniculate 
synapse." Neuron 28(3): 955-966. 
 
Cherfils, J. and M. Zeghouf (2013). "Regulation of small GTPases by GEFs, GAPs, and GDIs." 
Physiol Rev 93(1): 269-309. 
 
Chu, Y., X. Jin, et al. (2010). "Enhanced synaptic connectivity and epilepsy in C1q knockout 
mice." Proc Natl Acad Sci U S A 107(17): 7975-7980. 
 
Clement, A.C., M. Aceti, et al. (2012). "Pathogenic SYNGAP1 mutations impair cognitive 
developmentby disrupting maturation of dendritic spine synapses." Cell 151(4): 709-723. 
 
Cooper, E. M., A. W. Hudson, et al. (2004). "Biochemical analysis of Angelman syndrome-
associated mutations in the E3 ubiquitin ligase E6-associated protein." J Biol Chem 
279(39): 41208-41217. 
 
Cote, J. F. and K. Vuori (2007). "GEF what? Dock180 and related proteins help Rac to polarize 
cells in new ways." Trends Cell Biol 17(8): 383-393. 
 
Cowan, C. W., Y. R. Shao, et al. (2005). "Vav family GEFs link activated Ephs to endocytosis 
and axon guidance." Neuron 46(2): 205-217. 
 
Dailey, M. E. and S. J. Smith (1996). "The dynamics of dendritic structure in developing 
hippocampal slices." J Neurosci 16(9): 2983-2994. 
 
Dalva, M. B., A. C. McClelland, et al. (2007). "Cell adhesion molecules: signalling functions at 
the synapse." Nat Rev Neurosci 8(3): 206-220. 
 
Dalva, M. B., M. A. Takasu, et al. (2000). "EphB receptors interact with NMDA receptors and 
regulate excitatory synapse formation." Cell 103(6): 945-956. 
 
Dan, B. (2009). "Angelman syndrome: current understanding and research prospects." Epilepsia 
50(11): 2331-2339. 
 
Debily, M. A., A. Camarca, et al. (2004). "Expression and molecular characterization of 
alternative transcripts of the ARHGEF5/TIM oncogene specific for human breast 
cancer." Hum Mol Genet 13(3): 323-334. 
 
Dindot, S. V., B. A. Antalffy, et al. (2008). "The Angelman syndrome ubiquitin ligase localizes 
to the synapse and nucleus, and maternal deficiency results in abnormal dendritic spine 
morphology." Hum Mol Genet 17(1): 111-118. 
 
160 
 
Drachman, D. (2005). "Do we have brain to spare?" Neurology 64(12): 2004-2005. 
 
Dunaevsky, A. and C. A. Mason (2003). "Spine motility: a means towards an end?" Trends 
Neurosci 26(3): 155-160. 
 
Ebert, D.H. and M.E. Greenberg (2013). "Activity-dependent neuronal signalling and autism 
spectrum disorder." Nature 493(7432): 327-337. 
 
Egea, J. and R. Klein (2007). "Bidirectional Eph-ephrin signaling during axon guidance." Trends 
Cell Biol 17(5): 230-238. 
 
Ethell, I. M., F. Irie, et al. (2001). "EphB/syndecan-2 signaling in dendritic spine 
morphogenesis." Neuron 31(6): 1001-1013. 
 
Eva, A. and S. A. Aaronson (1985). "Isolation of a new human oncogene from a diffuse B-cell 
lymphoma." Nature 316(6025): 273-275. 
 
Fasen, K., D. P. Cerretti, et al. (2008). "Ligand binding induces Cbl-dependent EphB1 receptor 
degradation through the lysosomal pathway." Traffic 9(2): 251-266. 
 
Fischer, M., S. Kaech, et al. (1998). "Rapid actin-based plasticity in dendritic spines." Neuron 
20(5): 847-854. 
 
Flanagan, J. G. and P. Vanderhaeghen (1998). "The ephrins and Eph receptors in neural 
development." Annu Rev Neurosci 21: 309-345. 
 
Flavell, S. W., C. W. Cowan, et al. (2006). "Activity-dependent regulation of MEF2 transcription 
factors suppresses excitatory synapse number." Science 311(5763): 1008-1012. 
 
Frank, C. A., J. Pielage, et al. (2009). "A presynaptic homeostatic signaling system composed of 
the Eph receptor, ephexin, Cdc42, and CaV2.1 calcium channels." Neuron 61(4): 556-
569. 
 
Frisen, J., J. Holmberg, et al. (1999). "Ephrins and their Eph receptors: multitalented directors of 
embryonic development." EMBO J 18(19): 5159-5165. 
 
Fu, W. Y., Y. Chen, et al. (2007). "Cdk5 regulates EphA4-mediated dendritic spine retraction 
through an ephexin1-dependent mechanism." Nat Neurosci 10(1): 67-76. 
 
Fukazawa, Y., Y. Saitoh, et al. (2003). "Hippocampal LTP is accompanied by enhanced F-actin 
content within the dendritic spine that is essential for late LTP maintenance in vivo." 
Neuron 38(3): 447-460. 
 
Glaven, J. A., I. P. Whitehead, et al. (1996). "Lfc and Lsc oncoproteins represent two new 
guanine nucleotide exchange factors for the Rho GTP-binding protein." J Biol Chem 
271(44): 27374-27381. 
161 
 
 
Glessner, J. T., K. Wang, et al. (2009). "Autism genome-wide copy number variation reveals 
ubiquitin and neuronal genes." Nature 459(7246): 569-573. 
 
Govek, E. E., S. E. Newey, et al. (2005). "The role of the Rho GTPases in neuronal 
development." Genes Dev 19(1): 1-49. 
 
Graf, E. R., X. Zhang, et al. (2004). "Neurexins induce differentiation of GABA and glutamate 
postsynaptic specializations via neuroligins." Cell 119(7): 1013-1026. 
 
Greer, P. L., R. Hanayama, et al. "The Angelman Syndrome protein Ube3A regulates synapse 
development by ubiquitinating arc." Cell 140(5): 704-716. 
 
Grunwald, I. C., M. Korte, et al. (2004). "Hippocampal plasticity requires postsynaptic 
ephrinBs." Nat Neurosci 7(1): 33-40. 
 
Grunwald, I. C., M. Korte, et al. (2001). "Kinase-independent requirement of EphB2 receptors in 
hippocampal synaptic plasticity." Neuron 32(6): 1027-1040. 
 
Grutzendler, J., N. Kasthuri, et al. (2002). "Long-term dendritic spine stability in the adult 
cortex." Nature 420(6917): 812-816. 
 
Hall, A. (1994). "Small GTP-binding proteins and the regulation of the actin cytoskeleton." 
Annu Rev Cell Biol 10: 31-54. 
 
Han, S., C. Tai, et al. (2012). "Autistic-like behaviour in Scn1a+/- mice and rescue by enhanced 
GABA-mediated neurotransmission." Nature 489(7416): 385-390. 
 
Han, S., F. H. Yu, et al. (2012). "Na(V)1.1 channels are critical for intercellular communication 
in the suprachiasmatic nucleus and for normal circadian rhythms." Proc Natl Acad Sci U 
S A 109(6): E368-377. 
 
Harada, K., N. Hiramoto-Yamaki, et al. (2011). "Ephexin4 and EphA2 mediate resistance to 
anoikis through RhoG and phosphatidylinositol 3-kinase." Exp Cell Res 317(12): 1701-
1713. 
 
Hart, M. J., A. Eva, et al. (1991). "Catalysis of guanine nucleotide exchange on the CDC42Hs 
protein by the dbl oncogene product." Nature 354(6351): 311-314. 
 
Haslam, R. J., H. B. Koide, et al. (1993). "Pleckstrin domain homology." Nature 363(6427): 309-
310. 
 
Hayashi-Takagi, A., M. Takaki, et al. (2010). "Disrupted-in-Schizophrenia 1 (DISC1) regulates 
spines of the glutamate synapse via Rac1." Nat Neurosci 13(3): 327-332. 
 
162 
 
Heasman, S. J. and A. J. Ridley (2008). "Mammalian Rho GTPases: new insights into their 
functions from in vivo studies." Nat Rev Mol Cell Biol 9(9): 690-701. 
 
Henkemeyer, M., O. S. Itkis, et al. (2003). "Multiple EphB receptor tyrosine kinases shape 
dendritic spines in the hippocampus." J Cell Biol 163(6): 1313-1326. 
 
Hershko, A. and A. Ciechanover (1998). "The ubiquitin system." Annu Rev Biochem 67: 425-
479. 
 
Hill, C.S., J. Wynne, et al. (1995). "The Rho family GTPases RhoA, Rac1, and Cdc42Hs 
regulate  
transcriptional activation by SRF." Cell 81: 1159-1170. 
 
Hiramoto-Yamaki, N., S. Takeuchi, et al. (2010). "Ephexin4 and EphA2 mediate cell migration 
through a RhoG-dependent mechanism." J Cell Biol 190(3): 461-477. 
 
Holtmaat, A., L. Wilbrecht, et al. (2006). "Experience-dependent and cell-type-specific spine 
growth in the neocortex." Nature 441(7096): 979-983. 
 
Hooks, B. M. and C. Chen (2006). "Distinct roles for spontaneous and visual activity in 
remodeling of the retinogeniculate synapse." Neuron 52(2): 281-291. 
 
Horii, T., S. Morita, et al. (2009). "Epigenetic regulation of adipocyte differentiation by a Rho 
guanine nucleotide exchange factor, WGEF." PLoS One 4(6): e5809. 
 
Hussain, N. K., S. Jenna, et al. (2001). "Endocytic protein intersectin-l regulates actin assembly 
via Cdc42 and N-WASP." Nat Cell Biol 3(10): 927-932. 
 
Huveneers, S. and E. H. Danen (2009). "Adhesion signaling - crosstalk between integrins, Src 
and Rho." J Cell Sci 122(Pt 8): 1059-1069. 
 
Irie, F. and Y. Yamaguchi (2002). "EphB receptors regulate dendritic spine development via 
intersectin, Cdc42 and N-WASP." Nat Neurosci 5(11): 1117-1118. 
 
Jiang, W., T. M. Duong, et al. (1999). "The neuropathology of hyperthermic seizures in the rat." 
Epilepsia 40(1): 5-19. 
 
Jiang, Y. H., D. Armstrong, et al. (1998). "Mutation of the Angelman ubiquitin ligase in mice 
causes increased cytoplasmic p53 and deficits of contextual learning and long-term 
potentiation." Neuron 21(4): 799-811. 
 
Jontes, J. D., J. Buchanan, et al. (2000). "Growth cone and dendrite dynamics in zebrafish 
embryos: early events in synaptogenesis imaged in vivo." Nat Neurosci 3(3): 231-237. 
 
Jontes, J. D. and S. J. Smith (2000). "Filopodia, spines, and the generation of synaptic diversity." 
Neuron 27(1): 11-14. 
163 
 
 
Kano, M. and K. Hashimoto (2009). "Synapse elimination in the central nervous system." Curr 
Opin Neurobiol 19(2): 154-161. 
 
Katzav, S., D. Martin-Zanca, et al. (1989). "vav, a novel human oncogene derived from a locus 
ubiquitously expressed in hematopoietic cells." EMBO J 8(8): 2283-2290. 
 
Kayser, M. S., A. C. McClelland, et al. (2006). "Intracellular and trans-synaptic regulation of 
glutamatergic synaptogenesis by EphB receptors." J Neurosci 26(47): 12152-12164. 
 
Kayser, M. S., M. J. Nolt, et al. (2008). "EphB receptors couple dendritic filopodia motility to 
synapse formation." Neuron 59(1): 56-69. 
 
Kishino, T., M. Lalande, et al. (1997). "UBE3A/E6-AP mutations cause Angelman syndrome." 
Nat Genet 15(1): 70-73. 
 
Klein, R. (2009). "Bidirectional modulation of synaptic functions by Eph/ephrin signaling." Nat 
Neurosci 12(1): 15-20. 
 
Konur, S. and R. Yuste (2004). "Developmental regulation of spine and filopodial motility in 
primary visual cortex: reduced effects of activity and sensory deprivation." J Neurobiol 
59(2): 236-246. 
 
Kusuhara, S., Y. Fukushima, et al. (2012). "Arhgef15 promotes retinal angiogenesis by 
mediating VEGF-induced Cdc42 activation and potentiating RhoJ inactivation in 
endothelial cells." PLoS One 7(9): e45858. 
 
Kwon, H. B. and B. L. Sabatini (2011). "Glutamate induces de novo growth of functional spines 
in developing cortex." Nature 474(7349): 100-104. 
 
Lai, K. O. and N. Y. Ip (2009). "Synapse development and plasticity: roles of ephrin/Eph 
receptor signaling." Curr Opin Neurobiol 19(3): 275-283. 
 
Lee, H., S. J. Raiker, et al. (2008). "Synaptic function for the Nogo-66 receptor NgR1: regulation 
of dendritic spine morphology and activity-dependent synaptic strength." J Neurosci 
28(11): 2753-2765. 
 
Lemke, J. R., E. Riesch, et al. (2012). "Targeted next generation sequencing as a diagnostic tool 
in epileptic disorders." Epilepsia 53(8): 1387-1398. 
 
Lim, B. K., N. Matsuda, et al. (2008). "Ephrin-B reverse signaling promotes structural and 
functional synaptic maturation in vivo." Nat Neurosci 11(2): 160-169. 
 
Lin, Y., B. L. Bloodgood, et al. (2008). "Activity-dependent regulation of inhibitory synapse 
development by Npas4." Nature 455(7217): 1198-1204. 
 
164 
 
Linhoff, M. W., J. Lauren, et al. (2009). "An unbiased expression screen for synaptogenic 
proteins identifies the LRRTM protein family as synaptic organizers." Neuron 61(5): 
734-749. 
 
Lohmann, C. and T. Bonhoeffer (2008). "A role for local calcium signaling in rapid synaptic 
partner selection by dendritic filopodia." Neuron 59(2): 253-260. 
 
Lois, C., E. J. Hong, et al. (2002). "Germline transmission and tissue-specific expression of 
transgenes delivered by lentiviral vectors." Science 295(5556): 868-872. 
 
Luo, Z. P., G. R. Buttermann, et al. (1996). "Determination of spinal facet joint loads from extra 
articular strains--a theoretical validation." J Biomech 29(6): 785-790. 
 
Majewska, A. and M. Sur (2003). "Motility of dendritic spines in visual cortex in vivo: changes 
during the critical period and effects of visual deprivation." Proc Natl Acad Sci U S A 
100(26): 16024-16029. 
 
Margolis, S. S., J. Salogiannis, et al. (2010). "EphB-mediated degradation of the RhoA GEF 
Ephexin5 relieves a developmental brake on excitatory synapse formation." Cell 143(3): 
442-455. 
 
Marini, C., I. E. Scheffer, et al. (2011). "The genetics of Dravet syndrome." Epilepsia 52 Suppl 
2: 24-29. 
 
Matsuzaki, M., N. Honkura, et al. (2004). "Structural basis of long-term potentiation in single 
dendritic spines." Nature 429(6993): 761-766. 
 
Matus, A. (2005). "Growth of dendritic spines: a continuing story." Curr Opin Neurobiol 15(1): 
67-72. 
 
Meisler, M. H., J. E. O'Brien, et al. (2010). "Sodium channel gene family: epilepsy mutations, 
gene interactions and modifier effects." J Physiol 588(Pt 11): 1841-1848. 
 
Melendez, J., M. Grogg, et al. (2011). "Signaling role of Cdc42 in regulating mammalian 
physiology." J Biol Chem 286(4): 2375-2381. 
 
Melendez, J., K. Stengel, et al. (2011). "RhoA GTPase is dispensable for actomyosin regulation 
but is essential for mitosis in primary mouse embryonic fibroblasts." J Biol Chem 
286(17): 15132-15137. 
 
Michaelson, D., J. Silletti, et al. (2001). "Differential localization of Rho GTPases in live cells: 
regulation by hypervariable regions and RhoGDI binding." J Cell Biol 152(1): 111-126. 
 
Micheva, K. D. and S. J. Smith (2007). "Array tomography: a new tool for imaging the 
molecular architecture and ultrastructure of neural circuits." Neuron 55(1): 25-36. 
 
165 
 
Murai, K. K., L. N. Nguyen, et al. (2003). "Control of hippocampal dendritic spine morphology 
through ephrin-A3/EphA4 signaling." Nat Neurosci 6(2): 153-160. 
 
Murakoshi, H., H. Wang, et al. (2011). "Local, persistent activation of Rho GTPases during 
plasticity of single dendritic spines." Nature 472(7341): 100-104. 
 
Nakayama, A. Y., M. B. Harms, et al. (2000). "Small GTPases Rac and Rho in the maintenance 
of dendritic spines and branches in hippocampal pyramidal neurons." J Neurosci 20(14): 
5329-5338. 
 
Nakayama, A. Y. and L. Luo (2000). "Intracellular signaling pathways that regulate dendritic 
spine morphogenesis." Hippocampus 10(5): 582-586. 
 
Newey S.E., V. Velamoor, et al. (2005). "RhoGTPases, denritic structure, and mental 
retardation." J  
Neurobio 64(1): 58-74. 
 
Nimchinsky, E.A., B.L. Sabatini, et al. (2002). "Structure and function of dendritic spines." 
Annu Rev  
Physiol 64: 313-354. 
 
Noren, N. K. and E. B. Pasquale (2004). "Eph receptor-ephrin bidirectional signals that target 
Ras and  
Rho proteins." Cell Signal 16(6): 655-666. 
 
Ogita, H., S. Kunimoto, et al. (2003). "EphA4-mediated Rho activation via Vsm-RhoGEF 
expressed specifically in vascular smooth muscle cells." Circ Res 93(1): 23-31. 
 
Okabe, S., A. Miwa, et al. (2001). "Spine formation and correlated assembly of presynaptic and 
postsynaptic molecules." J Neurosci 21(16): 6105-6114. 
 
Oliver, A. W., X. He, et al. (2011). "The HPV16 E6 binding protein Tip-1 interacts with 
ARHGEF16, which activates Cdc42." Br J Cancer 104(2): 324-331. 
 
Pak, D. T., S. Yang, et al. (2001). "Regulation of dendritic spine morphology by SPAR, a PSD-
95-associated RapGAP." Neuron 31(2): 289-303. 
 
Paradis, S., D. B. Harrar, et al. (2007). "An RNAi-based approach identifies molecules required 
for glutamatergic and GABAergic synapse development." Neuron 53(2): 217-232. 
 
Park, H. D., S. R. Kim, et al. (2009). "Two novel HADHB gene mutations in a Korean patient 
with mitochondrial trifunctional protein deficiency." Ann Clin Lab Sci 39(4): 399-404. 
 
Penzes, P., A. Beeser, et al. (2003). "Rapid induction of dendritic spine morphogenesis by trans-
synaptic ephrinB-EphB receptor activation of the Rho-GEF kalirin." Neuron 37(2): 263-
274. 
166 
 
 
Penzes, P. and M. E. Cahill (2012). "Deconstructing signal transduction pathways that regulate 
the actin cytoskeleton in dendritic spines." Cytoskeleton (Hoboken) 69(7): 426-441. 
 
Pilpel, Y. and M. Segal (2004). "Activation of PKC induces rapid morphological plasticity in 
dendrites of hippocampal neurons via Rac and Rho-dependent mechanisms." Eur J 
Neurosci 19(12): 3151-3164. 
 
Ryan, X.P., J. Alldritt, et al. (2005).  “The Rho-specific GEF Lfc interacts with neurabin and    
spinophilin to regulate dendritic spine morphology.” Neuron 47(1): 85-100. 
 
Roberts, T. F., K. A. Tschida, et al. (2010). "Rapid spine stabilization and synaptic enhancement 
at the onset of behavioural learning." Nature 463(7283): 948-952. 
 
Rodrigues, N. R., A. M. Theodosiou, et al. (2000). "Characterization of Ngef, a novel member of 
the Dbl family of genes expressed predominantly in the caudate nucleus." Genomics 
65(1): 53-61. 
 
Ron, D., M. Zannini, et al. (1991). "A region of proto-dbl essential for its transforming activity 
shows sequence similarity to a yeast cell cycle gene, CDC24, and the human breakpoint 
cluster gene, bcr." New Biol 3(4): 372-379. 
 
Rossman, K. L. and S. L. Campbell (2000). "Bacterial expressed DH and DH/PH domains." 
Methods Enzymol 325: 25-38. 
 
Rossman, K. L., C. J. Der, et al. (2005). "GEF means go: turning on RHO GTPases with guanine 
nucleotide-exchange factors." Nat Rev Mol Cell Biol 6(2): 167-180. 
 
Rossman, K. L. and J. Sondek (2005). "Larger than Dbl: new structural insights into RhoA 
activation." Trends Biochem Sci 30(4): 163-165. 
 
Rossman, K. L., D. K. Worthylake, et al. (2002). "Functional analysis of cdc42 residues required 
for Guanine nucleotide exchange." J Biol Chem 277(52): 50893-50898. 
 
Sahin, M., P. L. Greer, et al. (2005). "Eph-dependent tyrosine phosphorylation of ephexin1 
modulates growth cone collapse." Neuron 46(2): 191-204. 
 
Sanes, J. R. and J. W. Lichtman (1999). "Development of the vertebrate neuromuscular 
junction." Annu Rev Neurosci 22: 389-442. 
 
Scheiffele, P., J. Fan, et al. (2000). "Neuroligin expressed in nonneuronal cells triggers 
presynaptic development in contacting axons." Cell 101(6): 657-669. 
 
Schmidt, A. and A. Hall (2002). "Guanine nucleotide exchange factors for Rho GTPases: turning 
on the switch." Genes Dev 16(13): 1587-1609. 
 
167 
 
Shamah, S. M., M. Z. Lin, et al. (2001). "EphA receptors regulate growth cone dynamics through 
the novel guanine nucleotide exchange factor ephexin." Cell 105(2): 233-244. 
 
Sharfe, N., A. Freywald, et al. (2003). "Ephrin-A1 induces c-Cbl phosphorylation and EphA 
receptor down-regulation in T cells." J Immunol 170(12): 6024-6032. 
 
Shi, L., B. Butt, et al. (2010). "Ephexin1 is required for structural maturation and 
neurotransmission at the neuromuscular junction." Neuron 65(2): 204-216. 
 
Shi, L., A. K. Fu, et al. (2010). "Multiple roles of the Rho GEF ephexin1 in synapse 
remodeling." Commun Integr Biol 3(6): 622-624. 
 
Shi, Y., C. G. Pontrello, et al. (2009). "Focal adhesion kinase acts downstream of EphB receptors 
to maintain mature dendritic spines by regulating cofilin activity." J Neurosci 29(25): 
8129-8142. 
 
Smith, W. J., B. Hamel, et al. (2005). "A Cdc42 mutant specifically activated by intersectin." 
Biochemistry 44(40): 13282-13290. 
 
Snyder, J. T., K. L. Rossman, et al. (2001). "Quantitative analysis of the effect of 
phosphoinositide interactions on the function of Dbl family proteins." J Biol Chem 
276(49): 45868-45875. 
 
Snyder, J. T., D. K. Worthylake, et al. (2002). "Structural basis for the selective activation of 
Rho GTPases by Dbl exchange factors." Nat Struct Biol 9(6): 468-475. 
 
Soisson, S. M., A. S. Nimnual, et al. (1998). "Crystal structure of the Dbl and pleckstrin 
homology domains from the human Son of sevenless protein." Cell 95(2): 259-268. 
 
Sondermann, H., S. M. Soisson, et al. (2004). "Structural analysis of autoinhibition in the Ras 
activator Son of sevenless." Cell 119(3): 393-405. 
 
Soskis, M. J., H. Y. Ho, et al. (2012). "A chemical genetic approach reveals distinct EphB 
signaling mechanisms during brain development." Nat Neurosci 15(12): 1645-1654. 
 
Sotelo, C. (1991). "Cerebellar synaptogenesis: mutant mice--neuronal grafting." J Physiol (Paris) 
85(3): 134-144. 
 
Sotiropoulos, A., D. Gineitis, et al. (1999). "Signal-regulated activation of serum response factor 
is  
mediated by changes in actin dynamics." Cel, 98: 159-169. 
 
Stevens, B., N. J. Allen, et al. (2007). "The classical complement cascade mediates CNS synapse 
elimination." Cell 131(6): 1164-1178. 
 
168 
 
Stoppini, L., P. A. Buchs, et al. (1991). "A simple method for organotypic cultures of nervous 
tissue." J Neurosci Methods 37(2): 173-182. 
 
Takasu, M. A., M. B. Dalva, et al. (2002). "Modulation of NMDA receptor-dependent calcium 
influx and gene expression through EphB receptors." Science 295(5554): 491-495. 
 
Tanegashima, K., H. Zhao, et al. (2008). "WGEF activates Rho in the Wnt-PCP pathway and 
controls convergent extension in Xenopus gastrulation." EMBO J 27(4): 606-617. 
 
Tashiro, A., A. Minden, et al. (2000). "Regulation of dendritic spine morphology by the rho 
family of small GTPases: antagonistic roles of Rac and Rho." Cereb Cortex 10(10): 927-
938. 
 
Tashiro, A. and R. Yuste (2004). "Regulation of dendritic spine motility and stability by Rac1 
and Rho kinase: evidence for two forms of spine motility." Mol Cell Neurosci 26(3): 429-
440. 
 
Tolias, K. F., J. B. Bikoff, et al. (2005). "The Rac1-GEF Tiam1 couples the NMDA receptor to 
the activity-dependent development of dendritic arbors and spines." Neuron 45(4): 525-
538. 
 
Tolias, K. F., J. B. Bikoff, et al. (2007). "The Rac1 guanine nucleotide exchange factor Tiam1 
mediates EphB receptor-dependent dendritic spine development." Proc Natl Acad Sci U 
S A 104(17): 7265-7270. 
 
Trachtenberg, J. T., B. E. Chen, et al. (2002). "Long-term in vivo imaging of experience-
dependent synaptic plasticity in adult cortex." Nature 420(6917): 788-794. 
 
Tsyba, L., O. Nikolaienko, et al. (2011). "Intersectin multidomain adaptor proteins: regulation of 
functional diversity." Gene 473(2): 67-75. 
 
Varoqueaux, F., A. Sigler, et al. (2002). "Total arrest of spontaneous and evoked synaptic 
transmission but normal synaptogenesis in the absence of Munc13-mediated vesicle 
priming." Proc Natl Acad Sci U S A 99(13): 9037-9042. 
 
Veeramah, K. R., L. Johnstone, et al. (2013). "Exome sequencing reveals new causal mutations 
in children with epileptic encephalopathies." Epilepsia. 
 
Verhage, M., A. S. Maia, et al. (2000). "Synaptic assembly of the brain in the absence of 
neurotransmitter secretion." Science 287(5454): 864-869. 
 
Wang, L., K. Zhu, et al. (2004). "Oncogenic Dbl, Cdc42, and p21-activated kinase form a ternary 
signaling intermediate through the minimum interactive domains." Biochemistry 43(46): 
14584-14593. 
 
169 
 
Wegner, A. M., C. A. Nebhan, et al. (2008). "N-wasp and the arp2/3 complex are critical 
regulators of actin in the development of dendritic spines and synapses." J Biol Chem 
283(23): 15912-15920. 
 
Wei, Q., X. Y. Lu, et al. (2004). "Glucocorticoid receptor overexpression in forebrain: a mouse 
model of increased emotional lability." Proc Natl Acad Sci U S A 101(32): 11851-11856. 
 
Williams, C. A. (2005). "Neurological aspects of the Angelman syndrome." Brain Dev 27(2): 88-
94. 
 
Wills, Z. P., C. Mandel-Brehm, et al. (2012). "The nogo receptor family restricts synapse number 
in the developing hippocampus." Neuron 73(3): 466-481. 
 
Xia, Z., H. Dudek, et al. (1996). "Calcium influx via the NMDA receptor induces immediate 
early gene transcription by a MAP kinase/ERK-dependent mechanism." J Neurosci 
16(17): 5425-5436. 
Xie, X., S. W. Chang, et al. (2005). "TIM, a Dbl-related protein, regulates cell shape and 
cytoskeletal organization in a Rho-dependent manner." Cell Signal 17(4): 461-471. 
 
Xu, T., X. Yu, et al. (2009). "Rapid formation and selective stabilization of synapses for 
enduring motor memories." Nature 462(7275): 915-919. 
 
Yang, G., F. Pan, et al. (2009). "Stably maintained dendritic spines are associated with lifelong 
memories." Nature 462(7275): 920-924. 
 
Yashiro, K., T. T. Riday, et al. (2009). "Ube3a is required for experience-dependent maturation 
of the neocortex." Nat Neurosci 12(6): 777-783. 
 
Yeh, B. J., R. J. Rutigliano, et al. (2007). "Rewiring cellular morphology pathways with 
synthetic guanine nucleotide exchange factors." Nature 447(7144): 596-600. 
 
Yen, H. C., Q. Xu, et al. (2008). "Global protein stability profiling in mammalian cells." Science 
322(5903): 918-923. 
 
Yohe, M. E., K. Rossman, et al. (2008). "Role of the C-terminal SH3 domain and N-terminal 
tyrosine phosphorylation in regulation of Tim and related Dbl-family proteins." 
Biochemistry 47(26): 6827-6839. 
 
Yohe, M. E., K. L. Rossman, et al. (2007). "Auto-inhibition of the Dbl family protein Tim by an 
N-terminal helical motif." J Biol Chem 282(18): 13813-13823. 
 
Yu, B., I. R. Martins, et al. (2010). "Structural and energetic mechanisms of cooperative 
autoinhibition and activation of Vav1." Cell 140(2): 246-256. 
 
Yuste, R. and T. Bonhoeffer (2004). "Genesis of dendritic spines: insights from ultrastructural 
and imaging studies." Nat Rev Neurosci 5(1): 24-34. 
170 
 
 
Zhai, R. G., H. Vardinon-Friedman, et al. (2001). "Assembling the presynaptic active zone: a 
characterization of an active one precursor vesicle." Neuron 29(1): 131-143. 
 
Zhang, W. and D. L. Benson (2001). "Stages of synapse development defined by dependence on 
F-actin." J Neurosci 21(14): 5169-5181. 
 
Zheng, J., S. M. Cahill, et al. (1996). "Identification of the binding site for acidic phospholipids 
on the pH domain of dynamin: implications for stimulation of GTPase activity." J Mol 
Biol 255(1): 14-21. 
 
Zhu, K., B. Debreceni, et al. (2000). "Identification of Rho GTPase-dependent sites in the Dbl 
homology domain of oncogenic Dbl that are required for transformation." J Biol Chem 
275(34): 25993-26001. 
 
Zito, K., V. Scheuss, et al. (2009). "Rapid functional maturation of nascent dendritic spines." 
Neuron 61(2): 247-258. 
 
Ziv, N. E. and S. J. Smith (1996). "Evidence for a role of dendritic filopodia in synaptogenesis 
and spine formation." Neuron 17(1): 91-102. 
 
Zukerberg, L. R., G. N. Patrick, et al. (2000). "Cables links Cdk5 and c-Abl and facilitates Cdk5 
tyrosine phosphorylation, kinase upregulation, and neurite outgrowth." Neuron 26(3): 
633-646. 
 
 
 
